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Abstract
Among the many advances in neonatal intensive care over the past few decades, few changes
can claim to have had an effect on outcomes in low birthweight infants as that of the
introduction of exogenous surfactant therapy. Avery and Mead (1959) are generally credited
with the discovery that surfactant deficiency leads to respiratory distress syndrome (RDS),
but discoveries of the composition, function and physiology of surfactant span the whole of
the 20th century.
This thesis reviews the current understanding of surfactant composition and function looking
at the early discoveries to the first use of exogenous surfactant therapies and more recently
the introduction of "designer" synthetic surfactants.
Several exogenous surfactants are currently available and whilst controlled trials have
demonstrated surfactant therapy is better than placebo, there are several unanswered
questions that this thesis addresses through a review of existing evidence;
1. Which surfactant preparation is clinically more efficacious
2. The choice between "rescue" (treatment after the development of RDS) or
"prophylaxis" (prevention of RDS)
3. How many doses of surfactant are needed and what is the evidence for the size of the
doses currently used
Four exogenous surfactant preparations - two synthetic and two animal-derived - have been
licensed in the United Kingdom. The development of each surfactant is traced through a
review of published trials. Current evidence from comparisons of synthetic and animal-
derived surfactants is reviewed and evidence from comparative trials presented in an over¬
view using meta-analysis. This argument is further examined in a multi-centre randomised
controlled trial looking at the effects ofALEC and Curosurf the two most commonly used
synthetic and animal-derived surfactants used in the UK. The trial was terminated early
because of a significantly higher mortality in the ALEC arm. Results of the trial are
discussed in relation to previous synthetic versus animal-derived surfactant trials.
ALEC had been the most frequently used surfactant within the former Northern health region
of England until publication of the study results and subsequent withdrawal of the ALEC by
the manufacturer. The implications for neonatal service provision in the region in light of the
iv
results of the ALEC versus Curosurf trial are explored using data from the region. This
functions as a geographic cohort and has developed a centralised model ofneonatal intensive
care provision through a collaborative consortium. The impact of neonatal respiratory
disease within it is examined with a survey of respiratory support and oxygen
supplementation in neonatal provider and non-provider units. Using data from this survey
and the ALEC versus Curosurf trial this thesis shows how a change in surfactant therapy can
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Abbreviations used in this thesis
BPD Bronchopulmonary dysplasia
CBFV Cerebral (arterial) blood flow velocity
CLD Chronic lung disease
CPAP Continuous positive airways pressure
DPPC Dipalmitoylphosphatidylcholine
ECMO Extracorporeal Membrane oxygenation
Fi02 Fraction of inspired oxygen
HMD Hyaline membrane disease
IVH Intraventricular haemorrhage
MAP Mean airway pressure
NEC Necrotising enterocolitis
NGH Newcastle General Hospital
PaC02 Arterial carbon dioxide concentration
Pa02 Arterial oxygen concentration
PDA Patent ductus arteriosus
PIE Pulmonary interstitial emphysema
PMMH Princes Mary Maternity Hospital
PPHN Persistent pulmonary hypertension
PROM Prolonged rupture ofmembranes
PVL Periventricular leukomalacia
RDS Respiratory distress syndrome
RVI Royal Victoria Infirmary




Index of Tables and Figures xi
Introduction xiv
1. Respiratory distress syndrome 1
1.1 Respiratory distress syndrome - an introduction. 2
1.2 Pulmonary complications of respiratory distress
syndrome 3
1.3 The history of respiratory distress syndrome 4
1.4 Risk factors and antenatal influences on respiratory
distress syndrome 6
1.5 Conclusion & summary 16
2. Surface tension, surfactant and the lung 17
2.1 Surface tension in the lung 18
2.2 Surface tension and the law of Laplace 18
2.3 Early discoveries of surfactant 19
2.4 Early trials of surfactant 22
2.5 Conclusion 23
3. The composition of surfactant 25
3.1 The type II pneumocyte 26
3.2 Surfactant phospholipids 27
3.3 Surfactant-associated proteins 28
3.4 Other proteins/polypeptides in surfactant 37
3.5 Conclusion 38
4. The surfactant era 39
4.1 Extracts of naturally-occurring surfactants 40
4.2 Synthetic surfactants 43
4.3 Conclusion 45
5. Surfactants available in the United Kingdom 47
5.1 ALEC (pumactant)
5.1.1 Development and early trials ofALEC 48
5.1.2 Meta-analysis ofplacebo controlled trials
ofALEC 53
5.2 Curosurf (poractant alfa)
5.2.1 Development and early trials ofCurosurf 60
5.2.2 Meta-analysis of placebo controlled trials
ofCurosurf 65
Page
5.3 Exosurf (colfosceril palmitate)
5.3.1 Development and early trials ofExosurf 75
5.3.2 Meta-analysis of placebo controlled trials
ofExosurf 92
5.4 Survanta (beractant)
5.4.1 Development and early trials of beractant 96
5.4.2 Meta-analysis of placebo controlled trials
of beractant 108
5.5 Overall conclusion 112
6. How, when, how much and how often? 115
6.1 Surfactant dose size 116
6.2 How many doses are required? 118
6.3 When should surfactant be administered?
6.3.1 Evidence from animal models ofRDS 119
6.3.2 Evidence from neonatal trials 121
6.4 Do all "at risk" infants require surfactant therapy? 141
6.5 Subsequent doses of surfactant 142
6.6 Conclusion 143
7. Evidence of differences between surfactants from in
vitro studies and animal models of RDS 145
7.1 Differences in surfactant composition 146
7.2 In vitro (biophysical) differences between
surfactants 147
7.3 Lavaged excised animal lung models of RDS 150
7.4 Lavaged in vivo lung models of RDS 150
7.5 In vivo physiological effects in preterm animal
models ofRDS 151
7.6 Conclusion 154
8. Comparison between different surfactants in neonates 155
8.1 Early changes in oxygenation, ventilation and
respiratory function 168
8.2 Changes in radiological appearances after natural
and synthetic surfactants 170
8.3 Effects on cerebral blood flow. 171
8.4 Effects of different surfactants on neonatal mortality
and complications of prematurity 172
8.5 Meta-analysis of the randomised trials comparing an
animal-derived surfactant extract versus a synthetic
surfactant 173




9. A randomised comparison between Curosurf and ALEC 183
9.1 Introduction 184
9.2 Methods 189
9.3 Outcome definitions used in the study 192
9.4 Early changes in oxygenation and ventilator
requirements 194




10. Surfactant deficient lung disease in the former Northern
health region of England 226
10.1 Introduction 227
10.2 The development of a collaborative neonatal
service in the former Northern health region 227
10.3 The current status ofneonatal services in the
former Northern region 230
10.4 Survey of all admissions of infants <32 weeks to
neonatal units in the former Northern region 235
10.5 The implications of the Curosurfand ALEC trial





Appendix 1: Statement of the Data and Safety
Monitoring Committee of the CandA (Curosurf
and ALEC) trial - December 1999
Appendix 2: Statement issued by Britannia
Pharmaceuticals - April 2000
Appendix 3: Anonymised data from the Curosurf
versus ALEC trial (Raw data for chapter 9)
Appendix 4: Anonymised data from the Northern





jndex of Tab[es and Figures
Page Title
20 Figure 1 The alveolus and the law of Laplace
31 Table 1 Summary of the putative functions of surfactant-associated protein A
(SP-A)
31 Table 2 Summary of the putative functions of surfactant-associated protein D
(SP-D)
36 Table 3 Summary of the putative functions of surfactant-associated protein B
(SP-B)
36 Table 4 Summary of the putative functions of surfactant-associated protein C
(SP-C)
41 Table 5 Classification of exogenous surfactants by origin
49 Table 6 Composition of surfactants available in the United Kingdom
52 Table 7 Significant outcomes reported in controlled trials ofALEC
56 Table 8 Summaries of the randomised-controlled trials involving ALEC
58 Figure 2 Meta-view charts of risk difference and relative risk between ALEC
treated infants and controls
62 Table 9 The CurosurfEURO trials
63 Table 10 Significant 28-day outcomes reported in randomised-controlled trials of
Curosurf
68 Table 11 Summaries of the controlled trials involving Curosurf
74 Figure 3 Meta-view charts of risk difference and relative risk between Curosurf
treated infants and controls
77 Table 12 The North American Exosurf trials and their follow-up studies
78 Figure 4 Birthweight ranges in the North American trials ofExosurf
79 Table 13 Summaries of the randomised trials involving Exosurf
87 Table 14 Summary of dosing schedules in the North American Exosurf trials
89 Table 15 Significant 28-day outcomes reported in controlled trials ofExosurf
95 Figure 4 Meta-view charts of risk difference and relative risk between Exosurf
treated infants and controls
97 Table 16 Summaries of the controlled trials involving Survanta and surfactant TA
106 Table 17 Significant outcomes reported in controlled trials ofSurvanta or
surfactant TA
111 Figure 5 Meta-view charts of risk difference and relative risk between beractant
{Survanta and surfactant TA) treated infants and controls
114 Figure 6 Meta-analysis of risk difference between surfactant treated infants and
controls for the four surfactants licensed in the UK
xi
Page Title
122 Table 18 Summaries of the trials involving early and late administration of
surfactant
129 Table 19 A summary of all published trials comparing two different strategies for
surfactant administration
132 Figure 7 Meta-view charts of risk difference and relative risk in trials comparing
pre-ventilation prophylaxis and post-ventilation rescue strategies
136 Figure 8 Meta-view charts of risk difference and relative risk in trials comparing
prophylaxis and rescue strategies
138 Figure 9 Meta-view charts of risk difference and relative risk between early and
late rescue strategies
149 Table 20 Surface tension of various surfactant preparations as measured using the
Wilhelmy-Langmuir balance
149 Table 21 Maximum and minimum surface tensions of various surfactant
preparations as measured using the Enhorning pulsating bubble
surfactometer
153 Table 22 Dynamic compliance in preterm lambs 4 hours after treatment with
various surfactant preparations
157 Table 23 Studies comparing two different surfactant preparations in neonatal
populations
159 Table 24 Summaries of the clinical trials involving two different surfactants
174 Table 25 Significant outcomes at 28 days of age and 36 weeks corrected gestation
reported in randomised trials comparing animal-derived and synthetic
surfactants
178 Figure 10 Meta-view charts of randomised trials comparing animal-derived and
synthetic surfactants
187 Table 26 The Northern region categories of care
197 Figure 11 The consort diagram for the trial between Curosurfand ALEC
199 Table 27 Summary of demographic data for infants in the trial between ALEC
and Curosurf
200 Table 28 Demographics of enrolled infants by centre
202 Figure 12 Time to first dose of allocated surfactant
203 Table 29 Number of doses of surfactant given
204 Figure 13 Mean (+/-SEM) appropriate Fi02 during the first 72 hours of life
205 Figure 14 Changes in mean airways pressure (mean +/-SEM) between Curosurf
and ALEC arms during the first 72 hours of life
207 Figure 15 Changes in oxygenation index (mean +/-SEM) during the first 6 hours
and mortality
209 Table 30 Cause of death of infants
xii
Page Title
210 Table 31 Neonatal and pre-discharge deaths according to gestation
211 Table 32 Neonatal and pre-discharge deaths according to centre and surfactant
allocation
212 Figure 16 Kaplan-Meier plot of deaths in the ALEC and Curosurfarms
213 Table 33 Complications of prematurity
214 Table 34 Pneumothorax rate according to centre and surfactant allocation
216 Table 35 Median values of the components of CRIB between the ALEC and
Curosurfarms
224 Figure 17 Relative risk ofmortality in trials comparing synthetic and animal-
derived surfactants
229 Figure 18 The trends of ventilation workload in the two Newcastle units 1972-92
232 Figure 19 Neonatal units in the former Northern region
233 Figure 20 Birthrate in the former Northern region 1981 - 1999
234 Figure 21 Perinatal mortality in the former Northern region 1981 - 1999
238 Figure 22 Hospital of booking for infants <32 weeks admitted to special care baby
units in the former Northern region 1998-9
239 Figure 23 Place of birth of infants <32 weeks admitted to special care baby units
in the former Northern region 1998-9
240 Figure 24 Livebirth rates in 1999 in hospitals in the former Northern region with
special care baby units
241 Figure 25 Early neonatal course in relation to place of birth and transfer status
242 Figure 26 No. of infants (<32 weeks) treated within the special care baby units of
the former Northern region 1998-99
244 Figure 27 Mortality rates of infants <32 weeks booked for delivery and admitted
to special care baby units in the former Northern region 1998-99
245 Figure 28 Kaplan-Meier plot of survival among infants <32 weeks gestation
admitted to special care baby units in the former Northern region 1998-
99
246 Table 36 Respiratory support in infants <32 weeks gestation admitted to the
special care baby units in the former Northern region 1998-99
248 Figure 29 Mortality (+/- 95% CI) by gestation according to place of booking
within the former Northern region 1998-99
249 Figure 30 Mortality (+/- 95% CI) by gestation according to transfer and place of
birth within the former Northern region 1998-99
251 Figure 31 Mortality by CRIB score and place of birth: all infants < weeks
gestation in the former Northern region 1998-99




Exogenous surfactant therapy has been in widespread clinical use in neonates for nearly a
decade. Its introduction was associated with a 30-40% reduction in neonatal mortality in
infants at risk of respiratory distress syndrome (RDS) in a group ofNorth American level III
neonatal intensive care units (Schwartz et al 1994). Complications of RDS, such as
pulmonary air leaks, are also reduced (Soli 1999a, Soil 1999b). When it is used in
conjunction with antenatal steroids, there is a combined synergistic effect (Jobe et al 1993).
Several exogenous surfactants are currently available and are divided into two types
according to their origins: animal-derived surfactant extracts and synthetic surfactants.
Although all are designed to treat and prevent RDS, these products differ in several ways.
Animal-derived surfactants contain proteins and lipids; whereas synthetic surfactants have
until recently have been protein-free. Recent developments in molecular biology have led to
the development of synthetic protein analogues and recombinant proteins that act in the same
way as the naturally occurring surfactant proteins.
Whilst randomised controlled trials have demonstrated surfactant therapy is better than
placebo, controversies remain regarding;
1. Whether one surfactant is better than another, in particular whether surfactants that
are animal-derived offer clinically better outcomes than currently available protein-
free synthetic surfactants
2. Whether there is a gestation or weight limit below which there is no or very little
benefit from surfactant treatment
3. The choice between "rescue" (treatment after the development of symptoms ofRDS)
or "prophylaxis" (prevention ofRDS by administering surfactant to all infants at risk
of developing it)
This thesis begins with a review of the current understanding of surfactant; its composition,
the function and the properties of its components, and the discoveries that led to its
development as a therapeutic agent. This is followed by a review of placebo-controlled trials
involving the four exogenous surfactant preparations that have been licensed in the United
Kingdom. - Artificial Lung Expanding Compound (A/.E'C/pumactant), Exosurf (colfosceril),
Curosurf (poractant) and Survanta (beractant). All four surfactants are demonstrably better
than placebo but comparative trials between the different surfactants are limited.
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The Scottish Health Purchasing Information Centre (SHPIC) had suggested ALEC should be
the choice of surfactant for prophylaxis and Survanta the surfactant of choice for rescue
therapy based published trials and the costs of surfactants (SHPIC report 1996). The report
assumed no clinical differences between surfactant types however the fallacy of this view is
examined using evidence from trials comparing synthetic and animal-derived surfactants in
neonates and the results are presented in an over-view using meta-analysis. This area is
further examined in a multi-centre randomised controlled trial looking at the effects of
ALEC and Curosurf the two most commonly used synthetic and animal-derived surfactants
used in the United Kingdom.
Neonatal care is provided in many ways; the former Northern region operates a consortium
of neonatal intensive care (provider) units working with several special care baby (non-
provider) units. The consortium provides long-term neonatal intensive care for the region's
33,000 livebirths per annum. How this organisation developed into its current status is
explored and the impact of surfactant and respiratory distress syndrome within the region is
examined. In addition this section examines whether in such an organisation place of birth
influences mortality
The final section of this thesis re-examines the area of healthcare resources use in relation to
surfactant therapy. ALEC was voluntarily withdrawn by the manufacturer following
publication of the outcomes of the Curosurf versus ALEC trial (appendix 2). Using data
extrapolated from the study and applying it to the geographically-defined population of the
former Northern region of England, it illustrates the potential economic effects of the




1.1 Respiratory Distress Syndrome - an introduction
1.2 Pulmonary Complications ofRespiratory Distress Syndrome
1.3 The history of Respiratory Distress Syndrome




1.4.4 Method of delivery
1.4.5 Perinatal asphyxia
1.4.6 Maternal diabetes mellitus
1.4.7 Familial and genetic factors
1.4.8 Multiple pregnancy
1.4.9 Hypothermia
1.4.10 Prolonged rupture ofmembranes
1.4.11 Chorioamnionitis
1.4.12 Antenatal steroid therapy
1.4.13 Antenatal thyrotropin-releasing hormone (TRH) therapy
1.4.14 Antenatal ambroxol
1.4.15 Antenatal aminophylline
1.5 Conclusion & summary
1
1.1 Respiratory Distress Syndrome - an introduction
Surfactant deficiency lung disease in neonates is usually taken to be synonymous with
respiratory distress syndrome (RDS). However as knowledge of the aetiology and
pathogenesis of RDS have changed various terms have been used in medical literature.
Initially RDS was called "hyaline membrane disease". This is strictly speaking a
pathological diagnosis and reflects the formation of a proteinaceous hyaline membrane in
the alveoli of the lungs of affected infants. As the condition became increasing recognised as
a distinct clinical entity with radiological and clinical features the name changed to
idiopathic respiratory distress syndrome. The "idiopathic" part has since become
superfluous with greater understanding of the disease and neonatologists use the term RDS
to describe respiratory failure that results from a primary surfactant insufficiency.
Some older textbooks refer to two "types" of RDS - types I and II. Type I is that which is
associated with surfactant deficiency in preterm infants whereas type II is that seen in more
mature infants in whom a diagnostic label of transient tachypnoea of the newborn (TTN)
may be used. Whilst the amount of surfactant in infants with TTN may be normal it may not
be functioning properly.
A type of RDS also affects older children and adults. This has a different pathophysiology
where there is surfactant dysfunction secondary to sepsis or multi-system organ failure. To
distinguish the two types the two conditions are sometimes called adult respiratory distress
syndrome (ARDS) and infant RDS. Just as with neonatal RDS there is some non-uniformity
in nomenclature that can cause confusion, and some authorities use the term "acute" rather
than "adult" reflecting the occurrence of the disease across the whole age spectrum.
This thesis concentrates on RDS in the newborn infant. This is an acute pulmonary
condition usually, but not exclusively, found in preterm infants. Unless stated otherwise use
of the term RDS in this thesis shall refer to this condition. Critical to the pathogenesis of
RDS is deficiency of pulmonary surfactant (Avery & Mead 1959). Surfactant lowers
alveolar surface tension and prevents alveolar collapse at the end of expiration. Deficiency,
or dysfunction, of surfactant results in a reduced functional residual capacity, reduced lung
compliance and ventilation perfusion mismatching.
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Histologically respiratory epithelial injury occurs with exudation of an eosinophilic
proteinaceous material into the alveolar airspaces. This triggers inflammatory cascades and
the result is the classical "hyaline membrane disease" appearance (Lauweryns 1970). This
hyaline membrane can still seen iin histological specimens despite the use of exogenous
surfactant replacement therapy (Pinar et al 1994, Toti et al 1996). Structural immaturity,
oxygen toxicity (free radical disease) and sometimes infection also contribute to the
evolving clinical picture over the course of the illness (Jobe 1989).
Most infants with RDS require some respiratory support in the form of supplemental
oxygen, continuous positive airways pressure (CPAP) or mechanical ventilation. The
classical clinical course is one of deteriorating respiratory failure over the initial 48-72 hours
after birth followed by a period of improvement. However this is seen only in infants of
approximately 29-32 weeks gestation. In more immature infants, the disease tends to be
more severe and mechanical ventilation is almost universally needed. These infants are also
more likely to die or to have a prolonged course leading to chronic pulmonary insufficiency
- variably called bronchopulmonary dysplasia (BPD) or chronic lung disease (CLD).
1.2 Pulmonary Complications of Respiratory Distress
Syndrome
Pulmonary complications of RDS can either be acute or long term. The acute problems are
inadequate gas exchange and respiratory failure, pulmonary air leaks (pneumothoraces,
pneumoperitoneum, pneumopericardium, pneumomediastinum and pulmonary interstitial
emphysema) and death.
In the longer term CLD can be a major problem. Initialy called bronchopulmonary dysplasia
(Northway et al 1967, Nash et al 1967), CLD has several definitions. A widely used
definition is that of oxygen dependency at 28 days postnatal age, with (Heneghan et al 1986)
or without (Tooley 1979) radiological changes. However a clinically more useful definition
is that of oxygen dependency at 36 weeks corrected post-menstrual age (Shennan et al
1988), this is a better predictor of long-term oxygen dependency and respiratory
insufficiency in infancy and later life (Gregoire et al 1998) because of the correction for
gestation at birth. For example in the trial in reported in chapter 9 of this thesis, 60.4% of
infants born between 25-29 weeks who survived to discharge were 02 dependent at 28 days
whereas only 53.8% were 02 dependent at 36 weeks corrected gestational age.
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CLD at 36 weeks predicts long-term respiratory morbidity (Coates 1997) and carries an
increased respiratory mortality (Fillmore & Cartlidge 1998). Growth (Johnson et al 1998)
and neurodevelopmental outcome (Hughes et al 1999) may also be adversely affected.
Success of treatment strategies for RIDS should be judged not only on the reduction of
neonatal mortality but also the reduction in morbidity.
The incidence of CLD varies according to the definition used. Most early surfactant trials
used a 28 day definition (see chapter 5), although more recent publications have included a
36 weeks corrected definition. This can make comparison over a long period of time
difficult (Young et al 1999). There are also population differences in the prevalence of
CLD; Fenton et al (1996a) reported a prevalence of 18.5% in one Canadian province and
6.4% in the Trent Health region in England whereas Young et al (1999) reported a
prevalence of 25% in North Carolina in the USA. The differences in CLD between these
populations may reflect differences in demography as well as medical care.
It is suggested that surfactant therapy and improved neonatal care may have led to an
increase in CLD (Parker et al 1992, Fenton et al 1996b) as a result of increased survival
although the proportion of surviving infants with CLD has remained unchanged.
1.3 The history of Respiratory Distress Syndrome
Hyaline membrane disease (HMD), the histopathological equivalent of RDS, was first
described by Hockheim (1903), but its nature only became clear when Gitlin & Craig (1956)
showed the membrane was formed as a result of exudation of proteinaceous material rather
than inspissation of aspirated amniotic fluid.
The diagnosis of HMD/RDS remained primarily pathological until the 1950's when attempts
were made to provide a clinically more useful definition. Some infants were noted to be
dying from an HMD-like illness yet their autopsies failed to reveal a typical hyaline
membrane (Briggs & Hogg 1958). These infants had RDS but were not old enough to have
the alveolar leak and transudation that leads to hyaline membrane formation that was
suggested as essential for the disease by Blystad et al (1951) and Miller & Jennison (1950).
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Radiological features of RDS were outlined by Donald & Steiner (1953) as the emphasis
changed to clinical and radiological diagnosis, however the term respiratory distress
syndrome did not appear until the end of the decade (James 1959). Even then the two terms
of HMD and RDS have continued to be used synonymously. Although discoveries regarding
the aetiology were beginning to appear Rudolph & Smith (1960) suggested the condition be
called "idiopathic" RDS and suggested clinical criteria that would fit the diagnosis.
RDS is a major cause of mortality and morbidity in preterm infants. It affects approximately
1 in 3 infants born before 34 weeks gestation (Roberton 1982). In the former Northern
region of England 66% of infants born <32 weeks gestation were ventilated and a further
14% required other respiratory support in the form of continuous positive airway pressure
(chapter 10). In 1988 it was estimated to cause over 3000 deaths per year in the USA
(Wegman 1989).
Although surfactant is seen to be one of the most important advances in neonatology, there
were improvements in mortality that preceded the introduction of surfactant and these
probably reflect improvements in both antenatal and postnatal care (Swyer 1993, Schwartz
et al 1994, Lee et al 1999). Antenatally these include improvements of obstetric care
(Richardson et al 1998), regionalisation of resources (Paneth et al 1982, Verloove-
Vanhorick et al 1988), use of tocolytic agents (largely to delay preterm labour long enough
to allow the administration of steroids - Palta et al 1998) and antenatal steroids (Crowley
1999).
Postnatal care has been improved by the better understanding of homeostasis, nutrition,
respiratory support and surfactant therapy. Successful respiratory support using mechanical
ventilators and, later, continuous positive pressure appeared in the late 1960's and early
1970's. However it was not until 1980 that the first report of successful surfactant
replacement appeared (Fujiwara et al 1980). Even though general improvements in perinatal
care were reducing mortality in infants with RDS as shown by Lee et al (1999), the
widespread introduction of surfactant in America led to a statistically significant drop in
mortality in infants who were 750-1749 grams at birth (Schoendorf& Kiely 1997).
5
1.4 Risk factors for and antenatal influences on RDS
Surfactant deficiency or dysfunction causes disturbance of alveolar gas exchange. This is
seen in the various forms of RDS. In the neonatal RDS, surfactant deficiency is a primary
problem whereas in adult or acute RDS various disease processes interfere with surfactant
production and function (the surfactant dysfunction is secondary to these processes). This
explains why exogenous surfactant therapy is less effective in ARDS (Cawley et al 1998).
It is recognised that certain risk factors predispose to the development ofRDS and that some
infants are more at risk than others are. The following have been found to have either a
positive or negative influence on RDS:
1.4.1 Prematurity
The biggest factor that predisposes to RDS is prematurity (defined as delivery before 37
weeks post-conception); the more immature the infant the greater the risk ofRDS (Farrell &
Avery 1975). The influence of prematurity on RDS is multifactorial with immaturity of the
lung architecture and cells, as well as immaturity of surfactant production (Holm 1993).
Even Avery & Mead (1959) acknowledge this in their important paper.
The lung develops in a series of stages (Hallman & Gluck 1977, Jobe 1997). The embryonic
stage (0-5 weeks post-conception) sees budding of the lung from the foregut and formation
of the early branches. The fetal stage occurs between 5 weeks to full term. Lungs become
potentially viable gas exchange units during the canalicular phase (weeks 16-25) as airways
and capillaries develop (Hislop & Reid 1974). Saturated phosphatidylcholine is produced
from type II cells with functional lamellar bodies around 20 weeks gestation. Alveoli
increase from around 30 x 106 at 28 weeks gestation to 150 x 106 at term during the terminal
sac stage (Hislop et al 1986). Surfactant replacement therapy is also less effective at lower
gestation (Battin et al 1998) suggesting that overall immaturity of lungs plays an important
role in the morbidity and mortality in these infants.
The composition of surfactant changes with increasing fetal maturity and this is reflected in
the declining incidence of RDS as the fetus approaches term (Farrell & Avery 1975).
Changing surfactant composition can be observed through analysis of fetal lung fluid and
amniotic fluid; these may be used clinically to estimate fetal lung maturity (Field & Gilbert
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1997). The lecithin/sphingomyelin (L/S) ratio reported by Gluck & Kulovich (1972) remains
the commonest used.
Lecithin (phosphatidylcholine) levels are measured relative to sphingomyelin, which is a
general membrane lipid. Sphingomyelin levels remain relatively constant throughout fetal
development until 32 weeks gestation when they fall, while lecithin levels rise. A value of
2.0 for the L/S ratio (normally achieved from 35 weeks gestation) is generally taken to
equate to "mature" surfactant and RDS is unlikely, between 1.5 to 2.0 surfactant is
"immature" but the risk of RDS is low. Below 1.0 the risk of RDS increases (Gluck et al
1974). Developmental changes in other surfactant phospholipids and proteins have also been
documented both in normal (Kulovich et al 1979) and complicated pregnancies (Kulovich &
Gluck 1979).
1.4.2 Gender
Male fetuses are at higher risk (1.4:1) of developing RDS than females of the same
gestation, and are more likely to die as a result (Farrell & Avery 1975, Perelman et al 1986,
Schwartz et al 1994). There is a relative delay in the maturation of surfactant in the male
fetus reflected in the L/S ratio and appearance of phosphatidylglycerol (Fleisher et al 1985,
Zachman et al 1989). In rabbits this delay in maturation is thought to be related to androgens
in the male fetus (Kotas & Avery 1971).
1.4.3 Ethnicity
There is evidence particularly from multiracial areas that ethnic origin may affect both the
risk of and outcomes from RDS. It has long been recognised that Afro-Caribbean infants
have a lower incidence of RDS than Caucasian infants (Fujikura et al 1966). It appears that
compared to Caucasian infants, they have a faster rate of lung maturation (Olowe et al 1978)
although there is some question of whether this is true for very preterm infants (Robillard et
al 1994).
The issue is complicated by the fact that Afro-Caribbean infants have a systematic tendency
to be born at lower gestational ages and to weigh less at birth than Caucasian infants
(Kleinman & Kessl 1987, Lyon et al 1994). When these factors are taken into account,
blacks of African but not Caribbean descent have a lower incidence of RDS than Caucasian
infants (Kawadia et al 1998). It is possible that racial differences in the incidence of RDS
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may reflect genotype susceptibility (section 1.4.7).
1.4.4 Method of delivery
The influence of delivery method is somewhat controversial particularly with regard to the
preterm infant. Most early studies (Usher et al 1964, Fedrick & Butler 1970, Usher et al
1971) but not all (Strang et al 1957) support the view that caesarean section performed
without labour increases the risk ofRDS.
Data on infants of gestations greater than 32 weeks also support this view (Cohen & Carson
1985, Morrison et al 1995, Shrivastava et al 1999). Confounding variables, such as maternal
illnesses, premature rupture of membranes and infection make data on immature infants of
<32 weeks gestation less clear. But when taking these variables into account it would seem
that caesarean section without labour increases the risk of RDS in the very preterm infant
(White et al 1985, Bryan et al 1990).
There are two main physiological reasons for an association between caesarean section and
RDS. Firstly, immediately prior to the onset of labour there is a surge in adrenaline in the
fetus (Faxelius et al 1983), leading to a reduction in the amount of lung fluid (Walters &
Oliver 1978) and an increase in both production and secretion of surfactant (Corbet et al
1977, Enhorning et al 1977, Kanjanapone et al 1980). Secondly, during labour itself there is
release of surfactant into the airways (Callen et al 1979).
Infants born by elective caesarean section have a lower L/S ratio in pharyngeal aspirates
(Whittle & Hill 1980), have larger residual volumes of lung fluid (Milner & Vyas 1982) and
secrete less surfactant in the period following delivery (Lawson et al 1977). With a smaller
reserve of endogenous surfactant these infants are therefore potentially more susceptible to
insults that affect surfactant function.
1.4.5 Perina tal asphyxia
Infants who are compromised at birth are at increased risk of RDS (Linderkamp et al 1978,
Thibeault et al 1984). Even in the absence of RDS, severe perinatal asphyxia adds to
respiratory morbidity (Thibeault et al 1984). The acidosis of perinatal asphyxia does not
cause RDS (Kenny et al 1976), but increasing acidosis affects choline synthesis and reduces
surfactant phospholipid metabolism (Merritt & Farrell 1976).
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In preterm infants the combination of an immature L/S ratio and asphyxia are more
predictive of RDS, than an immature L/S ratio alone. A 5-minute Apgar score <5 (Jones et
al 1975) and a poor umbilical arterial pH (Tejani & Verma 1989), both markers of perinatal
asphyxia, are associated with a higher risk of RDS in preterm infants. In preterm infants
with a mature L/S ratio asphyxia can precipitate RDS (Worthington & Smith 1978).
Hypoperfusion-reperfusion injury is thought to be the mechanism behind asphyxia and
surfactant dysfunction. Hypoperfusion leads to ischaemia of the fetal lung and is followed
by hyperperfusion after delivery and resuscitation (Dawes & Mott 1962). The alveolar
capillaries become damaged and proteinaceous fluid leaks into the alveolar space (Davis &
Stafford 1964, Jeffries et al 1984). Thus asphyxiated infants respond less well following
exogenous surfactant (Skelton & Jeffrey 1996).
1.4.6 Maternal diabetes mellitus
A widely held, but not universal (Usher et al 1971), view is that maternal diabetes increases
the risk of RDS (Robert et al 1976). Evidence of delayed maturation of surfactant,
particularly of phosphatidylcholine (Cunningham et al 1978, Ojomo & Coustan 1990) and
the L/S ratio (Kulovich & Gluck 1979) support this view. More recent data shows that strict
diabetic control reduces the incidence of RDS to that seen in non-diabetic controls
(Mimouni et al 1987).
Analysis of surfactant components provides conflicting evidence. Lung phospholipids in
amniotic fluid from both term diabetic and non-diabetic pregnancies are not different (Amon
et al 1986). However even when the phospholipids are normal, abnormalities of the
surfactant proteins may occur (Katyal et al 1984). All this suggests that the influences of
maternal diabetes on surfactant maturation are at very best incompletely understood.
Malformations rather than RDS are currently the largest cause of death in the infant of a
diabetic mother (Gabbe et al 1978). Whilst the mortality rate of infants of diabetic mothers
has declined from 250 per 1000 live births in the 1960s to a 20 per 1000 live births in the
1980s. Major congenital malformations are found in 5-8% of infants of diabetic mothers,
and these are responsible for 50% of perinatal deaths (Weintrob et al 1996).
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1.4.7 Familial and genetic factors
Familial factors play a role in several ways. Inherited deficiency of surfactant protein B (SP-
B) has been reported in term infants with alveolar proteinosis (Nogee et al 1993, Ball et al
1995). A number of different gene mutations have been recognised (Nogee et al 1994,
Nogee 1998) and can cause either a full or partial deficiency of this important surfactant
protein (Klein et al 1998). Affected infants present at all gestations with a severe and
intractable RDS-like illness that responds poorly to exogenous surfactant.
Even without SP-B deficiency, up to 19% of infants with RDS have a sibling who was also
affected (Lankenau 1976). This does not just reflect gestation at birth; infants of the same
gestation are more likely to have RDS if their sibling also had RDS (Nagoumey et al 1990).
Evidence from linkage studies suggests that there is a "susceptibility" gene for RDS that is
linked to the HLA antigens HLA-A3 and HLA-B14 (Hafez et al 1989), and it is this that
may account for interracial differences in the incidence of RDS.
From a maternal point of view, a woman who has had one previous preterm infant is at an
increased risk of subsequent pregnancies terminating prematurely (Graven & Misenhiemer
1965, Basso et al 1999). The risk is also increased after a previous spontaneous abortion
(Basso et al 1998) or if the mother herself was premature (Porter et al 1997). Some of this
may be attributable to a short cervix and cervical incompetence (Goldenberg et al 1998).
The locus for human surfactant protein A has been mapped to chromosome 10 and consists
of two classes of functional genes (White et al 1985, Katyal et al 1992) and one pseudogene
sequence (Korfhagen et al 1991). The product of each functional SP-A gene appears to be
required for stable mature SP-A (Voss et al 1991); the DNA sequences for these have been
denoted 6A and 1A. There are several allelic variants of the SP-A 6A (gene 1) and some
appear to be important in the predisposition to RDS (Ramet et al 2000).
1.4.8 Multiple pregnancy
Infants born as a result of a multiple pregnancy are likely to be more immature and generate
a disproportionately greater workload for obstetricians and neonatologists than singletons
(Nielsen et al 1997).
There seems to be some disagreement whether individuals from the same multiple
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pregnancy are at greater risk of RDS. Wolf et al (1992) and Gardner et al (1995) could not
find any increased RDS compared to singletons. On the other hand, Caspi et al (1980)
suggested both twins are at greater risk than singletons, whereas others (Weller et al 1976,
Dobbie et al 1983, Leveno et al 1984) have argued that only the second twin is at increased
risk of RDS. Surfactant maturation is accelerated in the presenting twin and may explain the
increased risk in the second twin (Obladen & Gluck 1977).
The second twin is also more likely to be intubated, to need resuscitation, to have lower 5
minute Apgar scores, and to have more nursery complications (Prins 1994). However the
increased risk of RDS in the second twin, if there is one, cannot be entirely explained by
perinatal asphyxia (Arnold et al 1987). Triplets seem to be at no further risk than twins of
the same gestation (Sassoon et al 1990).
Multiple pregnancies resulting from in-vitro fertilisation (IVF) techniques generate even
more problems than spontaneous multiple pregnancies; IVF mothers had more pregnancy-
induced hypertension, premature labour and preterm delivery; IVF infants had lower
birthweights and shorter gestations (Tallo et al 1995). Much of the increased workload
relates to the multiplicity of the pregnancy than the fact it was IVF (Wisanto et al 1996).
Surviving IVF infants had longer hospitalisations, more days of oxygen therapy, more days
of continuous positive airway pressure, and increased prevalence of respiratory distress
syndrome, patent ductus arteriosus, and sepsis (Tallo et al 1995). Beyond the neonatal
period, surviving IVF infants are no more likely to use, or importantly overuse, healthcare
resources than other infants (Leslie et al 1998).
Antenatal steroids, used to good effect in reducing the severity of RDS (see below) appear
to be less beneficial in twins (Turrentine et al 1996). The reasons for this are not clear.
1.4.9 Hypothermia
A major danger following preterm delivery is rapid heat loss from a small wet body with a
large surface area-volume ratio. Despite textbooks on neonatal resuscitation emphasising
thermoregulation in the preterm infant (Royal College of Paediatrics & Child Health 1997),
hypothermia (temperature <35°C) on admission to neonatal units has always been
problematic (Stanley & Alberman 1978, Loughead et al 1997). Hypothermia independently
increases the risk of RDS in an "at risk" population (Stanley & Alberman 1978), and
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increases the risk of complications of prematurity among RDS-affected infants (Herting et al
1992).
1.4.10 Prolonged rupture ofmembranes
Yoon & Harper (1973) first proposed the protective nature of prolonged rupture of
membranes (PROM) in RDS, and a number of studies (Chiswick 1976, Sell & Harris 1977,
Curet et al 1984, Bryan et al 1990, Suidan & Baassiri 1990) have supported their findings.
Acceleration of the maturation of the surfactant surface tension reducing properties occur
within 72 hours of membrane rupture in most infants with PROM between 29-37 weeks
gestation (Salzer et al 1980).
Other studies have disagreed with the findings. James et al (1975) and Papageorgiou et al
(1981) could find no evidence of an effect on either the incidence of RDS or its severity.
Berkowitz et al (1976) found a reduction of RDS in infants <32 weeks gestation born >16
hours after the rupture of membranes but not in infants >32 weeks. The same investigators
later refuted this finding and decided there did appear to be a protective effect in the more
mature infant (Berkowitz et al 1978). Hallak & Bottoms (1993) suggested that PROM was
associated with increased risk of RDS, especially if there was co-existing chorioamnionitis,
but pointed out that gestational age, gender and birthweight were more important
determinants than PROM. Overall evidence suggests PROM in the absence of infection
having a protective affect against RDS, although the effect is small and other factors, such
as gender and gestation, have a much greater influence (Mead 1980).
Very prolonged rupture of membranes presents problems other than RDS, particularly if the
period between rupture and delivery extends for several days, as hypoplasia of the
developing lungs may intervene. Wigglesworth et al (1981) reported that lungs which are
hypoplastic as a result of oligohydramnios are also structurally and biochemically immature
for gestational age. The authors suggest that the maturation arrest may be specifically
related to failure of retention of fetal lung liquid and the earlier the rupture occurs the
greater the likelihood of severe maturation and growth arrest.
The time from rupture of membranes to delivery is usually less than 48 hours at term,
however in preterm fetus this period is inversely related to gestational age (Merenstein &
Weisman 1996). Mid-trimester premature rupture of the membranes is uncommon
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(approximately 0.65% of all pregnancies) yet is associated with high perinatal morbidity
(Schucker & Mercer 1996). The subsequent neonatal course may be very variable.
Oligohydramnios with <lcm vertical pocket of amniotic fluid for 14 days is associated with
>90% mortality (Kilbride et al 1996). Death from pulmonary hypoplasia is more a problem
following preterm prolonged membrane rupture than ascending infection. (Mcintosh &
Harrison 1994).
Pulmonary hypoplasia is not inevitable even after prolonged periods of membrane rupture
(Mcintosh & Harrison 1994), and the major determining factor is whether or not the
amniotic fluid pool is large enough to prevent it. The more immature the fetus at the time of
membrane rupture the greater the risk of oligohydramios (Lauria et al 1995).
1.4.11 Chorioamnionitis
Recent evidence focussing on the presence of pro-inflammatory cytokines such as tumour
necrosis factor-a (TNF-a), the interleukins IL-1 and IL-8 (Kotecha 1996, Jonsson et al
1997, Hallman 1999, Speer 1999) and low-grade infection of the chorion with organisms
such as Ureaplasma urealyticum (Patterson et al 1998) suggests that these have a protective
effect against RDS. However the initiation of inflammatory cascades leads ultimately to
CLD that is out of proportion to the severity of the RDS (Watterberg et al 1996). As a result
the infants seem to have mild to moderately severe RDS and require little in the way of
respiratory support but then develop severe CLD. This pattern of CLD has a very different
aetiology compared to that described by Northway et al (1967) when positive pressure
ventilation was a major factor.
1.4.12 Antenatal steroid therapy
While investigating the physiology of parturition, Liggins (1969) was the first to observe the
acceleration of lung maturity following administration of glucocorticoids to fetal lambs.
This observation led to the first randomised-controlled trial of antenatal steroids in humans
(Liggins & Howie 1972). Two hundred and eighty two mothers were enrolled in threatened
preterm labour at 24-37 weeks gestation. Neonatal mortality was reduced from 11.2% in the
control group to 6.0% in the treatment arm, and the incidence of RDS among infants <32
weeks gestation reduced from 69% to 11%.
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Many more trials of antenatal steroids have followed. But despite evidence from these and
several excellent systematic reviews (Sinclair 1995, Crowley 1995) and the NIH Consensus
Conference (1995) obstetricians have been slow to adopt this beneficial treatment. The
reasons behind this were unclear (Crowley 1999).
Antenatal steroids act by triggering surfactant maturation. All components of surfactant are
induced by antenatal steroid therapy (Ballard 1989), and antenatal steroids enhance the
maturation of type II pneumocytes (Snyder et al 1981). There appears to be a synergistic
effect between antenatal steroids and postnatal surfactant (Jobe et al 1993) and protein
leakage into alveoli is diminished (Ikegami et al 1987).
Antenatally endogenous Cortisol levels rise progressively during the last trimester
(Donaldson et al 1991), and appear to parallel the changes in L/S ratio (Murphy et al 1978).
Infants with RDS frequently show an improvement in their lung function after 48-72 hours,
a timing consistent with accelerated surfactant production in response to a stress-mounted
Cortisol surge. Despite this postnatal hydrocortisone failed to show any benefit (Baden et al
1972), suggesting that antenatal influences are more important in determining outcome from
RDS.
The main problem is getting steroids to the "at risk" population in time. Many women do not
reach maternity units in time for the antenatal steroid to be of benefit (Golden et al 1998). In
addition there has been a reluctance of obstetricians to routinely administer steroids in the
face of ruptured membranes (Gardner et al 1997).
The other major question regarding antenatal steroids centres around their effect on fetal
growth, particularly whether more than one course of steroids has a greater impact on long-
term outcome. As a result there is a wide variation in obstetric practice across the country
(Brocklehurst et al 1999).
1.4.13 Antenatal thyrotropin-releasing hormone (TRH) therapy
Liggins was also instrumental in the discovery and development of antenatal thyrotropin-
releasing hormone (TRH) in prevention of RDS. Using preterm lambs, Liggins and his co¬
workers demonstrated an increase in lung phospholipids after antenatal TRH administration
(Schellenberg et al 1988) and that TRH could work synergistically with antenatal steroids
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(Liggins et al 1988).
Since then a number of trials examining TRH, both alone and in conjunction with antenatal
steroids, in a human population have been performed (Morales et al 1989, Ballard et al
1992, Knight et al 1994, The ACTOBAT Study Group 1995, Ballard et al 1998,
Collaborative Santiago Surfactant Group 1998). However in a recent Cochrane meta¬
analysis (Crowther et al 2000), the view was that currently TRH could not be recommended
for clinical practice. The meta-analysis demonstrated neither a reduction in neonatal
mortality nor a reduction in the incidence of chronic lung disease, whereas side-effects were
frequently reported in the mothers.
1.4.14 Antenatal ambroxol
Ambroxol, a metabolite of bromhexine (an anti-histamine used in older children and adults
as an expectorant or mucolytic drug) has been used predominantly in centres across Europe
to promote fetal lung maturation. Animal models had suggested that this drug was a suitable
alternative to antenatal steroids (Egberts et al 1976, Van Petten et al 1978). It appears to
work by causing an increase in the amounts of dipalmitoylphosphatidylcholine (DPPC),
however later work suggests that the increase may be small (Sun et al 1992).
Several studies have examined the effects of ambroxol in a human population. Some of the
studies that have shown benefit have either included mature infants (Wauer et al 1982) or
involved small numbers of infants (Kimya et al 1995). In a later, and larger, trial (Wauer et
al 1992) ambroxol reduced the 28 day incidence of CLD and intraventricular haemorrhage.
Luerti et al (1987) demonstrated that ambroxol may be as effective as antenatal steroids in
singleton pregnancies and may be more beneficial in twin pregnancies. On the other hand
Dani et al (1997) could not demonstrate any benefit in their trial.
Overall it would appear that ambroxol has yet to be shown to be more beneficial that
antenatal steroids. Ambroxol does have one major drawback in comparison to steroids in
that 5 days of treatment are required compared to 2 days for steroids.
1.4.15 Antenatal aminophylline
Animal models had suggested that antepartum administration of aminophylline might be as
effective as antenatal steroids in the prevention of RDS and two randomised trials showed a
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reduction in the incidence of RDS (Hadjigeorgiou et al 1979) and in perinatal mortality
(Granati et al 1984). However later studies suggested that the beneficial effect of
aminophylline can be attributed largely to a combination of accelerated fetal growth and
improved postnatal regulation of breathing rather than a specific influence on the
biochemical and functional maturation of the lung (Cosmi et al 1986). Furthermore concerns
regarding the narrow therapeutic index of aminophylline have led to this therapeutic
approach being abandoned (Papageorgiou & Stern 1986).
1.5 Conclusion & summary
Surfactant deficiency in the neonate manifests clinically as respiratory distress syndrome
(RDS). This was previously known as hyaline membrane disease (HMD) because of the
histopathological findings in affected infants who died. It is a major cause of respiratory
morbidity in infants born before 30 weeks post-conception, leading to both acute and
chronic complications.
There are many antenatal and perinatal influences that affect RDS, but the primary problem
is one of insufficiency and immaturity of surfactant production in affected infants. The
observation of acceleration of lung maturity following administration of glucocorticoids in
preterm lambs by Liggins (1969) led to one of the major therapeutic interventions in
treatment of RDS.
The other therapeutic intervention, exogenous surfactant therapy, although commonplace in
neonatology today, came about because of discoveries that span most of the 20th century.
These are recounted in the next chapter. This discusses early papers leading to the landmark
study of Avery & Mead (1959) that linked surfactant deficiency and RDS; through the
unsuccessful trials in the 1960's of simple surfactants; culminating in the report by Fujiwara
et al (1980) of the first successful use of exogenous surfactant in a neonate.
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Surface tension, surfactant and the lung
2.1 Surface tension in the lung
2.2 Surface tension and the law of Laplace
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2.4 Early trials of exogenous surfactant
2.5 Conclusion
2.1 Surface tension in the lung
It is the presence of a large air-tissue interface in the lungs that leads to tension at that
interface and causes the lung to collapse. This interface occupies an area of 2.8m2 in the
term newborn infant, and increases proportionally to growth so that by adulthood it occupies
75m2 (Dunnill 1962). The area is also affected by the number of alveoli, which number
around 24 x 106 at birth, increasing to 300 x 106 in the adult. There is however wide
variation in alveolar numbers among individuals, related to height and genetic factors
(Dunnill 1962, Angus & Thurlbeck 1972).
Surfactant accumulates at the air-tissue interface. Surfactant reduces the surface tension,
thereby stabilising alveoli and small airways against collapse and atelectasis on expiration
(helping to maintain the residual volume of the lung) and promoting expansion on
inspiration (reducing the work of breathing). Reduction of surface tension is the primary, but
not only, role of surfactant (these roles are discussed, particularly in relation to the
surfactant proteins, in chapter 3).
When alveoli collapse an increasing amount of pressure is required to open them again; this
leads to the genesis of shearing forces at the air-liquid interface within the walls of the
airways causing inflammation and tissue damage. As a result of tissue damage there is
leakage of a pink staining proteinaceous material into the epithelial lining and the airways.
This material forms a "hyaline membrane" and led to the alternative term for RDS of
hyaline membrane disease (or HMD).
2.2 Surface tension and the law of Laplace
The relationship between surface tension, the size of the airspace (alveolus) and the pressure
needed to maintain the shape may be demonstrated using the law of Laplace for thin walled
spheres:
P = 2§ / r
Where: 5 is the surface tension
r is the radius of the bubble
P is the pressure required to maintain a radius of r in the bubble.
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In circumstances where surface tension is high, a higher pressure is required to produce the
same size sphere. Applying this model to the alveolus in the absence of surfactant where the
surface tension is 72 mN/m2, a trans-surface pressure of approximately 28cm H20 is
required to maintain a radius of 50 micrometers. Translated to a human lung this means that
in the absence of surfactant it would be necessary to apply 28cm H20 of positive end
expiratory pressure to maintain an adequate functional residual capacity (Figure 1).
Using the law of Laplace like this is an over-simplification. Because of interconnections in
the interstitium, collapse of one alveolus leads to the expansion of other alveoli in the
vicinity. It is however a useful concept to think in terms of what happens at single alveolar
level and one that is used in the in vitro comparisons of surface tension reduction between
various surfactants (chapter 7).
2.3 Early discoveries of surfactant
The discoveries that led to the development of surfactant and its use in neonatal respiratory
distress syndrome span most of the twentieth century.
In the 1920's the Swiss scientist Kurt von Neergaard demonstrated the importance of
surface tension in the expansion of lungs of newborn infants. His work, entitled "New
notions on a fundamental principle of respiratory mechanics: the retractile force of the
lung, dependent on the surface tension in the alveoli" (von Neergard 1929) was the first to
suggest that surface tension played a role in the lungs. Using dog and pig lungs he
demonstrated that the pressure required to inflate an atelectatic lung was greater if a gas,
such as air or oxygen, was used than if the lung was inflated using saline or another liquid.
von Neergard explained his findings by saying there was surface tension at the air-tissue
interface developing menisci that prevented the air passing into the alveoli: using a liquid
abolished the air-tissue interface. Gruenwald (1946), using lungs from fresh stillborn human
infants and infants who died within three days of birth, repeated this experiment and reached
a similar conclusion.
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Figure 1: The alveolus and the law of Laplace (P = 25 / r)
P
f R \ ( r ij
The pressure (P) required to keep the alveolus of radius r open, is inversely proportional to the radius
(r) and is directly proportional to the surface tension (8). Although the law of Laplace is useful to
understand the relationship between pressure and surface tension, it must be remembered alveoli are
not spherical and are connected to other alveoli and other structures. Collapse of one alveolus will
have an effect on the neighbouring alveoli causing these to expand, which then reduces the tendency to
collapse in the original alveolus.
In this idealised diagram of two alveoli, it can be demonstrated that using the law of Laplace the
pressure required to keep the large alveolus (with radius R) open is less than that required to keep the
small alveolus open. Consequently with a pressure of P in the absence of surfactant there is a tendency
for small alveoli to collapse and larger alveoli to hyperinflate.
Surfactant reduces the surface tension in smaller alveoli to prevent some of the atelectasis that would
otherwise occur. Smaller air sacs are comparatively stable during expiration and are recmited
effectively during inspiration. This implies that alveolar surface tension is not constant but instead
varies as a function of alveolar radius during respiration.
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There followed a number of discoveries regarding alveolar lung fluid, both in terms of its
composition, and in terms of differences between infants who died from RDS and those who
died of other causes. However it was not until much later that Avery & Mead (1959) unified
the various discoveries.
Thannhauser et al (1946) reported that lung fluid contains a high proportion of dipalmityl
lecithin (dipalmitoylphosphatidylcholine or DPPC). However no connection was made
regarding the presence of DPPC and alveolar stabilisation. Later Pattle (1955) was to
demonstrate that alveolar fluid bubbles from cut surfaces of lungs taken from infants dying
of non-respiratory causes shrank and then stabilised for a period of time. The alveolar fluid
bubbles from infants who died after developing RDS were different: these failed to last as
long in a stable state before disintegrating.
Using the Wilhelmy-Langmuir balance to measure surface tension-lowering properties of
surfactant films, Clements (1957) showed that when compressed to a small volume, lung
fluid molecules exerted a high surface pressure preventing further compression. In turn this
meant that surface tension was very much reduced. He and his colleagues also suggested
that the surface tension of surfactant varied according to the compression (Clements et al
1957).
The Enhorning Pulsating-Bubble Surfactometer, developed in the 1960's, offered an
alternative to the Wilhelmy-Langmuir method for analysing surface tension reduction by
pulmonary surfactant (Enhorning et al 1965). This was devised as a model of the alveolus
and used the measured pressure difference across a spherical air bubble of a known radius to
calculate surface tension. The bubble is then pulsated (typically at a speed of 20 cycles per
second) between a maximum and minimum pressure that cause a 50% change in surface
area. It is possible to calculate the surface tension (§) using the law of Laplace (P = 25/r). A
similar surfactometer was devised by Boyle & Mautone (1982) and was used by Scarpelli et
al (1992) to compare different surfactants (chapter 7).
Avery & Mead (1959) are generally credited with the discovery that surfactant deficiency is
central to the pathogenesis of RDS. They also used the Wilhelmy-Langmuir balance. They
found that the surface tension reducing property of surfactant obtained from infants dying
from RDS was less than if the surfactant had been obtained from an infant dying from non-
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respiratory causes. This difference between extracts from the lungs of infants with and
without RDS was not limited to those who died but also those who had respiratory failure
(Reynolds et al 1965).
2.4 Early trials of exogenous surfactant
Following on from the findings of Avery & Mead (1959), and their own earlier work,
Clements and co-workers organised a clinical trial measuring various aspects of lung
function in infants with respiratory distress syndrome. They looked at DPPC as a surfactant
replacement. This was aerosolised into the lungs of the affected infants. The results of the
study were disappointing. Chu et al (1967) reported, "owr findings do not agree well with
the suggestion that the syndrome results from the primary lack ofpulmonary surface-active
material".
The lack of success in this trial and an earlier Canadian trial (Robillard et al 1964) was due
to the use of pure DPPC. It was not realised that DPPC requires other phospholipids in order
to function as a surfactant in humans. DPPC used in these trials simply lacked appropriate
additives to address this problem. Later research found that:
• At body temperature, DPPC is a gelatinous solid (Morley et al 1978).
• Nebulisation of surfactants causes the formation of micelles that do not release
their phospholipids well (Morley et al 1978).
• Pure DPPC requires too long to form a monolayer at the air-liquid interface
(Bangham et al 1979).
• When it does, the monolayer gives a surface tension reading greater than natural
surfactant (Bangham et al 1979).
A later trial of nebulised surfactant involving the addition of phosphatidylglycerol (PG) to
the aerosolised solution of DPPC in a ratio of 1:9 did however produce improvements in gas
exchange of treated infants (Ivey et al 1976). Research into nebulised surfactant still
continues; Dijk et al (1997) suggest that this route lessens the risk of hypotension and
reduced cerebral blood flow seen after intratracheal boluses of surfactant. However Fok et al
(1998) argue that so little surfactant reaches the alveoli after nebulisation that there is no
clinical effect, and hence no effect on blood pressure.
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Despite the lack of success in these early surfactant trials there was increasing evidence that
surfactant deficiency was indeed central to the pathogenesis of respiratory distress
syndrome. Gluck et al (1967) showed DPPC was produced in increasing quantities in the
developing lung and that it was secreted into the alveolar space. King & Clements (1972)
analysing canine surfactant found DPPC is the major component of surfactant lipid.
After the failure of nebulised artificial surfactant in the 1960's work concentrated on finding
other ways to administer surfactant, initially in experimental animals, and later in human
infants. Enhorning & Robertson (1972) reported the first successful exogenous surfactant.
They instilled surfactant, obtained from the alveolar washings of adult rabbits, in the trachea
of prematurely delivered rabbit pups and measured airway pressures and volumes. Treating
the rabbits with this surfactant produced pressure-volume curves that resembled those
obtained from mature lungs.
Enhorning et al (1975) later showed deposition of small volumes of adult rabbit surfactant
in the pharynx of premature rabbit pups improved both survival and lung expansion (shown
radiologically). Twenty-one of 26 treated rabbits survived compared with only 4 of 23
controls. Of the four surviving controls there was poor lung expansion in two animals
whereas in the surfactant treated group lung expansion was generally good.
The first successful use of exogenous surfactant therapy in human infants was reported by
Fujiwara et al (1980). A modified bovine lung extract made from minced lung tissue was
administered endotracheally to preterm infants with RDS between 4 and 33 hours of age
(mean age at administration 12 hours). All ten infants in this uncontrolled trial showed
improved oxygenation and a shortened duration of radiologically apparent RDS compared to
untreated historical controls. Eight of the ten infants survived. Of the deaths, one occurred at
36 hours of age, the other at 30 days of age (due to chronic lung disease and sepsis).
2.5 Conclusion
The 20th century has seen many advances in the understanding of surfactant composition and
how the components interact to give surfactant its wide range of biological functions. The
composition and function of the components of surfactant are discussed in chapter 3. The
development of exogenous surfactants as therapeutic agents arose following the work of
Avery & Mead (1959) that linked surfactant deficiency and RDS and although Fujiwara et
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al (1980) published the first report of successful endogenous surfactant in a neonatal
population several groups of investigators had independently developed exogenous
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Studies of surfactant composition in reptiles (Daniels et al 1995) and air-breathing fish
(Smits et al 1994) show some similarities. Surfactants in these animals are, like mammalian
surfactant, phospholipid-based and suggest a common evolutionary pathway. The exact
phospholipids however differ, reptiles having phosphatidylcholine (DPPC) but no
phosphatidylglycerol (PG), whereas the air-breathing fish have higher cholesterol contents.
Lung surfactant is very similar but not identical across several mammalian species
(Possmayer et al 1984). This has allowed researchers to extrapolate their findings from
animal models of RDS to the human infant.
There are two main fractions of surfactant: lipids and surfactant-specific proteins. In mature
human surfactant lipids account for approximately 90%, and of these the majority are
phospholipids. This chapter examines the composition and functions of both these surfactant
components, however it begins by looking at the cells that are responsible for the production
of surfactant within the lungs - the type II pneumocyte.
3.1 The type II pneumocyte
Macklin (1954) postulated that these cells, which he called "granular pneumocytes",
secreted material that reduced the surface tension at the air-surface interface, enhanced the
clearance of inhaled particles, was bacteriostatic and helped in the prevention of
transudation of proteinaceous fluids into the alveolus. Although he did not realise it at the
time these are some of the functions of surfactant as they are currently understood.
The major function of type II pneumocytes is the synthesis and secretion of surfactant.
Lamellar bodies of type II cells contain all the lipid and protein components of surfactant
(Barritussio et al 1994). There is a constant re-cycling process involving type II cells
involving both the intracellular (lamellar bodies) and extracellular pools of surfactant
(Hallman et al 1981).
A lesser known function of type II cells is that of regeneration of a continuous epithelium
after alveolar injury. Type II cell hyperplasia occurs after a variety of injuries, all of which
damage type I pneumocytes (Adamson & Bowden 1974, Evans et al 1975). Type I cells are
larger than type II cells (810 pm3 versus 340pm3) and also have a greater (4000 pm2 versus
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70 pm2) luminal surface area (Weibel 1974). This makes the type I cell ideal for gas
exchange but very vulnerable to damage. In addition type I cells are devoid of ribosomes
and mitochondria which are necessary for most cellular repair processes.
3.2 Surfactant phospholipids
Phosphatidylcholine is the most abundant phospholipid and comprises 70-80% of the total
amount of lipid in surfactant (Batenburg 1992). Most phosphatidylcholine is saturated with
one or two palmitic acid chains. The disaturated form DPPC accounts for 54.7 ± 3.9% of
mature surfactant in infants without RDS (Poets et al 1997).
Phosphatidylglycerol (PG) is the next most abundant lipid in mature human surfactant,
accounting for approximately 8% of the phospholipid (Poets et al 1997). This is a relatively
high concentration of this substance that is otherwise only present in tissues as a low
concentration substrate for cardiolipin (diphosphatidylglycerol) production. Cardiolipins are
phospholipids that are found throughout the body, especially in muscles and the heart
(Hatch 1996). Cardiolipin is localised primarily in the mitochondria and appears to be
essential for the function of several enzymes of oxidative phosphorylation (Hoch 1992).
Other surfactant phospholipids are phosphatidylethanolamine (5% of phospholipids),
phosphatidylinositol (3%), and small quantities of sphingomyelin, phosphatidylserine and
lysophosphatidylcholine (Goerke 1974). Cholesterol accounts for 2.4% of surfactant
composition by weight (Possmayer et al 1984). The phospholipid composition of the
intracellular pool of surfactant is very similar to that in the extracellular compartment (Jobe
et al 1980, Oulton et al 1986, Adachi et al 1989). This would suggest that there are no major
alterations of the composition of the surfactant once it is extruded into the alveolus from the
type II pneumocyte.
There is general consensus that DPPC is the primary surface-active component (Ikegami et
al 1979, Batenburg 1992). It is thought to exert its physiological function by lowering
surface tension at the end of expiration to values <10 mN/m2 (Clements 1977). Pure DPPC
does not adsorb rapidly to the air-tissue interface at physiological temperatures (Notter et al
1982, King & Clements 1972) nor does it spread well (Bangham et al 1979, Notter et al
1980) and the other phospholipids may improve these functions in vivo.
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The role of other phospholipids is less certain. Unsaturated phosphatidylcholine may aid in
spreading and rapid adsorption at the air-tissue interface (King & Clements 1972). It is
suggested that the DPPC component of surfactant changes throughout each compression and
expansion cycle (Holm et al 1996) and that the more "fluid" components (predominantly
unsaturated phosphatidylcholine and other phospholipids) are preferentially "squeezed out"
to further reduce surface tension at small volumes (Notter & Finkelstein 1984, Yu &
Possmayer 1992a). The surfactant proteins SP-B and SP-C are involved in the cyclical
changes of phospholipid concentrations that occur during the respiratory cycle, although the
nature of the involvement has not been fully explained (Taneva & Keough 1994, Putz et al
1999).
The anionic phospholipids, phosphatidylinositol (PI) and phosphatidylglycerol (PG), appear
to have similar functions but their quantitative contributions to the surface active function of
surfactant is unclear (Beppu et al 1983, Hallman et al 1985a). Low PG levels are found in
immature surfactant of humans (Hallman et al 1976) and rats (Egberts & Noort 1986).
Newborn term rabbits have very little PG, this appears shortly after birth, and coincides with
a decline in the amount of PI, yet these rabbits do not get RDS (Hallman & Gluck 1980).
In preterm human infants PI is produced in preference to PG, and PG levels increase with
increasing maturity (Hallman & Gluck 1976). The situation is not uniform among all
species. Levels of PI remain high in mature surfactant of the rhesus monkey (Egberts et al
1987), guinea pig (Khan et al 1985) and cat (Shelley et al 1984). Despite the differences
with regards to the relative amounts PI and PG levels, surface tension-lowering properties of
surfactants in vitro containing one but not the other are similar (Hallman et al 1985a).
3.3 Surfactant-associated proteins
Four surfactant-associated proteins have been described. These can be usefully divided into
two groups: the hydrophilic surfactant proteins SP-A and SP-D, and the hydrophobic
surfactant proteins SP-B and SP-C. These are described in detail below.
The importance of these proteins is probably best emphasised by the lethal nature of SP-B
deficiency (Nogee et al 1994, Ball et al 1995) and that experimental knockout of the SP-B
gene in transgenic mice produces respiratory distress syndrome (Clark et al 1995).
Nonetheless the currently available synthetic surfactants do not contain any surfactant
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proteins, yet are seen to be clinically effective in preterm infants. The endogenous surfactant
that is present, albeit in smaller amounts than in term infants, presumably supplements the
exogenous surfactant and enhances the surface-active properties in vivo (Holm 1993).
To explore the interaction between the biological system and exogenous surfactant Ikegami
et al (1993) instilled Exosurf Survanta and a non-commercial protein-free surfactant in the
lungs of preterm lambs. After 5 hours surfactant was recovered by lavage and analysed. It
was composed of a mixture of exogenous and endogenous surfactant. In all cases, recovered
surfactant was more effective when instilled in experimental rabbits compared with the
original surfactant. This reinforces the notion that endogenous surfactant systems need to be
taken into account when studying experimental therapeutics, for example in comparisons
between different surfactants.
Although there is great structural and compositional similarity between surfactants of
different species there remains the potential for immunological reactions when giving
exogenous surfactant to preterm infants (Merritt et al 1988, Strayer et al 1989, Strayer &
Robertson 1992). However to date there has been no evidence of disease that can be
attributed to the surfactant-anti-surfactant complexes that are known to be formed (Strayer et
al 1986).
3.3.1 Surfactant-associated protein A (SP-A)
SP-A was the first surfactant-associated protein to be discovered (King & Clements 1972)
but it was not isolated until much later (Phizackerley et al 1979). It is the most abundant of
the surfactant proteins accounting for approximately 50% (Sueishi & Benson 1981).
SP-A and SP-D are members of the family of C-type (calcium-dependent) lectins, or
collectins (collagenous lectins). The collectins are a group of soluble multimeric lectins,
which contain collagenous segments, and resemble the complement protein Clq in aspects
of their structures and functions. This group of proteins, which includes mannose binding
protein, SP-A, SP-D, conglutinin and CL-43, are known to act as opsonins in various
circumstances, and are likely to have roles in innate immunity (Malhotra et al 1994).
The common structural feature of the collectins is that they are composed of an elongated
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collagen-like part with a globular head containing a carbohydrate recognition domain. The
genes for the human collectins are found in a cluster on chromosome 10 (Crouch et al 1993,
Fisher et al 1987). There are two functional SP-A genes (Katyal et al 1992) and both appear
to be required for the formation ofmature SP-A (Voss et al 1991). SP-A can be detected in
endogenous surfactant from as early as 16 weeks gestation (Ballard et al 1986) and however
its levels begin to increase proportionate to gestation after 28 weeks (Batenburg & Hallman
1990).
SP-A is a large octadecameric protein with a total molecular weight of about 650 kDa (Voss
et al 1988). It is composed of a hexameric structure where each monomer is composed of
three polypeptide chains. There is a short cysteine-containing part at the N-terminus that is
involved in interchain disulphide bonding (Ross et al 1991). This is connected to a collagen¬
like segment, a short neck region and then the carbohydrate recognition domain. The
carbohydrate recognition domain contains two interchain disulphide bridges (Haagsman et
al 1989) forming two disulphide-dependent loops. The octadecameric SP-A molecule is
about 20 nm from the N-terminus to the peripheral parts of the carbohydrate recognition
domain, and these are separated by up to 28 nm (Voss et al 1988).
The putative functions of SP-A are summarised in Table 1. SP-A is not directly involved in
the surface tension lowering role of surfactant, but it may be involved in the regulation of
this (Schurch et al 1992). Although SP-A does not appear to have a function in the
spreading and adsorption of the monolayer, there is evidence that it is important in the
formation of tubular myelin (de Mello et al 1993). Tubular myelin is a distinctive cross-
hatched bilayer microstructure that is seen when aqueous suspensions of surfactant are
examined using electron microscopy. It is formed by interaction between phospholipids and
surfactant associated proteins. Tubular myelin is thought to give the maximal adsorption of
endogenous surfactant to the air-liquid interface (Magoon et al 1983). The formation of
tubular myelin is also thought to be central to the regulation of lipid insertion into the
monolayer. These properties of SP-A are dependent on the presence of calcium (Haagsman
et al 1990).
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Table 1: Summary of the putative functions of surfactant-associated protein A (SP-A).
Formation of tubular myelin
Regulation of phospholipid insertion into the surfactant monolayer
Modulation of uptake and secretion of phospholipids by type II
pneumocytes
Activation of alveolar macrophages
Binding and clearance of bacteria
Binding and clearance of viruses
Chemotactic stimulation of alveolar macrophages
Table 2: Summary of the putative functions of surfactant-associated protein D (SP-D).
Activation of alveolar macrophages
Agglutination of bacteria
Protection again non-bacterial micro-organisms and viruses
Regulation of phospholipid homeostasis
Role in phosphatidylinositol metabolism
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SP-A is located at the corners of the structural lattice of tubular myelin (Voorhout et al
1991) and the formation of the lattice is dependent on SP-A (Suzuki et al 1989). Transgenic
mice with SP-A deficiency showed normal respiratory function and survival but no tubular
myelin (Korfhagen et al 1996).
The addition of SP-A to hydrophobic surfactant enhances in vitro phospholipid adsorption
(Chung et al 1989); in particular SP-A has a high affinity for DPPC (Kuroki & Akino 1991).
Addition of SP-A to Curosurf did not improve the in vitro biophysical surface tension
lowering properties, however when this modified surfactant was given to experimental
rabbits in a dose of lOOmg/kg there were improvements in the lung-thorax compliance that
were only seen when twice the dose of non-modified surfactant was used (Sun et al 1997).
Clearly there is some interaction between SP-A and the surface-active components of
surfactant that cannot be demonstrated in an in vitro setting (Hallman et al 1991).
Tubular myelin and SP-A may be important in preventing the inactivation of surfactant by
serum proteins. SP-A has been shown to reverse the inhibition of surface activity of
phospholipids in vitro (Cockshutt et al 1990). Curosurfwith added SP-A was more resistant
to inactivation by meconium, fibrinogen, albumin and serum proteins than unmodified
Curosurf (Sun et al 1997). Bruni et al (1996), comparing Survanta, Exosurf and a porcine-
derived surfactant containing surfactant proteins SP-A, SP-B and SP-C, found Survanta and
Exosurf were inactivated to a greater extent after exposure to human serum than the
porcine-derived surfactant.
It appears that SP-A also has a role in the modulation of uptake and secretion of
phospholipids by type II cells. SP-A binds specifically to these cells (Kuroki et al 1988) and
has been shown to inhibit secretion of phosphatidylcholine from them (Rice et al 1987). Re¬
uptake of phospholipids in isolated type II cells also appears to be regulated by SP-A (Bates
et al 1994) although it appears that this process may be dependent on local concentrations of
phospholipids and SP-A than on a specific phospholipid receptor on the type II cell
(Haagsman et al 1993). Clearance of surfactant is also undertaken by alveolar macrophages
and this too is mediated by SP-A (Wright & Youmans 1995).
That SP-A is involved in lung defence is demonstrated by the fact human SP-A obtained
from lavage of lungs affected by alveolar proteinosis enhances the host defences of rat
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alveolar macrophages (van Iwaarden et al 1990). SP-A surface interactions are also required
to release oxygen radicals from the alveolar macrophages (Weissbach et al 1994) and SP-A
has also been shown to act as a chemotactic factor for alveolar macrophages (Wright &
Youmans 1995).
The role of SP-A in host defence is further shown by its ability bind to some bacterial
pathogens that infect lung tissue. SP-A acts as an opsonin through the carbohydrate binding
region. The opsonisation process is selective; Staphylococcus aureus is opsonised but not
Streptococcus pneumoniae (McNeely & Coonrod 1993). In the absence of opsonisation SP-
A also potentiates the antimicrobial activity of the alveolar macrophages (Kremlev et al
1994) through the stimulation of cytokines modulating inflammatory cell function in the
lung and immunoglobulin production (Kremlev & Phelps 1994). Opsonisation of viruses has
also been reported (van Iwaarden et al 1991, Benne et al 1995).
SP-A may also be protective against chronic lung disease as baboons with hyperoxic and
infection induced chronic lung disease were found to have a relative SP-A deficiency (King
et al 1995).
3.3.2 Surfactant -associated protein D (SP-D)
SP-D was the most recently identified of the surfactant-associated proteins. There has been
some debate whether it should be considered a true surfactant protein or not; it has no
known role in lung surfactant biophysics although it plays an important role in lung defence.
About 70% of the SP-D is recovered from the supernatant of lavaged lung surfactant
whereas the other proteins are recovered from the lipid-containing surfactant pellet (Kuroki
et al 1991). SP-D has also been detected (along with SP-A and SP-B) in gastric mucosa,
which is also known to secrete a surface-active material (Eliakim et al 1989, Eliakim et al
1991, Fisher & Mason 1995).
SP-D is a C-type lectin like SP-A, and shares many structural similarities. The gene for SP-
D is found on chromosome 10 (Crouch et al 1993). Mature human SP-D contains 355 amino
acids and weighs 43 kDa (Lu et al 1993). Electron microscopy suggests SP-D has a
homogeneous quaternary structure in the form of a cross (Crouch et al 1994). Four identical
rods of triple collagen-like helices emanate from the central point and terminate in the
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carbohydrate recognition domain (Lu et al 1993). Thus SP-D is essentially a tetramer
consisting of twelve polypeptide chains with a total molecular mass of 630 kDa.
The functions of SP-D within the surfactant system have not been fully elucidated. It does
not seem to have a role in the surface tension lowering effect of surfactant and most of its
putative functions relate to lung defence (Table 2).
It has been demonstrated that SP-D binds to the lipopolysaccharides of several bacteria
(Escherichia coli, Klebsiella pneumonia, Salmonella paratyphi and Pseudomonas
aeruginosa) but not to Staphylococcus aureus (Kuan et al 1992, Lim et al 1994). The shape
of SP-D gives it the ideal configuration for binding to bacteria with the carbohydrate
recognition domains spanning a long distance (Kuan et al 1992). It can also bind to alveolar
macrophages and induce the production of free oxygen radicals (Miyamura et al 1994).
Evidence that SP-D may play a role in non-bacterial lung defence has come from patients
suffering from human immunodeficiency virus (HIV) infection where pulmonary surfactant
abnormalities can be found. These are worsened by co-infection with Pneumocystis carinii
infection (Escamilla et al 1992). During P. carinii infection SP-D accumulates in the lung
(Limper et al 1994), and augments the binding of the P. carinii organism to alveolar
macrophages (O'Riordan et al 1995).
SP-D also binds with phosphatidylinositol in a calcium-dependent manner (Ogasawara et al
1992). The importance of this interaction is unclear, in mature human surfactant
phosphatidylinositol accounts for only 3% of the phospholipids. SP-D appears to play a role
in the homeostasis of surfactant phospholipid; transgenic SP-D (-/-) mice have abnormal
accumulations of surfactant phospholipid (Korfhagen et al 1998).
3.3.3 Surfactant-associated protein B (SP-B)
Phizackerley et al (1979) were the first to describe the presence of hydrophobic surfactant
proteins in lung surfactant. Currently two proteins are known, SP-B and SP-C. Their
structure and functions have been investigated in detail. They are soluble in organic solvents
such as chloroform-methanol (Perez-Gil et al 1993) and therefore are retained in the
extraction processes of the animal-derived surfactants (chapter 4).
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Both proteins are synthesised within the type II alveolar cells and undergo extensive
intracellular modification because of their hydrophobic nature (Voorhout et al 1992, Beers
& Lomax 1995). The close functional relationship of SP-B with SP-C is demonstrated by
abnormal functioning of SP-C in congenital SP-B deficiency (Vorbroker et al 1995). The
genes for SP-B are found on chromosome 2 (Pilot-Matias et al 1989) and SP-B deficiency
may be due to a one of a number of SP-B gene mutations (Nogee et al 1994).
SP-B is a small protein of 79 amino acids with a high cysteine content (Curstedt et al 1990).
The cysteine residues form a unique disulphide pattern of three intermolecular bonds and
one intermolecular bond. These stabilise the protein and form a dimeric form of SP-B
(Johansson et al 1991).
The most important function of SP-B is the enhancement of the surface tension reducing
properties of the surfactant lipids, but other functions have been described (Table 3). SP-B
greatly enhances the formation of a stable surface film (Oosterlaken-Dijksterhuis et al
1991a, Oosterlaken-Dijksterhuis et al 1991b). Positive charges within the SP-B protein are
essential for this (Cochrane & Revak 1991) as it interacts with the negatively charged PG
promoting adsorption of the phospholipids (Yu & Possmayer 1992b).
SP-B, together with SP-A, is necessary for the formation of tubular myelin (Poulain et al
1992). In SP-B deficiency there is an abundance of alveolar multilamellar structures but no
tubular myelin (de Mello et al 1994). It is thought that SP-B promotes the formation of
contact sites between bilayers in tubular myelin enabling flow of phospholipids between
bilayers. SP-B may also protect against the inactivation of surfactant by serum proteins
(Amirkhanian et al 1993).
Addition of SP-B increases the inter- and intra-molecular ordering of the phospholipid
membranes (Cochrane & Revak 1991). A single monomeric SP-B molecule influences 50-
70 phospholipid molecules (Shiffer et al 1993).
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Table 3: Summary of the putative functions of surfactant-associated protein B (SP-B).
Promotion ofphospholipid insertion into the air-tissue (liquid) interface
Formation of tubular myelin
Protection from inactivation by serum proteins
Influence on molecular ordering of phospholipid monolayer
Table 4: Summary of the putative functions of surfactant-associated protein C (SP-C).
Promotion ofphospholipid insertion into the air-tissue (liquid) interface
Alteration of proportion of phospholipids components to alter surface
tension lowering properties at smaller volumes
Regulation of phospholipid ordering
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3.3.4 Surfactant-associated protein C (SP-C)
SP-C was the second hydrophobic surfactant protein to be identified. It is a small
polypeptide of 35 amino acid residues. There are two genes for SP-C that can be found on
chromosome 8 (Glasser et al 1988). It is highly hydrophobic due to the high content of
valine residues (Johansson et al 1994a). These are present in two thirds of the molecule that
forms a regular a-helix (Johansson et al 1994b), the long axis of this helix being orientated
parallel to the acyl chains of the phospholipids (Vandenbussche et al 1992).
Both monomeric and dimeric forms of SP-C can be found in surfactant. The properties of
the two forms are probably different (Karaborni et al 1994), although the exact role each
form plays has not been clarified.
SP-C functions are broadly similar to SP-B (Table 4). Its major role is the stimulation of
insertion of the phospholipids into the air-tissue interface in a calcium-dependent manner
(Oosterlaken-Dijksterhuis et al 1991a). This process is preceded by the SP-C dependent
binding of phospholipid to the monolayer (Oosterlaken-Dijksterhuis et al 1991b). At high
pressures SP-C seems to be squeezed out of the monolayer (Keough et al 1994) and when
this occurs each molecule of SP-C takes with it 8-10 phosphatidylcholine molecules. This
raises the possibility that SP-C may alter the composition of the monolayer and thus alters
surface tension according to volume (Taneva & Keough 1994).
In mixtures of SP-C and phospholipid the protein alters the arrangement of the lipid bilayers
(Williams et al 1991), and monolayers (Perez-Gil et al 1992). This probably helps the
stabilisation of the phospholipids within the alveolus.
3.4 Other proteins/polypeptides in surfactant
Recently three heptapeptides have been isolated from ovine surfactant (Brogden et al 1996).
These contain a core of several aspartate residues and are bactericidal to Pasteurella
haemolytica. However the synthesis and exact functions of these small peptides have yet to
be delineated although it is suspected that they interact with other lung defences (Brogden et
al 1998). Similar polypeptides have been found to be present in porcine surfactant. These
are the prophenins and are derivatives of the cathelicidin family of antibacterial peptides
(Wang et al 1999). Interestingly these polypeptides are preserved by the usual methods for
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extracting the animal-derived lung surfactants and may be responsible for some of the
antibacterial action seen with some exogenous preparations (Sherman et al 1994).
3.5 Conclusion
Endogenous surfactant is a complex mixture of substances and current understanding of it is
incomplete. Surfactant has a role beyond reduction of surface tension. Knowledge of the
role of the surfactant-associated proteins is increasing, and it may be possible that they have
important roles to play in the prevention of chronic lung disease (King et al 1995).
Exogenous surfactant replacements are by contrast very simple, especially the synthetic
surfactants ALEC and Exosurf. It is unlikely that current exogenous surfactants replicate the
full range of properties seen with endogenous surfactant. What appears to be more likely is
that exogenous surfactant supplements the components of the endogenous surfactant.
The various surfactant preparations that have been reported in the literature are summarised
in chapter 4, and those that have become available commercially in the United Kingdom









The work by Fujiwara et al (1980) had demonstrated that exogenous surfactant replacement
could produce beneficial improvements in infants with RDS. During the early 1980's several
groups of researchers developed exogenous surfactants and published their results.
Surfactants can be classified as those of animal or human origin ("natural" surfactant
extracts) or those that are wholly synthetic (Table 5).
4.1 Extracts of naturally-occurring surfactants
The modified bovine lung surfactant used by Fujiwara and co-workers has undergone
several modifications since the original report and has been developed for clinical use as a
lyophilised powder called Surfactant TA/Surfacten (Tokyo Tanabe, Tokyo, Japan). The
surfactant extract is removed from finely ground bovine lung through a series of differential
centrifugation and flotation steps. Neutral lipids (predominantly cholesterol) are removed by
using ethyl acetate. The surfactant is then extracted using chloroform-methanol. This lung
surfactant extract is then supplemented with synthetic phospholipids to give a final product
that contains approximately 84% phospholipids, 7% tripalmitin, 8% palmitic acid and 1%
protein (Fujiwara & Robertson 1992). This supplemented surfactant extract is then sterilised
by high pressure filtration and lyophilised. The lyophilised Surfactant TA is reconstituted
prior to use in saline to give a concentration of 30 mg/ml of phospholipids.
Following the report by Fujiwara et al (1980) Drs M Avery and W Taeusch visited Japan
and took samples of Surfactant TA back with them to the United States of America.
Following this Surfactant TA became available more widely as a result of licensing
agreement between Tokyo Tanabe and Abbott Laboratories under the name Survanta
(beractant, Abbott Laboratories, Chicago, USA). It was launched in the United Kingdom in
1993. Both Surfactant TA and Survanta are made in the same way and are similar in
composition. It is important to note that both have additional phospholipids added after the
extraction process thus they are essentially a "modified natural-derived surfactant" rather
than a "natural surfactant". The only differences between Surfactant TA and Survanta are
that the latter is available as a suspension of 25 mg/ml (and not 30mg/ml) of phospholipids
and undergoes a terminal autoclave sterilisation process.
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Table5:Classificationofexogenousur actantbyi in. ALEC Exosurf Aposurf Turfsurf Surfaxin(KL4) Venticute(rSP-C)
Survanta SurfactantTA Curosurf SurfactantCK
Infasurf BovineLu g Extract Surfactant (bLES) Alveofact
SF-RI 1 (Alveofact; Boehringer, Ingelheim, Germany) is another bovine surfactant extract. It
was developed and tested in mainland Europe (Gortner et al 1990a, Gortner et al 1990b). It
differs from beractant in that it is obtained lavage of intact rather than minced cow lungs.
Nonetheless chloroform-methanol extraction features in its manufacturing process. It
consists of approximately 99% phospholipids and neutral lipids (including 4% cholesterol)
and 1% surfactant associated proteins SP-B and SP-C.
Two calf lung surfactant extract (CLSE) preparations have been developed. The first called
Infasurf (Forrest Pharmaceuticals, St Louis, USA) was developed in the United States
(Notter et al 1985). Infasurf is lavaged from the lungs of freshly killed calves and then
extracted using chloroform-methanol. There is some variation in the composition of
different batches of Infasurf and as a result reports of the composition do vary. A
representative composition (expressed as a percentage of dry weight) is phospholipids 94%
(of which 79% is phosphatidylcholine [63.2% DPPC] and 6% phosphatidylglycerol),
cholesterol and cholesterol esters 4% and surfactant associated proteins SP-B and SP-C 1%
(Kendig et al 1989).
The other calf lung surfactant extract was developed in Canada. Its use was first reported by
Smyth et al (1983) and later in a randomised clinical trial by Enhorning et al (1985). It is not
available currently in the United Kingdom, but has been commercially developed in Canada
by bLES Biochemicals Inc. (Ontario, Canada) and marketed under the name bLES (bovine
lipid extract surfactant). It has recently been compared to Exosurf in a randomised trial
(Peliowski et al 1998). Like Alveofact, bLES is a chloroform-methanol extract of surfactant
isolated after centrifugation of lung lavage from intact cows lungs. However an addition
extraction step using acetone is used to reduce the amounts of cholesterol and other neutral
lipids. After this acetone extraction step, bLES contains 98-99% phospholipids (79% of
which is phosphatidylcholine) and 1% surfactant associated proteins SP-B and SP-C.
Poractant (Curosurf Chiesi Farmaceutici S.p.A., Parma, Italy) has also been widely studied;
this was developed in Europe and is isolated from minced porcine lungs by a process of
washing, chloroform-methanol extraction and liquid gel chromatography (Noack et al 1987).
Poractant contains 99% polar phospholipids and 1% surfactant-associated protein. Pursuant
to a license agreement in 1991, Ares-Serono became the exclusive European licensee for
Curosurf except in Italy where Chiesi markets the product itself. The composition of
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Curosurf is shown more fully in chapter 5. It contains a higher percentage of tissue-derived
phophatidylethanolamine and sphingomyelin, and less phosphatidylcholine than lavaged
surfactant extracts.
A chloroform-methanol extract of lavaged porcine lung, surfactant CK, was one of the first
surfactants to be used clinically. It was shown to have beneficial effects on lung function
when administered to preterm infants in uncontrolled studies in the early 1980's (Kobayashi
et al 1981, Nohara et al 1983). It has never been developed commercially.
A homologous (human) surfactant has also been developed and tested (Hallman et al 1983,
Hallman et al 1985b, Merritt et al 1986, Merritt et al 1991). This is derived from term
amniotic fluid, which contains considerable amounts of surfactant. Amniotic fluid is
collected and processed in a sterile fashion with the active surfactant fraction being obtained
through density gradient separation and centrifugation. The final preparation contains 80-
83% phospholipids and 5% surfactant-associated protein (Hallman et al 1983). This material
currently represents the only surfactant replacement therapy of human origin and contains
all the surfactant-associated proteins. The donors are tested to ensure human viral agents are
not transmitted in the preparation. The major disadvantage of this type of surfactant is the
difficulty in harvesting enough for widespread utilisation. Uncontaminated amniotic fluid
from 100 births is required to make just 1 gram of surfactant phospholipids (Robertson
1987).
4.2 Synthetic surfactants
Pumactant {Artificial Lung Expanding Compound or ALEC; Britannia Pharmaceuticals,
UK) is a synthetic surfactant containing only the phospholipids, DPPC and PG. It was
developed and tested in the United Kingdom (Bangham et al 1984, Morley et al 1988, Ten
Centre Study Group 1987). It is discussed in greater detail in chapter 5.
Colfosceril {Exosurf neonatal, Burroughs Wellcome Co, California, USA) another
synthetic surfactant was developed in America by John Clements and co-workers. It is
composed of DPPC (84.5%), with hexadecanol (9.5%) and tyloxapol (6%) added to
facilitate dispersion within the lung. Exosurf has been widely tested in North America.
These early trials are discussed in detail in chapter 5.
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Turfsurf or the "Belfast surfactant" was reported (Halliday et al 1984). This was a mixture
of DPPC and high density lipoproteins in a ratio of 10:1. It has not been developed
commercially and is no longer in clinical use.
Aposurf was reported in a comparison with two porcine lung surfactant extracts (of which
one was Curosurf) in a rabbit model of RDS. Aposurfwas "reconstituted" from isolated low
molecular weight apoproteins, synthetic DPPC and dipalmitoylphosphatidylglycerol
(DPPG). It was found not to be as effective in the animal model as the natural surfactant
extracts and has not been made commercially (Robertson et al 1988).
A recent development in synthetic surfactants, Surfaxin (KL4 or lucinactant, Discovery
Laboratories, Inc. Pennsylvania, USA.) has been reported (Revak et al 1996, Cochrane et al
1996) but has undergone only phase I and II clinical trials. KL4 refers to the 21 amino acid
polypeptide sequence of lysine (K) and leucine (L) in a synthetic peptide that resembles the
periodic pattern of hydrophobic and hydrophilic residues found in the N-terminal part of
surfactant-associated protein B (SP-B) (Gustafsson et al 1996). KL4 is added to
phospholipids (DPPC, palmitoyloleoyl phosphatidylglycerol and palmitic acid). This
synthetic peptide forms a transmembrane a-helix in surfactant-like lipids and like SP-B
accelerates the spreading of the surfactant.
With improvements in recombinant technology it has become possible to manufacture
synthetic versions of SP-C. The most widely studied preparation contains a recombinant 34
amino acid analogue of human SP-C (Byk Gulden Pharmaceutical, Konstanz, Germany).
Three amino acids differ in this analogue compared to human SP-C - phenylalanine is
substituted for cysteine in positions 4 and 5, and isoleucine for methionine in position 32.
The rSP-C is added to phospholipids (DPPC, palmitoyloleoyl phosphatidylglycerol and
palmitic acid) to give 2% by weight in the final preparation. This surfactant has been shown
to be as effective as the current animal-derived surfactants in a rat model of ARDS (Hafner
et al 1998). A second recombinant SP-C that does not have the amino acid substitutions is
also under investigation for clinical use, this is sometimes designated rSP-C(Cys)2.
The major distinguishing feature between natural (animal- or human-derived) and synthetic
surfactants is the presence of surfactant-associated proteins in the natural products. To some
extent the synthetic peptide in Surfaxin and the recombinant SP-C in rSP-C surfactant
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mimic the structure and function of hydrophobic surfactant proteins. All animal-derived
surfactants contain SP-B and SP-C. Human amniotic fluid-derived surfactant contains all the
surfactant-associated proteins (SP-A, SP-B, SP-C and SP-D).
4.3 Conclusion
Several exogenous surfactant preparations have been developed and available commercially.
Early placebo controlled trials (those relating to the four surfactants available in the United
Kingdom are discussed in greater detail in chapter 5) showed surfactant therapy reduces
neonatal mortality and early respiratory morbidity. Nationally a significant reduction in
neonatal mortality in North America was attributed to the widespread introduction in
surfactant at the beginning of the 1990s (Schoendorf & Kiely 1997). Nonetheless there are
several outstanding questions regarding the use of surfactant therapy in neonates:
1. Which surfactant is best?
The main argument here revolves around whether animal-derived surfactants that
more closely resemble human surfactant offer any advantages over synthetic
surfactants. This question was first asked in the early 1990s and despite several
large randomised controlled trials comparing animal-derived and synthetic products
(reviewed in chapter 8), and meta-analyses of these trials (Halliday 1996, Soil
1999c), a clear answer has yet to emerge. However these trials between animal-
derived and synthetic surfactants concentrated on the exogenous surfactants that are
in widespread use in North America (namely Survanta or Infasurf against
Exosurf), whilst the market leaders for synthetic and animal-derived surfactants in
the United Kingdom are ALEC and Curosurf.
2. How much surfactant should be given?
In clinical trials of surfactant the dose of phospholipids used varies from as little as
25 mg irrespective of birth weight (Morley et al 1981) to 200 mg/kg (Collaborative
European Multicenter Study Group 1988, Collaborative European Multicentre
Study Group 1991, Bevilacqua et al 1993, Halliday et al 1993). These doses have
very little scientific basis, although as research in surfactant and surfactant
deficiency progressed it has become evident that a term infant who has been allowed
to adapt to extra-uterine life has a surfactant pool size of approximately 100 mg/kg
(Jackson et al 1986). Although there is some scientific basis for the dose of
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surfactants used (most use a phospholipid dose of lOOmg/kg), only three clinical
trials compare different doses. These are reviewed in chapter 6.
3. When should surfactant be given?
Evidence has emerged that early or prophylactic administration of surfactant is more
efficacious than treatment given once RDS has become established. Evidence from
animal studies and clinical trials is examined in chapter 6. It is becoming clearer that
earlier treatment with surfactant, whether given prophylactically to every infant at
risk of RDS or as early rescue therapy in those showing clinical signs of RDS, is
associated with a better outcome in terms of mortality and short-term respiratory
morbidity (Morley et al 1997, Soil & Morley 1999, Yost & Soli 1999).
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There are currently four exogenous surfactant preparations available commercially in the
United Kingdom - ALEC (Britannia Pharmaceuticals Ltd.), Curosurf (marketed by Serono
Laboratories Ltd. pursuant to a licensing agreement with Chiesi Farmaceutici SpA. of Italy),
Exosurf (Wellcome Laboratories) and Survanta (Abbott Laboratories). These surfactants
vary widely in their constituents (Table 6).
This chapter traces the development of each of these surfactants and the early trials that led
to their widespread acceptance on neonatal units. The placebo-controlled trials of each
surfactant are analysed in meta-analyses to give some idea of the benefits that may be
expected with each surfactant.
5.1 Artificial Lung Expanding Compound (ALEC /
pumactant) Britannia Pharmaceuticals
5.1.1 Development and early trials ofALEC
ALEC is a synthetic surfactant developed in Cambridge, England during the 1980's. The
initial trials used dry powder consisting of dipalmitoylphosphatidylcholine (DPPC) and
phosphatidylglycerol (PG).
To avoid the problems of using pure DPPC (a gelatinous solid at body temperature,
liquefying only at 41°C), PG was added to give the desired properties of rapid spreading and
reduction of surface tension (Bangham et al 1979). The dry powder was thought to be
superior to a liquid formulation, as it was believed the phospholipids in the liquid would
form micelles and not be released to the lung surface. In a separate study the in-vitro
(physiological) surface properties of the dry surfactant were shown to be superior to the
current reconstituted ALECboih when stored at 37°C and at 4°C (Takahashi et al 1994).
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An initial trial in preterm rabbits of dry powder DPPC and PG in a ratio of 7:3 compared
effects with controls (no treatment) and adult rabbit surfactant (Morley et al 1980). Rabbits
were delivered at 27 days post-conception (term being 31 days) and had a tracheostomy
fashioned. After instillation of either adult rabbit surfactant, dry powder DPPC: PG or
nothing the rabbits were ventilated for one hour. Improvements in static lung compliance
were noted in both surfactant treated groups but the numbers of rabbits developing
pneumothoraces were the same. Histological examination showed bronchiolar lesions of
necrosis, desquamation and hyaline membrane formation in both treated and untreated
animal lungs.
The first trial of the dry powder formulation of DPPC: PG in human neonates involved
infants of <34 weeks gestation intubated and ventilated from birth (Morley et al 1981).
Treatment with surfactant was only given if one of the investigators was able to attend the
delivery. Controls did not receive any placebo treatment and the trial was not blinded. This
trial was therefore open to criticism regarding treatment allocation and selection bias.
Nonetheless 55 infants (22 treated and 30 controls) were enrolled. The groups were similar
at entry in terms of gestation, birthweight and gender. Fewer infants in the treatment arm
(9/30 versus 1/22) required supplemental oxygen or respiratory support and among infants
that required ventilation, treatment with surfactant was associated with significantly lower
mean ventilatory pressures and fewer deaths.
A second randomised non-blinded trial using the same dry powder of DPPC: PG followed
(Wilkinson et al 1985). Infants were enrolled into one of two parallel trials: the first using
surfactant as "prophylaxis", and the second "rescue" treatment in established respiratory
distress syndrome. A total of 56 infants <31 weeks gestation were enrolled; 32 in the
"prophylaxis" trial and 24 in the "rescue" trial. Surfactant was administered using capsules
within a special adapter in a resuscitator bag, these were pierced to release the powder
during inflations, and in the case of the control arm the capsule was not pierced. The trial
could not demonstrate any difference in respiratory outcomes or survival.
The third trial of the dry powder was a sequential analysis of static compliance and blood
gas parameters after surfactant or saline control (Milner et al 1983). Dry surfactant and
saline were alternately insufflated at intervals of twenty minutes. Not surprisingly, given
that later trials showed compliance improves only slowly after surfactant (Morley &
50
Greenough, 1991, Armsby et al 1992), there were no demonstrable differences in
compliance, nor were there any differences in blood gas parameters.
The results of the last two trials suggested dry surfactant was not as effective as first thought
and work began to look at alternative ways of administering the phospholipids. Simply
dissolving the powder in saline did not work, ALEC stored at 37°C does not demonstrate
any surface tension reducing properties (Takahashi et al 1994). The solution was to cool
both the phospholipids and the medium used to administer them (Bangham et al 1984).
ALEC that has been stored at 4°C and mixed with saline whilst still cold reduced surface
tension (Takahashi et al 1994).
A randomised-controlled study using this formulation began in 1982 in Cambridge and
Nottingham (Morley et al 1988). Enrolled infants of 23-34 weeks gestation received a
pharyngeal deposition of 50mg ofALEC after birth with further doses at 10 minutes, 1 hour
and 24 hours if they remained intubated. Controls received 1ml saline. The pharyngeal
deposit prior to the first postnatal breath was used so that this would be inhaled and was
intended to be quicker than after intubation.
Changes were made to the protocol after an interim analysis. It became evident that infants
>30 weeks gestation had very little RDS. The trial then concentrated on infants of <30
weeks gestation. Concurrent with the change in gestation criteria was an increase in the
dosage ofALEC from 50mg to lOOmg.
Treatment and control groups were well matched at entry. Among infants >30 weeks
differences in outcome were not significantly different however in the more immature group
there were reductions in neonatal death, intraventricular haemorrhage and death/oxygen
dependency at 28 days (Table 7).
The original two centre trial therefore enlarged to become a larger multi-centre trial to show
conclusively whether surfactant was beneficial (Ten Centre Study Group 1987). This
followed the protocol from the earlier trial (Morley et al 1988) but concentrated on infants
of 25-29 weeks gestation. The primary outcome was mortality, irrespective of cause, with
other complications of prematurity being analysed as a secondary outcome.
Table7:Significantoutcom sreportedic n r ll dtri lsfALEC. StudyOutcomeSurfactanttre tedPlaceboRela ive95%CIisk5 I infantsriskdifference Twocentrestudy (Morleyeta1988)IVH(allb bies)13/164(8.0%)29/63( 7.7%)Q 50.2to8 -9.7-16.to-2.5% Neonatald ath (babies<30we ks) Deathbefore discharge(babies <30weeks) IVH(babies<30 weeks)10/69(14.5%)2 /67(31.3%)Q.460.24to0.91- 6 9-30.7to-3.0% 12/69(17.4%)24/6(35.8%)0.49.2to0 8- 8-33.0to-3 9% 13/69(18.8%)27/67(40.3%)Q 470.2to8-21.5-3 .4to-6.5% TenCentreStudyNeo atald ath (1987) Deathpriorto discharge23/159(14.5%)40/147(26.8%.540.34to8 -12.8-21.4to-3.4% 30/159(18.9%)44/147(29 5 )Q.640. 3to-10.7-2 .2to-1.1%
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All infants in the treatment and placebo arms received at least one dose of their allocated
surfactant/placebo. Seventeen infants (10.7%) in the treatment arm and 21 infants (14.1%)
in the control arm were not intubated and received only the pharyngeal dose (Personal
communication - Professor C Morley). Treatment or control arms were well matched.
ALEC was found to reduce mortality both at 28 days and prior to discharge.
On the strength of the Ten Centre Study, ALEC was granted a licence. The dosing schedule
has remained largely unchanged except for the pharyngeal deposit, which was dropped as
there was insufficient data to support its use and very few infants in the 25-29 week
gestation range did not get intubated. The consensus between the investigators and the
company was that prescribers could not justify the cost in the absence of evidence of clinical
efficacy {personal communication - Professor C Morley).
ALEC was also shown to be a safe drug. Adverse events associated with its use related
largely to transient bradycardia and/or hypoxia during administration. Occasionally there is
obstruction of the endotracheal tube requiring reintubation. None of these events are
exclusive to ALEC and occur with a similar frequency with other surfactants (Ahluwalia &
Morley 1995). Longer-term follow-up (Morley & Morley 1990) again suggested the drug is
safe. In particular there was no increase in the numbers of handicapped children among the
increased number of survivors.
Whilst the study of in vitro properties by Takahashi et al (1994) suggests that both synthetic
surfactants ALEC and Exosurf have inferior surface active properties compared to the
bovine-derived Survanta / Surfactant TA no trials comparing ALECwith another surfactant
in a neonatal population have yet been published.
5.1.2 Meta-analysis of the randomised controlled trials ofALEC.
Method
The objective of this meta-analysis was to assess the effect of intra-tracheal administration
of ALEC administered either prophylactically or in premature infants with established RDS.
Searches were made of the Oxford Database of Perinatal Trials, Medline, BIDS (Embase),
the National Research Register, previous reviews including cross references, abstracts,
conference and symposia proceedings, expert informants, and hand-searching of journals
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written in the English language to find randomised controlled trials that compared the effect
ofALEC to controls in preterm infants with RDS or at risk of RDS.
Data was collected regarding clinical outcomes, particularly relating to neonatal mortality
and respiratory complications of prematurity were excerpted from published reports of the
clinical trials. Analyses of the data were performed using relative risk and risk difference
(Bracken 1992).
Relative risk (also known as event rate ratio or incident rate ratio) is the traditional estimate
of effect derived from prospective studies. In case controlled studies the relative risk is also
approximated by odds ratio. It provides some idea as to the proportion of treated patients
that experience an event (such as death, treatment of patent ductus, etc.) relative to the
proportion of control patients that experienced the same event.
Relative risk is independent of the baseline rate of events (that is the rate of events seen in
controls). In trials where there is no difference between event rates in treated and control
arms the relative risk is 1.0, where the result favours treated groups the relative risk is less
than 1.0 and greater than 1.0 when the result favours controls. A statistically significant
result occurs when the 95% confidence interval does not cross unity.
Risk difference (also known as event rate difference) reflects the baseline event rate (seen in
the control arm) and the reduction (or otherwise) seen in the treated arm. Therefore, it may
have more relevance to the clinicians than relative risk or odds ratio. Where there is no
difference between event rates in the treated and control arms the risk difference is 0.0%,
where the result favours treated groups the risk difference is less than 0.0% (it achieves a
negative value) and greater than 0.0% (remains positive) when the result favours controls. A
statistically significant result occurs when the 95% confidence interval does not cross the
zero value.
In meta-analyses/over-views of randomised clinical trials there are inherent biases (Egger &
Smith 1998), not least depending on the data presented in the literature. Meta-analysis of
published results with heterogeneity among the trials, possibly arising from differences
among centres, populations, treatment protocols and different surfactants may lead to both
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an under- and over-estimation of the treatment effect and also the statistical significance
(Thompson & Pocock 1991). One alternative is to retrieve the raw data; this has been done
by Egberts et al (1997) in comparison of prophylactic versus rescue Curosurf Meta¬
analyses are not a substitute for properly conducted randomised controlled trials however
the pooling of results may identify areas where research is lacking and prevent unnecessary
new trials from being carried out. The uses and abuses of meta-analyses are reviewed by
Petticrew (2001).
Studies were included only if they fulfilled the following criteria:
(a) Types of study - Randomised (or quasi-randomised) controlled trial comparing ALEC to
control (placebo or no treatment).
(b) Types of participants - preterm neonates at risk of or with clinical and radiological
evidence ofRDS requiring assisted ventilation.
(c) Types of intervention - Infants randomised to receive ALEC versus control treatment
(intratracheal administration of saline placebo).
(d) Types of outcome measures - Data for the following clinical outcomes are included in
the meta-analysis: neonatal mortality, pulmonary air leak, patent ductus arteriosus,
necrotising enterocolitis, intraventricular haemorrhage, bronchopulmonary dysplasia (at
28 days in survivors), bronchopulmonary dysplasia or death (at 28 days).
Where data were only available from a single study these are presented using risk difference
and relative risk to allow comparisons to be drawn with outcomes after treatment with the
other surfactants.
Results
Only two studies were identified. Morley et al (1988) Two Centre Study ofALEC and The
Ten Centre Study (1987). Infants under thirty weeks gestation were enrolled in both studies
but the data presented by Morley et al (1988) allows extraction of the outcomes for the more
mature infants enrolled only in that trial. Summaries for these trials are shown in Table 8.
Other publications reporting outcomes with ALEC were excluded for the following reasons:
• Morley & Greenough (1991) - examined respiratory compliance in a subgroup of
the Ten Centre Study infants
• Morley (1989) - reviews the two centre and ten centre trials, and also includes the
results from the earlier non-randomised dry-powder trial
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• Ahluwalia & Morley (1995) - examined oxygenation and heart rate changes after
ALEC in a non-randomised cohort of infants
• The three dry powder ALEC trials (Morley et al 1981, Milner et al 1983, Wilkinson
et al 1985) were excluded, as this preparation is considered ineffective. Morley
(1989) is a review of the outcomes of infants in these trials treated prophylactically.
Treatment of premature infants with ALEC was shown to improve oxygenation and
ventilatory requirements in treated infants. It has the following clinical impact (Figure 2):
NeonatalMortality: Both trials report on the risk of neonatal mortality. Both the Ten
Centre Study and a subgroup analysis within the Two Centre Study of infants less than 30
weeks gestation reported a decrease in the risk of neonatal mortality associated with ALEC
use. However when analysing the more mature infants in the Two Centre Study there is
insufficient data due to the relative infrequency of both RDS and its complications in this
gestation group. The typical estimate from the meta-analysis suggests a decrease in the risk
of neonatal mortality associated with ALEC (typical relative risk 0.58, 95% CI 0.36 to 0.94;
typical risk difference -6.8%; 95% CI -12.6 to -0.9%).
Pulmonary Air Leak: Again both trials report this outcome, but using different forms.
The larger Ten Centre Study uses an all-encompassing definition of pulmonary air leak
syndrome, whereas the Two Centre Study reports pneumothoraces only. The typical
estimate from the Ten Centre Study suggests a trend towards a decrease in the risk of
pulmonary air leak associated with ALEC (typical relative risk 0.89, 95% CI 0.62 to 1.28;
typical risk difference -3.1%; 95% CI -13.2 to +6.9%). Similarly a trend towards a decrease
in the risk of pneumothorax was reported in infants <30 weeks gestation in the Two Centre
Study, but an increase in the risk for infants >30 weeks.
Patent Ductus Arteriosus: Both trials reported on the incidence of patent ductus
arteriosus. The typical estimate from the Ten Centre Study suggests a trend towards an
increase in the risk of patent ductus arteriosus associated with ALEC (typical relative risk
1.22, 95% CI 0.89 to 1.84; typical risk difference +3.2%; 95% CI -3.2 to +9.6%).
Necrotising Enterocolitis: NEC is given as an outcome in the Ten Centre study but
not the Two Centre Study. This reported small non-significant decrease in the risk of
necrotising enterocolitis after ALEC (typical relative risk 0.77, 95% CI 0.39 - 1.51; typical
risk difference -2.6%; 95% CI -9.3 to +4.1%).
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Total Intraventricular Haemorrhage: Total IVH (irrespective of severity) was only
reported in the Two Centre Study. This reported a decrease in the risk of IVH after ALEC
(typical relative risk 0.45, 95% CI 0.24 - 0.84; typical risk difference -9.7%; 95% CI -16.9
to -2.5%). This was largely as a result of reductions in total IVH in ALEC treated infants
<30 weeks gestation.
Bronchopulmonary Dysplasia / Chronic Lung Disease: Only the Two Centre Study
reported oxygen dependency at 28 days postnatal age, the Ten Centre Study limited itself to
persistence of an oxygen requirement beyond the 10th day of life. The Two Centre Study
reported a non-significant decrease in the risk of BPD/CLD among surviving infants (of any
gestation at birth) who had received ALEC (typical relative risk 0.73, 95% CI 0.41 - 1.32;
typical risk difference -4.1%; 95% CI-11.9 to +3.6%).
Bronchopulmonary Dysplasia / Chronic Lung Disease OR Death: Again because
the Ten Centre Study did not report the outcome of BPD/CLD at 28 days this outcome is
limited to the result published in the Two Centre Study. This reported decrease in the risk of
BPD/CLD or neonatal death among all infants (any gestational age) who had received
ALEC (typical relative risk 0.68, 95% CI 0.45 - 1.03; typical risk difference -8.4%; 95% CI
-17.4 to +0.5%). However the subgroup analysis of infants of <30 weeks gestation showed a
decrease in the risk of BPD/CLD or neonatal death among infants who had received ALEC
(typical relative risk 0.58, 95% CI 0.40 - 0.85; typical risk difference -24.9%; 95% CI -41.2
to -8.7%). This is more significant because it represents those infants more at risk of RDS.
Conclusion
ALEC was shown to be an effective drug for reducing neonatal and pre-discharge mortality.
It reduced oxygen and ventilator requirements during the acute phase of RDS. The incidence
of intraventricular haemorrhage was also significantly reduced. However other
complications of prematurity, including pneumothoraces and pulmonary air leak, showed
only trends towards better outcomes after ALEC. There was no reduction in the numbers of
survivors of any gestation that required supplemental oxygen at 28 days postnatal age
compared to the control arm. However when mortality and CLD is combined as an outcome
in the sub-group of infants <30 weeks gestation there were significantly more infants who
survived without requiring oxygen.
There are however some unanswered questions regarding ALEC, the published trials only
compare ALEC when used prophylactically in infants at risk of RDS. Whilst prophylactic
administration of surfactant is more clinically advantageous than rescue treatment, ALEC
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has not been demonstrated to be an effective "rescue" therapy for RDS. It is unlikely that a
placebo-controlled trial of "rescue" ALEC would be considered ethical. The Ten Centre
Study (1987) concentrated on infants of 25-29 weeks gestation and the two centre study
enrolled few mature infants, therefore the clinical efficacy ofALEC in larger mature infants
has not been demonstrated.
5.2 Curosurf (poractant alfa) Chiesi Farmaceutici S.p.A.,
Italy
5.2.1 Development and early trials of Curosurf
Curosurf (poractant alfa) is a porcine-derived surfactant developed by Tore Cursledt and
Bengt Robertson at the Karolinska Institute of Stockholm, Sweden. It was subsequently
licensed to Chiesi Farmaceutici SpA. of Italy. Pursuant to a license agreement in 1991, Ares-
Serono became the exclusive European licensee. Curosurf was a late newcomer on the
American market receiving FDA approval in 1999. It is distributed in America by Dey
Laboratories, California.
The use of porcine surfactant was first reported by Noack et al (1987) in a trial of natural-
derived surfactants in 10 infants with severe RDS. The final three infants in the series were
treated with porcine lung extract that had been isolated from minced pig lungs by a
combination of washing, centrifugation, and extraction with chloroform-methanol and liquid
gel chromatography. Curosurf continues to be manufactured in this manner. The product
differs from that obtained from lavage of the lungs in that it contains phospholipids from the
cells of the lungs.
The final composition of Curosurf is phosphatidylcholine 60-80% (of which DPPC at least
40%), acidic phospholipids 10-15% (Phosphatidylserine, phosphatidylinositol,
phosphatidylglycerol), lysophosphatidylcholine < 4%, other phospholipids < 20%
(phosphatidylethanolamine, sphingomyelin), surfactant proteins SP-B and SP-C 1.0 ± 0.5%,
cholesterol and triglycerides < 2%. There are in addition trace amounts of ethanol (<0.5%)
and chloroform (<10 ppm) representing residual manufacturing components.
In the report by Noack et al (1987), treatment was a last-ditch effort in infants with severe
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RDS but nonetheless improvements in gas exchange and clinical course were seen. The
radiological appearances of RDS also improved after treatment (Mortensson et al 1987).
Two non-randomised studies followed (Speer et al 1988, Speer et al 1991). A single
200mg/kg dose of Curosurf produced improvements in gaseous exchange, and in
comparison to matched controls the second study showed improved outcomes in neonatal
deaths, numbers of pneumothoraces and duration of ventilation. A series of multi-centre
trials looking at the effects of Curosurf on neonatal mortality followed. These trials were
the EURO I to EURO VI trials (Table 9).
Some centres, notably Belfast, published results on the infants they enrolled in the EURO
trials (McCord et al 1988, Halliday et al 1989, Walti et al 1990). Some EURO trials have
appeared in the literature but others have only been presented at neonatal meetings.
Randomised trials outside the EURO series have looked at the timing of Curosurf
administration (Egberts et al 1993, Walti et al 1995, Bevilacqua et al 1996). Curosurfuse in
infants on nasal CPAP (Verder et al 1994, Verder et al 1999) and two alternative methods of
administration have been reported (Valls-i-Soler et al 1997, Valls-i-Soler et al 1998).
To some extent the research into other surfactants reduced the need for placebo-controlled
trials and thus few trials indicate how Curosurf compares with no treatment/placebo. The
three trials that achieve this (Collaborative European Multicenter Study Group 1988, Walti
et al 1990, Verder et al 1994) all compare 200mg/kg of Curosurf administered to infants
who had established RDS. In the case of the Collaborative European Multicenter Study
Group (1988) and Walti et al (1990) the infants were ventilated and required an Fi02 >0.6.
In the case of the Verder et al (1994) study the infants were in supplemental oxygen and
were given Curosurf if they reached an Fi02 >0.6 and were then started on nasal CPAP.
Statistically significant outcomes from these trials are shown in Table 10.
The trials of Bevilacqua et al (1993), Egberts et al (1993), Walti et al (1995), Bevilacqua et
al (1996) and Verder et al (1999) all compare early versus late administration of Curosurf
Bevilacqua et al (1993) and Verder et al (1999) use severity of disease to differentiate early
versus late, whereas Egberts et al (1993), Walti et al (1995) and Bevilacqua et al (1996) use
a temporal criteria to differentiate the concept of early ("prophylaxis") versus late rescue.




























































































The two other areas of Curosurf research have been; the number and frequency of doses
(Speer et al 1992, Halliday et al 1993) and the method of administration of Curosurf (Valls-
i-Soler et al 1997, Valls-i-Soler et al 1999).
Speer et al (1992) showed that multiple doses of Curosurf improved early ventilator and
oxygen requirements, and had a greater protective effect against pulmonary air leak with a
significant reduction in pneumothoraces. Halliday et al (1993) found similar early
improvements in ventilator and oxygen requirements with their high dose group (up to
600mg/kg) compared to their low dose group (up to 300mg/kg), but could not demonstrate
any longer-term differences.
The two studies from Spain (Valls-i-Soler et al 1997, Valls-i-Soler et al 1999) looked at
administration technique. In all previous trials Curosurfwas administered as a bolus via a
nasogastric tube passed down the endotracheal tube (ETT), this method had not been altered
much since Fujiwara et al (1980). In particular the authors were interested in trying to
reduce the number of episodes of hypoxia (transcutaneous oxygen saturation less than 80%)
and bradycardia (heart rate less than 80/minute) during surfactant administration. These
episodes are transient but have been reported frequently in surfactant trials (approximately
28% with Survanta, between 25-39% with Exosurf and between 17-58% with Infasurf).
There were some reductions in the number of hypoxic and bradycardic episodes when
Curosurfwas administered via the dual lumen ETT but not the ETT side-port.
Whether these transient hypoxic and bradycardic episodes are significant is unclear. Even
when transient cerebrovascular changes have documented during surfactant administration
they have not correlated with any longer-term evidence of neurological impairment. Both
changes in cerebral haemodynamics (Cowan et al 1991, Bell et al 1994) and transient
depression of brain electrical activity (Hellstrom-Westas et al 1992) have been reported
during Curosurfadministration.
Since dual lumen ETT cost more (£2.20 each) compared to a standard soft ETT of the same
internal diameter (source; Vygon catalogue, Vygon UK Ltd. 1998) and have added dead-
space (the ETT cannot be cut to the right length) the authors were cautious regarding the
significance of their results and suggested that a larger trial is required before dual lumen
ET tubes are routinely used in infants likely to require surfactant.
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The studies by Verder and colleagues (Verder et al 1994 and Verder et al 1999) are worth
special mention in that they investigate the use of Curosurf as a means to preventing the
need for long-term ventilation. Nasal CPAP if frequently used in Scandinavian countries to
treat RDS (Lundstrom 1996, Jonsson et al 1997). A UK based study, the EFDAS trial, looks
at the same approach in this country and has recently finished recruiting (source: The
National Research Register, http://www.update-software.com/nrronline/NRROpen.htm).
Verder et al (1994) demonstrated that Curosurf used with routine nasal CPAP can
significantly reduce the need for ventilation, and that early rather than late treatment has
better results (Verder et al 1999). Unfortunately there was no comparison with conventional
management of a ventilated group of infants with which to compare longer-term benefits of
this mode of therapy.
Although Curosurf has been compared to controls in only two fully randomised controlled
trials, results from these and extrapolation from other surfactant trials mean further placebo-
controlled trials can no longer be seen to be ethical. The single versus multiple dose study of
Speer et al (1992) and the low versus high dose regime study (Halliday et al 1993) suggest
most infants can be treated with two lOOmg/kg doses. The evidence (reviewed in detail in
chapter 6) from the "early" versus late trials (Bevilacqua et al 1993, Egberts et al 1993,
Walti et al 1995, Bevilacqua et al 1996 and Verder et al 1999) suggests the first dose is
administered as soon as possible.
Only two randomised trials (Speer et al 1995, Kukkonen et al 2000) have compared
Curosurf with another surfactant in a neonatal population. These reviewed in chapter 8
along with two non-randomised comparisons between Curosurf and Exosurf (Rollins et al
1993 and Stenson et al 1994), and a study of the effects of these two surfactants on cerebral
blood flow (Murdoch & Kempley 1998).
5.2.2 Meta-analysis of the randomised controlled trials of Curosurf
Method
The objective of this section was to assess the effect of intra-tracheal administration of
Curosurf administered either prophylactically or in premature infants with established RDS.
The search strategy outlined in section 5.1.2 was used to examine outcomes in randomised
controlled trials that compared the effect of Curosurf to controls in preterm infants with
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RDS or at risk of RDS. Data regarding clinical outcomes, particularly relating to neonatal
mortality and respiratory complications of prematurity were excerpted from published
reports of the clinical trials and analysed using the statistics outlined in section 5.1.2.
Studies were considered if they fulfilled the following criteria:
(a) Types of studies - Randomised controlled trials comparing Curosurf to control
treatment whether using placebo or no treatment.
(b) Types of participants - preterm neonates at risk of or with clinical and radiological
evidence of RDS requiring assisted ventilation.
(c) Types of intervention - Infants randomised to receive Curosurfversus control treatment
(no treatment or intratracheal administration of air or saline placebo).
(d) Types of outcome measures - Data for the following clinical outcomes are included in
the meta-analysis: neonatal mortality, pulmonary air leak (reported as PIE and
pneumothorax), patent ductus arteriosus, intraventricular haemorrhage,
bronchopulmonary dysplasia (at 28 days in survivors), bronchopulmonary dysplasia or
death (at 28 days). Necrotising enterocolitis, often reported as an outcome in surfactant
trials was not reported by any Curosurftrial suitable for inclusion in the meta-analysis.
Results
Only two studies were identified as suitable for inclusion - the EURO I Study by the
Collaborative European Multicenter Study Group (1988) and Verder et al (1994). These
trials were somewhat different however in that Verder et al (1994) used Curosurf in infants
receiving nasal CPAP whereas the EURO I infants were treated with conventional
ventilation. Despite the differences in mode of respiratory support, the point at which infants
became eligible for randomisation was very similar (Fi02 >0.6).
A third report comparing Curosurf against saline placebo (Walti et al 1990) has been
published; however some of the infants in this study were enrolled in the EURO I study
(Collaborative European Multicenter Study Group 1988). The report by Svenningsen et al
(1987) was also excluded as this report concentrated on early outcomes. Summaries for
these trials are shown in Table 11. All other publications shown below were excluded from
the analysis:
• Collaborative European Multicenter Study Group (1991) - The EURO II study. An
open non-randomised study of a single dose of Curosurf
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• Bevilacqua et al (1993) - The EURO III study. A comparison of "early" (treatment
at a stage of less severe RDS) versus "late" Curosurf
• Speer et al (1992) - A comparison of single versus multiple doses.
• The EURO V study (manuscript available from Serono Laboratories UK. Ltd) - a
non-randomised open design study of Curosurf in severe RDS.
• Halliday et al (1993) - High versus low dose regimes of Curosurf.
• Noack et al (1987) - non-randomised trial.
• Mortensson et al (1987) - report on the radiological outcomes in the above study.
• Speer et al (1988) and Speer et al (1991) - non-randomised studies.
• McCord et al (1988) - report on the prevalence of IVH in Belfast infants enrolled in
EURO I study.
• Halliday et al (1989) - report on changes in pulmonary blood after surfactant in
Belfast infants enrolled in EURO I study.
• Egberts et al (1993) - randomised controlled trial ofprophylactic versus rescue.
• Walti et al (1995) - randomised controlled trial ofprophylactic versus rescue.
• Bevilacqua et al (1996) - randomised controlled trial of prophylactic versus rescue.
• Valls-i-Soler et al (1997) - randomised controlled trial of two methods of
administering Curosurf
• Valls-i-Soler et al (1998) - randomised controlled trial of two methods of
administering Curosurf
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Table11:Summari softhcontrolledri lsinv lvingCurosurf StudyMetho sParticipantsExcl sionOu me Svenningsenta(1987) Rescuetrial(8infants) CollaborativeEuropean multicenterSt dy Group(1988)-The EUROIstudyRescue trial(146infants) Bevilacquata(1993)- TheEUROIIIstudy (182infants)-early versuslateCuros rfRandomised(?method) Singlecentrestudy Noblinding 200mg/kgCurosurforai placebo Randomised Eightcentrestudy Sealedenvelopes (stratificationbyweight) Notblinded 200mg/kgCurosurforai placebo Randomised Multicentrestudy(26 centres) Sealedenvelopes Notblinded 200mg/kgCurosurfGestation26-30weeks Clinicalandradiological RDS Fi02>0.6 Birthweight700-2000 grams Clinicaland/orradiological RDS Age2-15hours Ventilatedwi hFi02>0.6 Birthweight600-2000 grams. Between2-24hoursld. Clinicalandradiological diagnosisofRDS. VentilatedwithFi020.4- 0.59Notstated Congenitalabnormality Prolongedrupturef
membranes(>3 weeks)
GradeIIIorVH Birthasphyxia GBSinfection Congenitalabnormality Prolongedrupturef membranes(>3 weeks) GradeIIIorVH Birthasphyxia GBSinfection Fi02̂0.6
Survivaltodischarge Earlychangesinventilator andoxygen requirements Complicationsof prematurity Ventilatorandoxygen requirements Complicationsf prematurity Ventilatorandoxygen requirements Complicationsof prematurity
ON
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Table11:SummariesofthcontrolledtriinvolvingCurosurf(c tinued) StudyMethodsParticipantsExclusionsO tcomes Speertal(1992)-Th EUROIVStudy;single versusmultipledose (343infants)Randomised Multicentrestudy(26 centres) Sealedenvelopes (stratifiedbycentre weight) Notblinded 200mg/kgCurosurf,with 2ndand3rdosesf 100mg/kgat2hourly intervalsmultiple dosearmBirthweight700-2000 grams Clinicaland/orrad ological RDS Age2-15hours Ventilatedwi hFi02>0.6Congenitalabnormality Prolongedrupturef
membranes(>3 weeks)
GradeIIIorVH Birthasphyxia(Apgar<3t 5minutes,cordpH <7.1orearlynset seizures) (14postall cation exclusions)
BPDorneonataldeath Ventilatorandoxygen requirements Complicationsof prematurity
Hallidayetl(1993)-The EUROVIStudy(2186 infants)
Randomised Multicentrestudy(82 centres) Telephonerandomisation (stratifiedbycentre) Notblinded Upto300mg/kgCurosurf, versusupto600mg/kg inmultipledoses
<72hoursld. Clinicalandradiological RDS. a/AP02<0.22.
Severecongenital malformations
BPDorneonataldeath BPDordeathb fo e discharge/EDD Ventilatorandoxygen requirements Complicationsof prematurity
G\
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TableIT.Summariesofthecontrolledrialsinv lvingCur surf(conti ue ) StudyMethodsParticipantsExclusionsOut omes Waltieal(1990)-r scue trialofCurosurf(30 infants) Egbertseal(1993)- comparisonf prophylaxisandrescue Curosurf(147infants) Verdertal(1994)-N sal CPAPandCurosurf trial(68infants)Randomised Singlecentrr portofpart ofEUROIstudywith additionalpatients Sealednve opes (stratificationbyweight) Notblinded 200mg/kgCurosurforai placebo Multicentretr al(4centres) Sealednve opes (stratificationbycentre) Notblinded 200mg/kgCurosurfwithin 10minutesofdel v ry orwhenFi02>0.6. Multicentretrial Sealednve opes (stratificationbycentre) AllbabiesreceivingCPAP, treatmentrmgive 200mg/kgCurosurfBirthweight700-2000 grams Clinicala d/orradiological RDS Age2-15hours VentilatedwithFi02>0.6 26-30weeks'gestation 25-35weeks'g station Clinicalandr diological RDS. NasalCPAPinu e(>6cm H20 a/AP02<0.22.Congenitalabnormality Prolongedrupturef
membranes(>3 weeks)
GradeIIIorVH Birthasphyxia GBSinfection Prolongedrupturef membranes(>3 weeks) Congenitalabnormal ies
(2postallocation exclusions) Congenitalabnormality Prolongedrupturef membranes(>2 weeks) BirthasphyxiawiApgar score<3at5minutes Congenitalp eumoni (5babieswithdrawnpost- allocation)
Ventilatorandoxygen requirements Complicationsf prematurity ReductioninDS Ventilatorysupport Complicationsf prematurity Needform chanical ventilationbeyond periodofsurfactant administration Neonatalmort ity Oxygenrequirements Complicationsf prematurity
O
Table11:Summari softhecontrolledrialsinv lvingCurosurf(continued) StudyMetho sPar icipantsExclusionOu ome Waltiel(1995)- prophylaxisversu rescuet ialofCuros rf (256infants) Bevilacquatal(1996)- prophylaxisversus rescuet ialofCuros rf (266infants)Randomised Multicentre(12cent s) Telephonerandomisation (stratificationbycentre) Notblinded 100mg/kgCurosurfwithin 15minutesofbirthrif CXRshowsRDSand Pa02:Fi02<20kPa between3-18hoursf age Multicentretr al(18 centres) Sealedenvelopes (stratificationbycentre, andgestation) Notblinded 200mg/kgCurosurfwithin 10minutesofdeliv ry orifventilatedfRDSGestation25-31weeks In-borniparticipating centre 24-30weeks'gestationCongenitalabnormality Prolongedrupturef
membranes(>3 weeks) Prolongedrupturef membranes(>3 weeks) Congenitalabnormalities Congenitalinfection (19postallocation exclusions)
SurvivalwithoutBPDat28 days Ventilatorandoxygen requirements CXRappearances Complicationsf prematurity ReductioninDS Complicationsf prematurity
Table11:Summariesofthecontrolledtri lsinv lv ngCur surf(conti ue ) StudyMethodsParticipants
Exclusions
Outcomes
Valls-i-Soleret(1997) Curosurfadmini tration viaaside-portors bolus(68infants) Valls-i-Soleret(1998) Curosurfadmini tration viaadual-lumenETT orasb lus(68 infants)
Multicentretr al Sealednve opes (stratifiedbycentre) 200mg/kgCurosurf administeredv aeith r anETTside-portors conventionalbolus throughNGube Multicentretr al Sealednvelopes (stratifiedbycentre) 200mg/kgCurosurf administeredv aeithe anETTside-portors conventionalbolus throughNGtube
600-200grams birthweight Lessthan24hourld Clinicalandr diological RDS VentilatedwithFi02>0.4 600-200grams birthweight Lessthan24hourld Clinicalandr diological RDS VentilatedwithFi02>0.4
Congenitalabnormality Pre-existingsevereIVH Birthasphyxia(Apgar score<3at5minut s) Congenitalabnormality Pre-existingsevereIVH Birthasphyxia(Apgar score<3at5minut s)
Episodesoftransient hypoxiaand/or bradycardiaduring Curosurf administration Neonatalmort ity Complicationsf prematurity Episodesoftransient hypoxiaand/or bradycardiaduring Curosurf administration Neonatalmort ity Complicationsf prematurity
Verdertal(1999)-N sal CPAPandearlyversus lateCurosurf(60 infants)
Multicentretr al Sealedenve opes (stratificationbycen re) AllbabiesreceivingCPAP, given200mg/kg Curosurfat randomisationiearly armorif/AP02<0.22 inlatearm.
<30weeks'gestation Clinicalandr diological RDS. NasalCPAPinu e(>6cm H20 a/AP02between0.35nd 0.22
Congenitalabnormality Prolongedrupturef membranes(>2 weeks) BirthasphyxiawiApgar score<3at5minutes Congenitalpneumonia
Needform chanical ventilationbeyond periodofsurfactant administration Neonatalmort ity Oxygenrequirements Complicationsf prematurity
Treatment of premature infants with Curosurf leads to an improvement in oxygenation and
ventilatory requirement. It has the following clinical impact (Figure 3):
Neonatal Mortality: Both trials report on the risk of neonatal mortality. The typical
estimate from the meta-analysis suggests a decrease in the risk of neonatal mortality
associated with Curosurf (typical relative risk 0.59, 95% CI 0.39 to 0.90; typical risk
difference-16.0%; 95% CI-28.3 to-3.7%).
Pulmonary Air Leak: Again both trials report this outcome, but using the two forms
of PIE (not reported by Verder et al 1994) and pneumothorax rather than an all-embracing
air leak syndrome. The typical estimate from the meta-analysis of both trials shows a
decrease in the risk of pneumothorax associated with Curosurf use (typical relative risk
0.53, 95% CI 0.30 to 0.93; typical risk difference -12.1%; 95% CI -22.6 to 1.5%). The
typical estimate (from the EURO I study only and therefore not included in the meta-view
chart) suggests a decrease in the risk of PIE associated with Curosurf use (typical relative
risk 0.27, 95% CI 0.13 to 0.54; typical risk difference -28.7%; 95% CI -42.1 to -15.4%).
Patent Ductus Arteriosus: Both trials reported on the incidence of PDA. The typical
estimate suggests an increase in the risk of significant PDA (requiring treatment) associated
with Curosurf (typical relative risk 1.41, 95% CI 1.04 to 1.92; typical risk difference
+15.4%; 95% CI +2.3 to +28.6%).
Severe Intraventricular Haemorrhage: Severe IVH (defined as Papile grades III and
IV) was reported by both eligible studies. The typical estimate from the meta-analysis
suggests a no difference in the risk of severe IVH after Curosurf (typical relative risk 1.00,
95% CI 0.59 - 1.69; typical risk difference -0.1%; 95% CI-10.9 to +10.8%).
Bronchopulmonary Dysplasia / Chronic Lung Disease: Surviving infants with
BPD/CLD at 28 days were reported by both studies. The typical estimate from the meta¬
analysis of both trials shows a decrease in the risk of BPD/CLD in infants who had received
Curosurf (typical relative risk 0.53, 95% CI 0.29 - 0.98; typical risk difference -14.4%;
95% CI-28.2 to-0.5%).
Bronchopulmonary Dysplasia / Chronic Lung Disease OR Death: This reported by
both studies. The typical estimate from the meta-analysis of both trials shows a decrease in
the risk of BPD/CLD or neonatal death in infants who had received Curosurf (typical
relative risk 0.62, 95% CI 0.46 - 0.83; typical risk difference -22.1%; 95% CI -35.2 to
-9.1%).
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Figure 3: Meta-view charts of risk difference and relative risk between Curosurf
treated infants and controls.
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Curosurfhas been shown to be an effective drug for reducing neonatal mortality. It reduces
oxygen and ventilator requirements during the acute phases of RDS. The incidences of
intraventricular haemorrhage, pneumothoraces and PIE are also significantly reduced. There
is also a reduction in surviving infants who required supplemental oxygen at 28 days
postnatal age, and either BPD/CLD or death at 28 days.
The main disadvantage of Curosurf is the relatively high cost of a vial (£400 per 120mg
vial. Source: British National Formulary). It is currently the most expensive surfactant
available in the UK. Whether the additional expense is negated by gains in other areas
(reductions high dependency care, other drugs as well as health outcomes) compared to
cheaper surfactants is explored in chapters 9 and 10.
5.3 Exosurf Neonatal (Colfosceril palmitate) Burroughs
Wellcome Co., California, USA
5.3.1 Development and early trials ofExosurf
Exosurf Neonatal was developed by John Clements and is based on DPPC (colfosceril
palmitate). Clements hoped that designing a synthetic surfactant might "avoid the potential
problems of variable composition ofmaterial extracted from animals, sensitivity to foreign
proteins, and contamination with infectious agents" (Clements 1997). Although animal-
derived surfactants have yet to be shown to transmit prion or other diseases, the recent
experience in the United Kingdom with bovine spongiform encephalopathy still causes
reluctance in some people's minds when it comes to using these products (Lacey 1999).
To improve the properties of DPPC, hexadecanol was added to aid adsorption in the lung
and tyloxapol to facilitate dispersion. Given in a dosage of 67mg/kg of DPPC, Exosurf is
prepared as a lyophilised powder stored under vacuum in individual vials and reconstituted
with sterile water prior to use. Animal studies had shown that this surfactant improved lung
function in prematurely delivered rabbits (Tooley et al 1987) and improved survival among
preterm lambs by 50% (Durand et al 1985).
The first study in a neonatal population used both "prophylaxis" and "rescue" strategies (see
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chapter 6 for further discussion regarding strategies of surfactant administration). A single
dose of Exosurf reduced both ventilator and oxygen requirements (Phibbs et al 1991), but,
apart from fewer respiratory deaths in the "prophylaxis" study, did not appear to improve
overall mortality or the complications of prematurity. The authors suggested this was due to
the size of the trial; they were however encouraged enough to proceed to larger controlled
trials.
The further clinical trials with Exosurf were conducted in numerous institutions in North
America under sponsorship from the manufacturers, Burroughs Wellcome Co., as part of the
process of obtaining approval from the Food and Drug Administration. These studies
enrolled much larger numbers of infants. The aim was to demonstrate the clinical
effectiveness of Exosurf and to discover the optimum dosing schedule for the treatment of
RDS. Some of the trials were long-term follow-up. Table 12 summarises the relationships
between the trials and their follow-up studies.
The trials were of similar structure in that all were double blind, randomised, and controlled.
Placebo, where used, was air rather than saline. Blinding was achieved through the use of
drug administration teams who were responsible for the surfactant/placebo dosing in secret.
These teams were not involved in the subsequent management of the infants. Parents and the
clinical team responsible for the infants were unaware of the allocation.
There was stratification of infants by birthweight (Figure 4) and gender. In general the
weight criteria of the trials were designed to include infants of a specific gestation (the 03
trial looked at very immature infants of 500-699 grams, whereas the 06/09 trial looked at
more mature infants of > 1250 grams). Summaries of the trials, their entry and exclusion
criteria as well as the primary and secondary outcomes are given in Table 13.
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Figure4:BirthweightrangesitNorthAmericanrialsfExosurf ~~11lI 5001 005203
Birthweight(grams)
Table13:Summari softher ndomisedtri linv lv ngEx surf StudyMethodsParticipantsExclusionsOutcomes Phibbseta/(1991) Prophylaxist ial(77infant ) Phibbsetal(1991) Rescuetrial(110infants) Boseetal(1990) Prophylaxist ial(385 infants) Exosurftrials01/2Randomised Singlecentrstudy Sealednve opes(n stratification) Noblinding 5ml/kgExosurfrai placebo Randomised Singlecentrstudy Sealednve opes(n stratification) Noblinding 5ml/kgExosurfrai placebo Randomised Twocentrestudy Sealednvelopes (stratificationbygender andweight) Blinded(drugadministration team) 5ml/kgExosurfrai placeboIn-borni fants Gestation<34weeks Birthweight>650grams
Congenitalabnormality(3 infantsexcludedfrom analyses)
Birthweight>650grams ClinicalRDS Ventilated(MAP>7cmH20, FiOz>0.4) Between4-24hoursld In-borni fants Birthweight700-1350grams
Congenitalabnormality(6 infantsdidnotmeeall entrycriteria- excluded) Congenitalabnormality Provenlungmaturity (methodoftestingnot stated) Growthretardation Hydropsfetalis Maternalopiatebus Maternalchorioamnionitis (24post-natalexclusions- malformationso congenitalpneumonia)
IncidenceofRDS Ventilatoryrequirements Complicationsf prematurityriorto discharge Complicationsf prematurityp iorto discharge Survivalat28d yswithout BPD Ventilatoryrequiremen s Complicationsf prematurity




























































































Table13:Summari softhrandomisedrialinvolvingEx surf(continued) StudyMetho sPar icipantsExclusioOu ome Longetal(1991a) Rescuetrial(1237infants) Exosurf06/9trialsRandomised Multicentre(36centr s) Sealedenvelopes (stratificationbygender andweight) Blinded(drugadministration team) 5ml/kgExosurfrai placebowithsecond doseat12h ursifstill ventilatedBirthweight>1250grams (Canadiancentres)o >1350grams(USA centres) ClinicalRDS a/AP02<0.22 Lessthan24hourld
Congenitalabnormality Provenlungmaturity (methodoftestingnot stated) Growthretardation Hydropsfetali
Neonatald ath SurvivalwithoutBPD Respiratorysupport Complicationsof prematurity
Smytheal(1995) Rescuetrial(226infants) Exosurf07trial
Randomised Multicentre(12centr s) Sealedenvelopes (stratificationbygender andweight) Blinded(drugadministration team)
5ml/kgExosurfrai placebowithsecond doseat12h ursifstill
Birthweight500-749grams ClinicalRDS a/AP02<0.22 2-24hoursld
Congenitalabnormality Provenlungmaturity (methodoftestingnot stated) Growthretardation Hydropsfetali Maternalopiatebus Maternalchorioamnionitis
Neonatalmor ity BPD Survivalat28d yswithout BPD Complicationsof prematurity
ventilated
Table13:Summari softherandomisedri linvolvingEx surf(continued) StudyMetho sPar icipantExcl sionsOu come McMillanetal(1995) Rescuetrial(344infants) Exosurf08trialRandomised Multicentre(12centr s) Sealedenvelopes (stratificationbygender andweight) Blinded(drugadministration team) 5ml/kgExosurfrai placebowithsecond doseat12h ursifstill ventilatedBirthweight750-1249 grams ClinicalRDS a/AP02<0.22 2-4hoursldCongenitalabnormality Provenlungmaturity
(methodoftestingnot stated)
Growthetarda ion Hydropsfetali Maternalopiatebus Maternalchorioamnionitis
SurvivalwithoutBPD Respiratorysupport Complicationsofprematurity
Berrytal(1994) Doserangingstudy(263 infants) Exosurf12st dy
Randomised Multicentre(14centr s) Sealedenvelopes (stratificationbygender, weightand/AP02t entry) Blinded(drugadministration team) 2.5-7ml/kgExosurfr airplacebowithsecond dose(samvolume)t 12hoursifstillventilated
Birthweight>1250grams ClinicalRDS a/AP02<0.22 Lessthan24hourld
Congenitalabnormality Provenlungmaturity (methodoftestingnot stated) Growthetarda ion Hydropsfetali
Deathby14days DeathfromRDS Durationofventilatory support Complicationsfprematurity
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Table13:Summari softherandomisedri linvolvingEx surf(continu d) StudyMetho sParticipantsExcl sioOu ome CorbetetaI(1995a) Singleversus3dose prophylaxistrial(826 infants) Exosurf13st dyRandomised Multicentre(33cent s) Sealedenvelopes (stratificationbygender andweight) Blindedfor2ndan3r doses,1st segiv nt allb bies(drug administrationteam) 5ml/kgExosurfatbirthwit furtherdosesat12nd 24hoursifstillventilatedBirthweight700-1100grams
Congenitalabnormality Provenlungmaturity (methodoftestingnot stated) Growthretardation Hydropsfetali Maternalopiateabus Maternalchorioamnionitis
Survivalat28d yswithout BPD Ventilatorandoxygen requirements Complicationsf prematurity
Pramaniketl(1992) Twoversusfourdose rescuetrial(522infants) Exosurf17trial
Randomised(methodot stated) Multicentre(36centr s)
5ml/kgExosurfwith subsequentdo esat12 hourlyintervalsfstill ventilated
Birthweight>1250grams ClinicalRDS a/AP02<0.22 2-24hoursld
Notstated
Neonatald ath Complicationsof prematurity(pulmonar airleak,NEC,IVH)
Longetal(1992a) Threeversussixdos prophylaxistrial(348 infants) Exosurf19st dy
Randomised(methodot stated) Multicentre(36centr s)
5ml/kgExosurfwith subsequentdo sat12 hourlyintervalsfstill ventilated
Birthweight<750grams
Notstated
Neonatald ath Complicationsf prematurity(pulmonar airleakndIVH) Publisheddatavailableon only228babies.
OO
U)
Table13:Summari softhrandomisedri linvolvingEx surf(continued) StudyMetho sPar icipantsExcl sionOu ome OSIRISstudygroup(1992) Earlyversuslatexosurf (2690infants) OSIRISstudygroup(1992) Twoversusfourdosef Exosurf(6757infants)Randomised Multicentre Telephonerandomisation Notblinded 5ml/kgExosurfat randomisationorwhen a/AP02<0.22with seconddoseat12 hoursifstillventilated (andthirfou thdoses ifallocatedund rthe concurrentst dy) Randomised Multicentre Telephonerandomisation Notblinded 5ml/kgExosurfat randomisationorwhen a/AP02<0.22with furtherdos sat12 hourlyintervalsAtriskofRDS Lessthan2hourld Ventilated
Congenitalabnormality
AtriskofRDS Lessthan2hourld Ventilated a/AP02<0.22or" triskf RDS"
Congenitalabnormality
Deathanyst ge Deathorxygen dependencyat28ys Deathorxygen dependencyat"EDD" Complicationsf prematurity Deathanyst ge Deathorxygen dependencyat28ys Deathorxygen dependencyat"EDD" Complicationsf prematurity
CO
Table13:Summariesoftherandomisedtri linvolvingEx surf(cont nued) StudyMethodsParticipantsExclusionsOutcom s EuropeanExosurfStudy (1992)-Earlyversuslate Exosurf(420infants)Randomised Multicentre Sealedenvelopes,str tifi d bygestationands x. Blindedfirstdo fEx surf orairplacebowith rescueifa/AP02<0.22. Seconddoseat18 hoursGestation26-9weeks Lessthan2hoursld
Congenitalabnorm lity Hydropsfetalis Maternalchorioamnionitis
Neonatalsurviv lwithout cranialUSS abnormalities RDSrequiringr sc e therapy Durationofintensivecar , oxygentherapy Complicationsf prematurity
OO Lyi
Outcome measures of the complications of prematurity were pre-defined. The primary
outcomes most commonly used were the incidence of bronchopulmonary dysplasia (BPD) or
chronic lung disease (CLD), neonatal mortality or neonatal survival without BPD/CLD.
Trials 01 and 02 (Bose et al 1990), 03 (Stevenson et al 1992) and 04 (Corbet et al 1991a and
1991b) were "prophylaxis" trials using a single dose of Exosurf 5ml/kg (67.5mg/kg of
DPPC) administered as soon as possible after birth. Trials 05 (Long et al 1991b), 06 and 09
(combined and reported as a single study by Long et al 1991a), 07 (Smyth et al 1995) and
07 (McMillan et al 1995) were "rescue" trials whereby Exosurfwas administered to infants
who were clinically and radiologically diagnosed as having RDS. To standardise the severity
of RDS at which infants became eligible for these trials, a cut-off employing the
arterial/alveolar pressure ratio (a/AP02) of <0.22 was used. This ratio was used because the
"normal" range is more stable with changing inspired oxygen concentrations. This stability
has allowed a value of 0.75 to be defined as the lower limit of normal in an adult (Gilbert &
Keighley 1974).
Trials 12, 13, 17 and 19 looked at different dosing schedules and amounts of phospholipids
(Table 14). Trials 10, 11, 14 and 18 were follow-up studies, and 15 and 16 were bridging
protocols.
In trials where a single dose ofExosurfwas given prophylactically there were reductions in
the ventilator and oxygen requirements. The 03 trial (Stevenson et al 1992) did not
demonstrate the same benefits for infants treated with Exosurf that were seen in the other
trials. This trial had investigated a less mature population of infants and the only result to
reach statistical significance was an increase in CLD among surviving infants in the treated
arm. The result was not fully explained, but several ideas were postulated. These include;
whether the more immature infants require more than one dose (i.e. the more immature
infants have less endogenous surfactant and a single dose of exogenous surfactant might be
"used up" or inactivated fairly readily); there was an excess of male infants in the treatment
arm - this is one of the risk factors for RDS and also a risk factor for a worse outcome
(chapter 1); there is also a co-existing immaturity of non-pulmonary organs that contribute
to mortality in this birth weight/gestation group - surfactant therapy has no direct influence
on these.
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*Onedos=5ml/kgExosurfne atalunle sstated Studies10,14and8werfollow-upstu i5and16werebridgingprotocols
It is likely that a number of these different factors played a role in the results from the 03
trial. Increasing immaturity is reported to predict poor response to exogenous surfactant
(Skelton & Jeffrey 1996) and infants in whom there is a poor response to surfactant have
worse outcomes (Hamvas et al 1993, Kuint et al 1994).
Whether these infants would have benefited from additional doses of surfactant was not
addressed in infants this immature, however the 13 trial (Corbet et al 1995a, Gerdes et al
1991) examined whether a further two doses after the initial prophylaxis dose was of benefit
in slightly more mature infants. Neonatal death and NEC were significantly reduced after
multiple doses rather than a single dose. The study also demonstrated better oxygenation and
lower mean airway pressures after 24 hours of age for this group.
Another consideration regarding the 03 trial is that outcomes are reported at 28 days. The
average gestations at birth were 24.9 weeks (treatment group) and 24.8 weeks (placebo).
Thus the 28 day outcome relates to a corrected gestational age of <29 weeks, the clinically
more meaningful definition of CLD at 36 weeks corrected age was not used and there may
have been differences if this definition had been used.
The 01/02 (Bose et al 1990) and 04 (Corbet et al 1991a and 1991b) trials both demonstrated
significant reductions in pulmonary air leaks, but only in the 04 trial was this accompanied
by a reduction in neonatal mortality.
The two dose "rescue" trials - trial 05 (Long et al 1991b), trial 07 (Smyth et al 1995), trial
08 (McMillan et al 1995) and trials 06 / 09 (Long et al 1991a) - all used Exosurf in infants
with clinical and radiological RDS, and in whom the a/APCb was <0.22. A second dose was
given 12 hours later to infants who remained ventilated. In all these "rescue" trials there was
improved neonatal mortality (Table 15) but in the 07 trial (looking at the most immature
infants of 500-749 grams birth weight) this was a trend only and did not achieve statistical
significance. Fewer pulmonary air leaks were reported in "rescue" all the trials except the 07
trial. Again like the prophylaxis (03) trial in very immature infants (Stevenson et al 1992) it
appears that Exosurfhas a less beneficial effect than in more mature infants.
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Although the investigators had embarked on these trials of Exosurf using a dosage of
67.5mg/kg (5ml/kg) of DPPC, there was little evidence to suggest that this was the optimum
dosage for a neonate. Work by Jackson et al (1986) had suggested the alveolar surfactant
pool after adaptation to extra-uterine life was lOOmg/kg, this compared with 4-5 mg/kg
found in preterm infants with RDS (Adams et al 1970, Hallman et al 1986). The Exosurf 12
trial (Berry et al 1994) attempted to discover if there was any benefit to using a smaller or
larger dose. Recognising that very large numbers of infants would be needed to demonstrate
differences in mortality and chronic lung disease, the researchers concentrated on ventilation
requirements, duration of ventilation and death from RDS.
Both the 5ml/kg and 7.5ml/kg groups showed improvements over the 2.5ml/kg group but
only in terms of ventilatory requirements in the short term. The authors concluded from this
that 5ml/kg and 7.5ml/kg were better than 2.5ml/kg but that there was no additional benefit
of 7.5ml/kg over 5ml/kg. The findings are very much in keeping with those of the
Surfactant TA trial of Konishi et al (1990) looking at doses of 60 mg/kg versus 120 mg/kg
ofphospholipids.
The question of optimum number of doses raised by the Exosurf 13 trial was further
explored in the 17 (Pramanik et al 1992) and 19 (Long et al 1992) trials. The results
obtained showed that the more doses that were given the more favourable the outcomes.
Whereas the 13 trial had shown a reasonably large benefit of three over one dose, there was
less benefit to be gained when using four as opposed to two doses (17 trial) or six as
opposed to three doses.
The optimum number of doses was also investigated as part of a UK based study - the
OSIRIS (Open Study of Infants at high risk of or with Respiratory Insufficiency - the role of
Surfactant) trial. This trial (The OSIRIS Collaborative Group 1992) looked at two aspects of
drug administration under the auspices of a single trial; the first - whether early or late
administration was better is discussed more fully in chapter 6; the second - looking at the
optimum number of doses (up to two versus up to four 5ml/kg doses) - suggests that third,
and subsequent, doses of surfactant do not significantly improve outcomes. Treatment
investigational new drug experience with Exosurf under the regulations of the Food and
Drug Administration (Easa et al 1992) agreed with the OSIRIS trial but stated that some
infants might benefit from the third dose.
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The last large Exosurf trial to be discussed also came from Europe. This study (The
European Exosurf Study Group 1992) examined early versus late treatment using Exosurf
but underwent a change in protocol after publication of the Exosurf 05 trial (Long et al
1991b). It is discussed in chapter 6.
Overall Exosurf was shown to be both safe and efficacious. Few adverse events were
reported in the North American Exosurf and the two European studies. The 03 trial
(Stevenson et al 1992) reported what was a worrying adverse event of an increase in
pulmonary haemorrhage from 2% to 12%. In other trials there was no difference. A
retrospective analysis did not reveal any evidence that Exosurf affected coagulation (Long
et al 1992b). Most pulmonary haemorrhages occur as a result of pulmonary oedema and
patent ductus (Garland et al 1994), and authors of the 03 study suggested that a non¬
significant excess of treated ducts in the Exosurf group might have contributed to this.
Chatfield et al (1994) reported adverse experiences with Exosurf treated outside the trials,
postulating that the relatively large volume (5ml/kg) might be a problem and Saliba et al
(1994) suggested the large volume may also cause hypercarbia and altered cerebral blood
flow during rapid instillation. Longer-term follow-up of Exosurf-treated infants (Table 12)
suggested that despite better neonatal survival there was no increase in the numbers of
handicapped children.
As with other surfactants further placebo-controlled trials of Exosurf can no longer be
considered to be ethical. Exosurf is the synthetic surfactant most widely used on a global
basis. It is not surprising that most trials between synthetic and animal-derived surfactants
use Exosurf These trials are discussed in chapters 8.
5.3.2 Meta-analysis of the randomised controlled trials ofExosurf
Method
The objective of this section was to assess the effect of intra-tracheal administration of
Exosurf administered either prophylactically or in premature infants with established RDS.
The search strategy outlined in section 5.1.2 was used to examine outcomes in randomised
controlled trials that compared the effect ofExosurf to controls in preterm infants with or at
risk of RDS. Data regarding clinical outcomes, particularly relating to neonatal mortality
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and respiratory complications of prematurity were excerpted from published reports of the
clinical trials and analysed using the statistics outlined in section 5.1.2.
Studies fulfilling the following criteria were included
(a) Types of studies - Randomised controlled trials comparing Exosurf to control receiving
either placebo or no treatment.
(b) Types of participants - preterm neonates at risk of or with clinical and radiological
evidence of RDS requiring assisted ventilation.
(c) Types of intervention - Infants randomised to receive Exosurf versus control treatment
(intratracheal administration of air placebo).
(d) Types of outcome measures - Data for the following clinical outcomes are included in
the meta-analysis: neonatal mortality, pulmonary air leak, patent ductus arteriosus,
necrotising enterocolitis, severe intraventricular haemorrhage (Papile Grade III) and/or
periventricular echodensities (Papile Grade IV), bronchopulmonary dysplasia (at 28
days in neonatal survivors), bronchopulmonary dysplasia or death (at 28 days). In
particular for the North American Exosurf trials BPD was defined as:
1). Presence of tachypnoea and retraction
2). Need for supplemental oxygen
3). Chest x-ray changes rating a score of >4 using Edwards' classification
(Edwards 1982).
Results
The following studies were identified as suitable for inclusion:
Preliminary trial of Exosurf (Phibbs et al 1991)
Exosurf Trial 01 / 02 (Bose et al 1990)
Exosurf Trial 03 (Stevenson et al 1992)
Exosurf Trial 04 (Corbet et al 1991a and 1991b)
Exosurf Trial 05 (Long et al 1991b)
Exosurf Trial 06 / 09 (Long et al 1991 a)
Exosurf Trial 07 (Smyth et al 1995)
Exosurf Trial 08 (McMillan et al 1995)
The trials that compared different doses, different dosing schedules and early versus late
administration were unsuitable for inclusion. All these trials are summarised in Table 13.
Treatment of premature infants with Exosurf leads to an improvement in oxygenation and
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ventilatory requirement. It has the following clinical impact (Figure 4):
Neonatal Mortality: All trials report on the risk of neonatal mortality and all trials
except the 03 trial (Stevenson et al 1992) and 07 trial (Smyth et al 1995) reported a decrease
in the risk of neonatal mortality associated with Exosurf use. These two trials examined the
use of Exosurf in the most immature infants where a high mortality from non-respiratory
causes would negate some of the benefit gained by improving respiratory disease. However
even when the meta-analysis includes the 03 and 07 trials the typical estimate suggests a
decrease in the risk of neonatal mortality associated with Exosurf treatment (typical relative
risk 0.74, 95% CI 0.64 to 0.86; typical risk difference -4.9%; 95% CI -7.4 to -2.5%).
PulmonaryAir Leak: Again all trials report this outcome, using an all-encompassing
definition of pulmonary air leak syndrome. As such this does not differentiate
pneumothoraces from PIE. The typical estimate suggests a decrease in the risk of pulmonary
air leak syndrome associated with Exosurf use (typical relative risk 0.68, 95% CI 0.62 to
0.75; typical risk difference -12.5%; 95% CI-15.6 to -9.3%).
Patent Ductus Arteriosus: All trials reported on the incidence of PDA requiring
treatment (indomethacin or surgical ligation). The typical estimate shows no difference in
the risk of significant PDA associated with Exosurf (typical relative risk 0.96, 95% CI 0.91
to 1.02; typical risk difference -2.2%; 95% CI-5.5 to +1.2%).
Necrotising Enterocolitis: The typical estimate shows small non-significant increase
in the risk ofNEC after Exosurf (typical relative risk 1.34, 95% CI 0.95 - 1.89; typical risk
difference +1.1%; 95% CI -0.2 to +2.3%).
Intraventricular Haemorrhage: The Exosurf trials report the incidence of severe
(grade III) IVH and/or periventricular echodensities (periventricular haemorrhage and
ischaemia). The typical estimate reported a trend to decreased risk of severe IVH/
periventricular echodensities after Exosurf (typical relative risk 0.91, 95% CI 0.74 - 1.13;
typical risk difference -0.8%; 95% CI -2.8 to +1.1%).
Bronchopulmonary Dysplasia / Chronic Lung Disease: This was one of the primary
outcomes ofmost of the North American Exosurf trials. There had been a fairly widespread
expectation prior to these trials, which were among the first large trials of surfactant in a
neonatal population that RDS and all its complications would be reduced. The typical
estimate of oxygen dependency at 28 days postnatal age in survivors shows a decrease in the
risk of BPD/CLD among surviving infants treated with Exosurf (typical relative risk 0.82,
95% CI 0.69 - 0.97; typical risk difference -3.2%; 95% CI -6.0 to -0.4%).
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Figure 4: Meta-view charts of
treated infants and controls.




























Bronchopulmonary Dysplasia / Chronic Lung Disease OR Death: The typical
estimate of oxygen dependency or death at 28 days postnatal age shows a decrease in the
risk of BPD/CLD among surviving infants treated with Exosurf (typical relative risk 0.82,
95% CI 0.74 - 0.91; typical risk difference -6.0%; 95% CI -9.1 to -2.9%).
Conclusion
Exosurf was shown to be both safe and efficacious It reduces oxygen and ventilator
requirements during the acute phases of RDS. It is the only surfactant that has been shown
to reduce the incidence of BPD/CLD in surviving infants although the limitations of using a
28 day definition need to be taken into consideration. Incidence of neonatal death and
pulmonary air leak were significantly reduced, but other complications of prematurity
including PDA and NEC were not.
5.4 Survanta (beractant) Abbott Laboratories, Chicago,
Illinois, USA
5.4.1 Development and early trials of Survanta:
Survanta (beractant) is a derivative of the bovine surfactant used by Fujiwara et al (1980).
This was developed and became commercially available under the name Surfactant TA
(Surfacten, Tokyo Tanabe, Tokyo, Japan). This product was then licensed by Abbott
Laboratories and subsequently launched under the Investigational New Drug program in the
USA, acquiring the name Survanta in 1993. Beractant is widely available and is also known
as Survanta-Vent in Sweden, Switzerland and Malaysia. This review considers all the
published trials of beractant irrespective of the name and place of manufacture (see Table
16). The only differences between Surfactant TA and Survanta relate to phospholipid
concentration (30 mg/ml versus 25 mg/ml) and an additional final stage autoclaving of
Survanta. These differences are insufficient to consider the surfactants as separate entities.
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Survanta initially became available in the United States under the name Surfactant TA, thus
some early trials use the name Surfactant TA. Following US Food and Drug Administration
(FDA) approval, the product that was made by Ross/Abbott Laboratories became known as
Survanta {personal communication - RF Soli). It is therefore possible to find an abstract,
such as that by Horbar et al (1988), using the name Surfactant TA and the full-published
trial using the name Survanta (Horbar et al 1990). In general Surfactant TA is the name of
the product of the Japanese manufacturers, whereas Survanta is that used by the American
Ross/Abbott Laboratories.
Beractant is a modified lung surfactant extract obtained from minced bovine lung by organic
solvent extraction. The extract is first sterilised by autoclaving and then modified through
the addition of DPPC, tripalmitin and palmitic acid. This is then dispersed in physiological
saline to give a phospholipid concentration of 25mg/ml. The final preparation contains
approximately 88-90% phospholipids, 3% triglycerides, 6% free fatty acids, 1% protein and
0.2% cholesterol. During the early trials the surfactant preparation (usually Surfactant TA)
was frozen and stored as a lyophilised powder at -20°C. It was thawed at room temperature
for about 20 minutes prior to use and mixed with variable amounts of saline. Survanta is no
longer frozen and is available ready mixed. The in vitro properties of Surfactant TA have
been reviewed by Taeusch et al (1986).
Survanta is given at a dose of lOOmg/kg of phospholipids. The volume (4 ml/kg), therefore,
represents a substantial proportion of the infants' tidal volume and to avoid flooding the
lungs it is given in aliquots of 2 ml/kg. After each aliquot the infant is reattached to the
ventilator or bag and mask and given about one minute of positive pressure ventilation. Thus
compared with the two small volume surfactants (Curosurf and ALEC), Survanta is more
difficult to administer.
Fujiwara and colleagues were responsible for the initial development of beractant. It was
shown to improve pulmonary mechanics in immature rabbits (Fujiwara et al 1979a) and to
reduce the lung injury sustained as a result of positive pressure ventilation (Fujiwara et al
1979b). It was then tested in an unselected human neonatal population (Fujiwara et al 1980).
Ten infants of a mean gestation of 30 weeks and severe RDS were treated with a single dose
of the surfactant. Within 3 hours of surfactant administration the mean Fi02 had decreased,
and within 6 hours mean airway pressure had decreased.
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Eight of the infants survived. The two deaths were unrelated to RDS: one infant died with
post-operative complications 36 hours after surgery for tracheo-oesophageal fistula, the
other died at 30 days of age with Serratia sepsis). All nine infants who survived the first
week developed patent ducts - an unexplained finding but one that came to dominate the
thinking in some of the later trials. Of the eight long-term survivors, one remained oxygen
dependent at several months.
The next published trials ofSurfactant TA appeared in 1987 (Raju et al 1987, Gitlin et al
1987, and were small trials that compared a single dose of Surfactant TA against a saline
placebo in established RDS. The aim of the trials was to establish the safety and efficacy of
the surfactant, and to demonstrate the changes in oxygenation that occurred.
In the meantime work was being undertaken to establish the optimum dosage for Surfactant
TA (Konishi et al 1988). Although the early trials had used a dose of approximately
lOOmg/kg of phospholipids, it was unclear whether this was the best dose for infants with
RDS. This trial compared doses of 60mg/kg versus 120mg/kg in infants who were shown to
have immature endogenous surfactant (screening their gastric aspirates prior to enrolment).
The trial was designed to look at the relatively short-term outcomes of oxygenation in the
period after surfactant rather than the neonatal outcomes. It was found that both doses
improved oxygenation but that the higher dose produced a more sustained response. The
high dose group also had fewer survivors with CLD. It is likely that the comparable initial
improvements followed by a later worsening of the RDS was due to exogenous surfactant
being effective initially but in the low-dose group the smaller amounts of surfactant were
inactivated by proteinaceous leak. In the end a dose of lOOmg/kg of phospholipids was
recommended for the commercially available product.
The move into the American and world market by Survanta was preceded by several trials
that paralleled the Asian trials of Surfactant TA and further studies using animal models
(Vidyasagar et al 1985). The major difference between the two sets of trials is that the Asian
investigators screened all infants using a stable microbubble test (Pattle et al 1979) on their
gastric aspirates. A "less than weak" stable microbubble rating (<10 bubbles per mm3)
indicated surfactant deficiency. All infants in the Asian studies (Konishi et al 1988, Chen et
al 1990, Fujiwara et al 1990, Konishi et al 1992) had immature surfactant.
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The stable microbubble test had been developed by Pattle et al (1979) and was intended for
use on samples of amniotic fluid. The investigators in the Surfactant TA studies reported
that it was easy to use and reliable (Chida et al 1991) and to be 100% predictive on testing
amniotic fluid (Chida & Fujiwara 1993). On tracheal aspirates the sensitivity of the stable
microbubble test remained high (>90%) but its specificity was only 52% (Friedrich et al
1998). Testing for surfactant maturity using samples other than the amniotic fluid such as
gastric aspirates has been found to be even less reliable (Rtidiger et al 1998, Teeratakulpisan
et al 1998).
Two identical studies in North America (Horbar et a/1989) and Europe (Horbar et al 1990)
followed looking at a single "rescue" dose of Survanta in established RDS. They were
designed to establish the early (<72 hours) efficacy of Survanta compared to air placebo.
Despite this simply primary outcome the trials also showed significant reductions in
pneumothoraces in treated infants however the FDA halted the European Survanta trial
(Horbar et al 1990) after an excess of severe (grades III and IV) IVH was found in the
Survanta arm. No explanation could be offered for this finding. With the exception of a
non-significant excess of severe IVH in the Survanta arm of a multiple dose versus control
study (Hoekstra et al 1991) this finding was not confirmed elsewhere.
Soli et al (1990) used a single dose of Survanta prophylactically and again both ventilation
and oxygen requirements were shown to be better in the treated group. Of the outcomes at
28 days, there were statistically significantly fewer pneumothoraces in the surfactant group
but significantly more cases of necrotising enterocolitis.
Larger multicentre placebo controlled studies involving 400 (Hoekstra et al 1991) and 800
infants (Liechty et al 1991) comparing multiple doses of Survanta followed. Up to four
doses of surfactant were used, with additional doses given to infants who remained
ventilated with an Fi02 > 0.3. These trials produced similar results that clearly demonstrated
the early benefits of Survanta (oxygen and ventilator requirements), but they also
demonstrated that Survanta treatment reduced both overall neonatal mortality and mortality
from RDS.
Overall the placebo-controlled trials of Surfactant TA/Survanta were fairly consistent in
reporting reductions in early oxygen and ventilator requirements. Most studies also reported
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significant reductions in pulmonary air leaks (reported variably as pulmonary interstitial
emphysema, pneumothorax or "air leak"). Only Hoekstra et al (1991) and Liechty et al
(1991) demonstrated a significant reduction in neonatal mortality, most of which arose
because of a similarly significant reduction in deaths from RDS. It is perhaps significant that
these studies were large multicentre studies recruiting 428 (Hoekstra et al 1991) and 798
infants (Liechty et al 1991), and therefore statistically powered to do so. Only the study of
Fujiwara et al (1991) reported a reduction in survivors with CLD at 28 days. However the
small numbers mean that one additional infant in the treatment arm requiring oxygen at this
stage would prevent the study reaching significance. All statistically significant outcomes in
the placebo-controlled trials of beractant, irrespective of commercial source, are shown in
Table 17.
The other studies involving one of the beractant preparations that have been reported are:
• Konishi et al (1992) - a randomised comparative trial between early and late
administration ofSurfactant TA (discussed further in chapter 6).
• Zola et al (1993a) a comparison of three methods of administering Survanta in
infants with established RDS.
• Zola et al (1993b): Treatment Investigational New Drug (TIND) experience
with Survanta.
• Trials that compare Survanta with another surfactant (versus Exosurf
Curosurfand Infasurf) are discussed in chapter 8.
The work by Zola et al (1993a) arose because of concerns about the administration
technique involving disconnecting the infant from the ventilator on 3-4 occasions whilst
giving surfactant. This procedure was based on the work of Fujiwara et al (1980), and
persisted through the subsequent development of beractant. Other surfactants can be
administered in a single aliquot that clearly is easier to administer, although some have the
advantage in that they were smaller volumes.
Zola et al found some minor differences between the groups, for example administering
Survanta in 2ml/kg aliquots produced more reflux up the ET tube, four lml/kg aliquots took
longer to administer than two aliquots. However there were no differences in the numbers of
infants who had bradycardia and/or hypoxia during surfactant administration, nor were there
differences in long-term outcomes.
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A Treatment Investigational New Drug (TIND) programme under an FDA agreement added
to the experience gained through randomised trials (Zola et al 1993b), and reflected use of
Survanta outside academic centres. The results in this programme were consistent with
those in the controlled trials. No new safety problems were identified and the rate of adverse
events was, if anything, lower in the TIND programme than in the trials.
Longer-term follow-up of infants in the above studies is limited to those infants enrolled in
the two multiple dose trials. At an adjusted age of 6 months, beractant-treated infants had
significantly more wheezing than control infants but had a significantly reduced need for
supplemental oxygen and a significantly lower incidence of cerebral palsy (Survanta
Multidose Study Group 1994).
Concerns regarding the immunological effects of beractant were also dispelled. Specific
immunological responses to the bovine surfactant proteins present in Survanta could not be
detected during the neonatal period (Whitsett et al 1991) or at 6 and 12 months of age
(Survanta Multidose Study Group 1994).
Further placebo-controlled trials of beractant can no longer be seen to be ethical. However
research into beractant has continued in the form of comparative trials (versus synthetic and
other animal-derived surfactants). These are discussed in chapter 8.
5.4.2 Meta-analysis of the randomised controlled trials of beractant
(Survanta or Surfactant TA).
Method
The objective of this section was to assess the effect of intra-tracheal administration of
beractant (either Survanta or Surfactant TA) administered either prophylactically or in
premature infants with established RDS. The search strategy outlined in section 5.1.2 was
used to examine outcomes in randomised controlled trials that compared the effect of
beractant to controls in preterm infants with or at risk of RDS. Data regarding clinical
outcomes, particularly relating to neonatal mortality and respiratory complications of
prematurity were excerpted from published reports of the clinical trials and analysed using
the statistics outlined in section 5.1.2.
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Studies fulfilling the following criteria were included
(a) Types of studies - Randomised controlled trials comparing beractant (as either
Surfactant TA or Survanta) to control receiving either placebo or no treatment.
(b) Types ofparticipants - preterm neonates at risk of or with clinical and radiological
evidence of RDS requiring assisted ventilation.
(c) Types of intervention - Infants randomised to receive beractant versus control treatment
(intratracheal administration of air or saline placebo).
(d) Types of outcome measures - Data for the following clinical outcomes are included in
the meta-analysis: neonatal mortality, pulmonary air leak syndrome, PIE, pneumothorax,
patent ductus arteriosus, necrotising enterocolitis, total and severe intraventricular
haemorrhage (Papile Grade III-IV), bronchopulmonary dysplasia (at 28 days in neonatal
survivors), bronchopulmonary dysplasia or death (at 28 days).
Results
The following studies were identified as suitable for inclusion:
• Raju et al (1987): Randomised controlled, double blind trial of
Surfactant TA in established RDS
• Gitlin et al (1987): Randomised controlled trial of single dose
Surfactant TA in established RDS
• Horbar et al (1989): Randomised controlled trial of a single dose of
Survanta in established RDS
• Horbar et al (1990): European randomised controlled trial of a single
dose ofSurvanta in established RDS
• Soil et al (1990): Randomised controlled trial of single dose Survanta
in prevention ofRDS
• Chen (1990): Randomised controlled trial ofSurfactant TA
• Fujiwara et al (1990): Randomised controlled trial of single dose of
Surfactant TA in treatment ofRDS
• Hoekstra et al (1991): Randomised controlled trial ofmultiple doses of
Survanta in prevention of RDS
• Liechty et al (1991): Randomised controlled trial ofmultiple doses of
Survanta in established RDS
The other trials comparing different dosing schedules and early versus late administration
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were deemed unsuitable for inclusion in this meta-analysis. Details of all these trials are
summarised in Table 16. Trials between beractant and different surfactants are reviewed in
chapter 8.
Treatment of premature infants with beractant leads to an improvement in oxygenation and
ventilatory requirement. It has the following clinical impact (Figure 5):
Neonatal Mortality: All trials report on the risk of neonatal mortality. Only the
large trials of Hoekstra et al (1991) and Liechty et al (1991) are able to demonstrate
significant reductions in neonatal mortality after beractant. There are trends to reduced
neonatal mortality in the beractant group in all other trials except Horbar et al (1989) where
no difference existed. The typical estimate from the meta-analysis suggests a decrease in the
risk of neonatal mortality associated with beractant (typical relative risk 0.67, 95% CI 0.56
to 0.82; typical risk difference -7.4%; 95% CI -11.0 to -3.8%).
Pulmonary Air Leak: The trials vary in how they report this. Hoekstra et al (1991)
and Liechty et al (1991) report both PIE and other air leak separately. Horbar et al (1990)
reports other air leak without qualifying this further. All the other trials report both PIE and
pneumothorax as separate outcomes. No trials report any trend to fewer air leaks among
control infants and most trials report significant reductions in whatever air leak category that
they use. The typical estimate suggests a decrease in the risk of PIE associated with
beractant use (typical relative risk 0.49, 95% CI 0.41 to 0.59; typical risk difference -19.3%;
95% CI -23.9 to -14.8%). The typical estimate also suggests a decrease in the risk
associated with beractant use for pneumothoraces (typical relative risk 0.29, 95% CI 0.18 to
0.44; typical risk difference -21.8%; 95% CI -28.5 to -15.2%). Similarly for air leak
syndrome in general (typical relative risk 0.47, 95% CI 0.36 to 0.60; typical risk difference
-13.0%; 95% CI-17.1 to -9.0%).
Patent Ductus Arteriosus: All trials reported on the incidence of PDA requiring
treatment (indomethacin or surgical ligation). The typical estimate shows no difference in
the risk of significant PDA associated with beractant (typical relative risk 1.02, 95% CI 0.92
to 1.12; typical risk difference +0.8%; 95% CI -3.8 to +5.4%).
Necrotising Enterocolitis: All the North American trials and the European trial
(Horbar et al 1990) report this outcome. The typical estimate shows small non-significant
increase in the risk of NEC after beractant (typical relative risk 1.22, 95% CI 0.82 to 1.82;
typical risk difference +1.1%; 95% CI -1.0 to +3.2%).
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Figure 5: Meta-view charts of risk difference and relative risk between beractant







































Intraventricular Haemorrhage: The beractant trials report the incidence of total and
severe (grade III-IV) IVH. One trial of Survanta (Horbar et al 1990) reported a statistically
significant increase in both total and severe IVH in treated infants that led to termination of
that trial by the FDA. Nonetheless the typical estimate shows no difference in the risk of
IVH (any grade) after beractant (typical relative risk 1.01, 95% CI 0.91 to 1.12; typical risk
difference +0.3%; 95% CI -A.8 to +5.3%). Similarly there was no difference in the risk of
severe IVH (typical relative risk 0.99, 95% CI 0.83 to 1.17; typical risk difference -0.3%;
95% CI -4.1 to +3.5%).
Bronchopulmonary Dysplasia / Chronic Lung Disease: This was reported in all
trials of beractant. The typical estimate of oxygen dependency at 28 days postnatal age in
survivors shows a no difference in the risk of BPD/CLD among surviving infants treated
with beractant (typical relative risk 0.95, 95% CI 0.86 to 1.06; typical risk difference -4.1%;
95% CI-11.9 to+3.6%).
Bronchopulmonary Dysplasia / Chronic Lung Disease OR Death: The typical
estimate of oxygen dependency or death at 28 days postnatal age shows a decrease in the
risk of BPD/CLD among infants treated with beractant (typical relative risk 0.91, 95% CI
0.84 to 0.98; typical risk difference -8.4%; 95% CI -17.4 to -0.5%).
Conclusion
Beractant (as either Survanta or Surfactant TA) has been shown to be an effective drug for
reducing neonatal mortality. It reduces oxygen and ventilator requirements during the acute
phases of RDS. Neonatal death and pulmonary air leak (whether this is reported as
pneumothorax, PIE or a general air leak syndrome) are significantly reduced. But other
complications of prematurity including PDA and NEC are not. Horbar et al (1990) reported
an increase in total and severe IVH, however the meta-analysis suggests this result is
unusual and there is no increased risk.
5.5 Overall conclusion
All four of the surfactant preparations that received licenses in the UK have been shown to
be better than placebo for reducing neonatal mortality and early respiratory morbidity. Of
the four, ALEC has been subjected to the fewest number of trials. The only large
randomised trials of ALEC are the Ten Centre Study (Ten Centre Study Group 1987) and
the Two Centre Study (Morley et al 1988). Whereas Curosurf Exosurf and Survanta have
undergone a wider range of trials that not only looked at benefits compared to placebo but
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also examined other questions regarding timing of the first dose, the quantity of each dose,
the number of doses and different methods of administration. A simple comparison of the
results of the four meta-analyses (Figure 6) would suggest Curosurfmight be the best of the
currently available surfactants, however this method fails to take into account population
variables that can influence the incidence and severity of RDS. The only fair methods for
comparing different surfactants are direct comparisons. These are discussed in chapters 7
and 8.
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Figure 6: Meta-analysis of risk difference between surfactant treated infants and
controls for the four surfactants licensed in the UK.
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There are many questions that remain unanswered from simple placebo controlled trials of
exogenous surfactant. Data obtained from studies of any given surfactant may not be
applicable to the other preparations, but similarities in the doses and dosing schedules have
emerged with all surfactant preparations. This chapter reviews the evidence for the dose,
number of doses and timing of administration of surfactant.
6.1 Surfactant dose size
In clinical trials of surfactant the dose of phospholipids used varied from as little as 25 mg
irrespective of birth weight (Morley et al 1981) to 200mg/kg (Collaborative European
Multicenter Study Group 1988, Collaborative European Multicentre Study Group 1991,
Bevilacqua et al 1993).
Use of these dose sizes had very little scientific basis, although as more became known
about surfactant and surfactant deficiency it has become evident that a term infant who has
adapted to extra-uterine life has a surfactant pool size of approximately lOOmg/kg (Jackson
et al 1986). By comparison an infant with RDS has a surfactant pool size of 5-10mg/kg
(Hallman et al 1986).
Three trials have examined the effects of a varying dose of surfactant:
• Halliday et al (1993) - The EURO VI Study comparing multiple doses of Curosurf
in high (up to 600mg/kg, initial dose 200mg/kg) and low (up to 300mg/kg, initial
dose lOOmg/kg) dose regimens.
• Berry et al (1994) - Exosurf 12 study, a dose ranging study comparing 2.5ml/kg
(34mg/kg), 5ml/kg (67.5mg/kg) and 7.5ml/kg (lOlmg/kg) ofExosurf.
• Konishi et al (1988) - high (120mg/kg) versus low (60mg/kg) dose regimen of
Surfactant TA.
In the EURO VI study, infants treated with an initial dose of 200mg/kg of Curosurf
demonstrated better physiological improvements in ventilator and oxygen requirements in
the immediate post surfactant period. The nature of the trial comparing not only the
difference between doses but also the different number of doses precluded analysis of the
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effect of high versus low doses on longer-term outcomes as the number of doses and hence
total accumulated surfactant dose can also affect outcome (see section 6.2).
Thus question of whether an initial dose of 200mg/kg produces better longer-term outcomes
than lOOmg/kg remains unclear. Within the EURO VI study (Halliday et al 1993) no
statistically significant differences could be found in outcomes at 28 days or at discharge.
Where there were differences these were of a small magnitude (the greatest difference was
found in a 2.5% reduction in air leak in the high dose regime).
The other two trials compared the effects of a single dose of surfactant but using different
amounts. Konishi et al (1988) examined the effects of the two dose sizes (60mg/kg and 120
mg/kg) of Surfactant TA in infants of 1000-1499 grams ventilated for RDS soon after birth.
All infants had surfactant deficiency results on testing of their gastric aspirates. Both groups
initially showed reductions in Fi02 values and rises in calculated arterial-alveolar tension
ratio (a/AP02) after treatment, however after 6 hours there were differences with values in
the low-dose group showing a worsening of RDS. The high dose group required
significantly less oxygen between 6-72 hours after treatment, and had significantly higher
a/AP02 between 6-120 hours. In the longer-term significantly fewer infants in the high dose
group were ventilated at 30 days of age. There were no significant differences in neonatal
mortality probably due to the small numbers, but incidences of CLD at 28 days and IVH
were significantly lower in the high dose (120 mg/kg) group.
In the other study, Berry et al 1994 looked at doses of 2.5ml/kg, 5ml/kg and 7.5ml/kg
(34mg/kg, 67.5mg/kg and lOlmg/kg of phospholipids) of Exosurf in infants of >1250
grams. Infants were enrolled and given "rescue" surfactant once the a/AP02 was <0.22.
They could receive up to two doses. Infants in both the 5ml/kg and 7.5ml/kg groups showed
greater improvements compared to the 2.5ml/kg group in their short-term ventilatory
requirements. There were two extra deaths in the 2.5ml/kg group due to RDS (not
statistically significant), but the duration of ventilation was no greater in surviving infants.
Outcomes such as pulmonary air leak and the other complications of prematurity were not
reported. The authors nevertheless concluded that doses of 5ml/kg and 7.5ml/kg were better
than 2.5ml/kg but that there was no additional benefit of 7.5ml/kg over 5ml/kg.
It would seem from the studies of Konishi et al (1988) and Berry at al (1994) that low doses
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of surfactant are less effective than ones that give infants approximately 70-100mg/kg of
phospholipids. This would support evidence from a rabbit model of RDS with immediate
and delayed times of surfactant administration where Seidner et al (1995) showed that a
higher surfactant dose counteracted some of the surfactant inactivation that occurs with
proteinaceous leak. What remains unclear is whether much higher doses such as that used by
Halliday et al (1993) lead to clinically better outcomes. Neither this study nor the Berry et al
(1994) study could show any difference at 28 days, although both showed lower oxygen and
ventilator requirements in the early course of RDS. Evidence from a porcine model of RDS
using the surfactants Survanta and Curosurf showed greater changes in systemic and
cerebral blood flow after doses of 200mg/kg than after lOOmg/kg (Moen et al 1998). This
could potentially lead to ischaemic or haemorrhagic cerebral damage.
Conclusion
Whilst it appears that phospholipid doses of 70-100mg/kg are better than smaller doses,
there is no evidence that more is better and some evidence to suggest that it might be
counter-productive causing unwanted effects on systemic and cerebral circulations. Whether
by accident or design most surfactants are given in a dose of approximately 70-lOOmg/kg of
phospholipids.
6.2 How many doses are required?
Exogenous surfactant is lost from the alveolus in several ways. Some is incorporated into
the metabolic and re-cycling pathways and becomes mixed with endogenous surfactant
(Jobe et al 1993) and inactivation by serum proteins also plays a role (Ikegami et al 1983).
The amount of exogenous surfactant lost seems to be about 15-20% of the total (Pettenazzo
et al 1986), but this does not take into account the inactivated portion. With the
incorporation into endogenous surfactant only 20-30% of the dose can be recovered by
alveolar lavage in preterm lambs with RDS after 24 hours and turnover of alveolar
phosphatidylcholine in this model ofRDS was about 13 hours (Jobe et al 1989).
Several trials addressed the question of what is the optimum number of doses of surfactant.
These are:
• Corbet et al (1995a) - the Exosurf 13 study. A single versus up to three doses of
Exosurfused prophylactically in infants of 700-1100 grams.
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• Pramanik et al (1992) - the Exosurf 17 trial. Two versus four doses of Exosurf
used to treat infants >1250grams in a "rescue" strategy.
• Long et al (1992a) - the Exosurf 19 study. Three versus six doses ofExosurfused
prophylactically in infants of <750 grams.
• OSIRIS study group (1992) - Two versus four doses of Exosurf (some given as
early treatment, some given as late treatment).
• Speer et al (1992) - The EURO IV Study; single versus multiple doses of Curosurf.
The results among the studies were variable, but among the statistically significant results
were a reduction in neonatal mortality in a three dose group ofExosurf (Corbet et al 1995a),
and fewer pneumothoraces in infants treated with multiple rather than a single dose of
Curosurf (Speer et al 1992). There were no significant differences in the neonatal outcomes
in the studies that looked at two versus four or three versus six doses. The conclusion of the
authors of the largest study (OSIRIS study group 1992) was that third, and subsequent,
doses of surfactant do not significantly improve outcomes over two doses.
Conclusion
There is general consensus that most infants with RDS benefit from two doses of surfactant
irrespective of the type of surfactant used. Some more mature infants, particularly those that
have received antenatal steroids, may manage with only a single dose whereas in a minority
of infants more than two doses may be beneficial. In all studies the dosing regime employed
was predominantly a 12-hour interval between doses. No study has looked at the effects of a
variable dosing regime based on illness severity as determined using oxygenation index,
a/P02 or other parameter looking at ventilation or oxygenation.
6.3 When should the first dose of surfactant be
administered?
6.3.1 Evidence from animal models of RDS
The pathological processes that lead to the formation of the hyaline membrane seen in
postmortem histology begin soon after birth and may be exacerbated by factors such as
resuscitation manoeuvres, mechanical ventilation and oxygen therapy. Increasing maturity
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protects against this protein leakage (Ikegami et al 1996).
Leak of protein into the alveoli has long been recognised as an inhibitor of surfactant
function and contributory to RDS (Tierney & Johnson 1965, Taylor & Abrams 1966). Most
protein leak occurs early in the course of RDS, and this diminishes so that by 24 hours of
age there is a six-fold reduction in net influx of serum protein to the alveolus (Ikegami et al
1992). Protein leak would appear to be related to more than just ventilation and oxygen
exposure; Berry et al (1991) delivered and ventilated preterm lambs in which segments of
lungs were obstructed. There was still evidence of protein leak in the obstructed segments,
but not as much as in the ventilated portions of the lungs.
Treatment of RDS using conventional positive pressure ventilation exacerbates the protein
leak in RDS. It is thought that the cyclical volume changes that occur with shear forces lead
to alveolar disruption allowing protein leak. High frequency oscillatory ventilation (HFOV)
uses a higher mean airway pressure but with cycle volumes that are smaller than the tidal
volume of the ventilated infant. In comparison to conventional ventilation HFOV has been
shown to limit the development of proteinaceous material in animals with RDS (Coalson et
al 1989, Niblett et al 1989). When HFOV is combined with exogenous surfactant there is a
greater reduction in lung injury than if surfactant or HFOV had been used alone (Jackson et
al 1994). In addition reducing the protein leak with early use of HFOV prolongs the
effectiveness of exogenous surfactant (Froese et al 1993).
Prevention of the protein leak may also be achieved through surfactant administration
(Robertson et al 1985, Ikegami et al 1992, Seidner et al 1995). The sooner surfactant is
given the more effective it is: Maeta et al (1988) showed delaying surfactant for two hours
in a baboon model of RDS adversely affected compliance and oxygen requirements;
Cummings et al (1995) used preterm sheep to show similar differences in those receiving
early and late surfactant. Seidner et al (1995) showed that the amount of protein leak
correlated with the delay in surfactant administration - preterm rabbits treated at 30 minutes
of age had more severe RDS than those treated either immediately after delivery or at 15
minutes.
Researchers have questioned whether surfactant should be given before the first breath if it
is to be entirely protective. Most preterm neonates receive resuscitation that involves the
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establishing a resting lung volume through the use of positive airways pressure, either via a
pressure limited gas supply or a resuscitation bag. Both of these may give uncontrolled tidal
volumes that in turn may contribute to the start of pulmonary inflammation (Spears et al
1991, Bjorklund et al 1997, Wada et al 1997).
Pre-resuscitation treatment with surfactant can be protective against protein leak but whether
a clinically apparent advantage can be gained is not clear (Klopping-Ketelars et al 1994).
Intra-amniotic fluid administration of Exosurf has been shown to be no better than post¬
natal administration in preterm rabbits (Galan et al 1992). Intra-amniotic surfactant has been
reported in 6 neonates who developed only minimal RDS after treatment (Cosmi et al 1997).
The technical difficulties of administering surfactant intra-amniotically - close to the fetal
nostrils under ultrasound guidance and then stimulating respiratory activity using
aminophylline administered to the mother - are not inconsiderable. Despite this and the fact
that there is a net expulsion of lung fluid both in utero and during parturition the authors of
this report proposed that the intra-amniotic route offered a reliable option for antenatal
prevention ofRDS.
6.3.2 Evidence from trials in neonatal populations
There are several studies that have tried to examine this question in a neonatal population
(Table 18). "Prophylactic" surfactant has been advocated as being more beneficial than
"rescue" therapy (Morley 1997, Soli & Morley 1998) and early "rescue" is more beneficial
pthan late "rescue" (Yost & Soil 1999).
The literature, however, is confusing in the use of terms. This relates largely to the absence
of accepted definitions of "prophylactic" and "rescue" treatment. "Rescue" therapy is that
which is given when infants have developed respiratory failure due to RDS. A number of
different criteria, such as oxygen requirement >0.4 or a/AP02 <0.22 have been used to
decide when "rescue" surfactant should be given (Table 19). "Prophylaxis" should by
definition mean that all "at risk" infants receive surfactant before the onset of symptoms.
The issue of "prophylaxis" has been further complicated by the use of tests of surfactant
maturity such as the L/S ratio. Morley (1997) suggested that these preclude the trial being
from being "prophylaxis" whereas Soil & Halliday (1998) disagreed.
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Table18:Summariesofthri linvolvingearlyndl tadminist ationfsurfac a t StudyMethodsParticipantsEx lusionsOutcomes Dunnetal(1991)-trialof bLESindeliveryroom versusr sc eat6hour (122infantswithfurther 60controlsreceivingn surfactant) Kendigtal(1991)-trialof deliveryroomversus rescueInfas rf(479 infants)Randomised Singlecentre Sealedenvelopes(str tifi d bygestationand antenatalst roids) Notblinded EarlyarmintubatedASAP andgiven3-4mlof surfactant,latearm treatedifrequiring ventilationw thany02t >7cmH20 Randomised Multicentre(3cent s) Sealedenvelopes(str tifi d bycentre) Notblinded Earlyarmgiven3ml surfactantboluspriort respiration,latearmif radiologicalRDS, ventilatedw thFi020.4 at>7cmH20In-borni fants<30weeks gestation
Chromosomalrcongenital abnormality Rupturedmembranes>2 weeks MatureLISratioinamn tic fluid
In-borni fants<30weeks gestation
Congenitalabnormality consideredlethal
Differencesnthea/Aratio Ventilationrequireme ts anddurationofsupport Complicationsof prematurity Neonatalmortality SeverityofRDS(v ntilator andoxygen requirements) Complicationsof prematurity Allana ysedon"intentiont treatbasis"
Table18:Summariesofthtri linvolvingearlyandl tadminist ationfsur acta t(c tinued) StudyMethodsParticipantsEx lusionsOutcomes Merrittefa/(1991)- deliveryroomversus rescuehumansurfactant (trialofsingletonbirths- 107infantswithfurther 50non-surfactanttreated controls) Merritta/(1991)- deliveryroomversus rescuehumansurfactant (trialofmultiplebirths- 43infants)Randomised Multicentretrial Sealedenvelopes(str tified bycentrea dg station) Earlyarmgiven3.5ml/kg afterfewinfla ion breaths,latearmif ventilatedw thFi02>0.5 Quasi-randomised(otwin toeacharm,f rtriplets twoo"late"ande "early") Multicentretr al Sealedenvelopes(str tified bycentrea dgestation) Earlyarmgiven3.5ml/kg afterfewinflation breaths,latearmif ventilatedw thFi02>0.5Between24-29weeks gestation Between24-29weeks gestation
Congenitalabnormality Chromosomalabn rmality MatureLISratio Ruptureofmembranes>3 weeks Congenitalabnormality Chromosomalabn rmality MatureL/Sratio Ruptureofmembranes>3 weeks
Neonatald athrCLD Ventilatorysupport Complicationsof prematurity Neonatald athrCLD Ventilatorysupport Complicationsof prematurity
to
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Table18:Summariesofthri linvolvingearlyandl tadministrationfsur ac a t(c tinued) StudyMethodsParticipantsExclusionsOutcomes Konishiefa/(1992)-early versuslatesingledo ofsurfactantTA(32 infants)Randomised Multicentre Randomisationmethodnot stated Blindingmethodotstate Earlyarmgivensurfactant within30minutes,la e armt6hoursifFi02 0.4at>7cmH20Birthweight500-1500 grams. Intubated. Stablemicrobubbleteston gastricaspirateProlongedrupturef
membrane(>72 hours).
Evidenceofinfection (maternalfeveror gastricaspirate leucocytec untof <10). Congenitalmalformations Oligo-orpolyhydramnios. Apgarscore<4at5 minutes.
Differencesina/AP02t72 hours Differencesns v rityof RDS Outcomesat7nd28day
OSIRISstudygroup(1992) Earlyversuslatexos rf (2690infants)
Randomised Multicentre Telephonerandomisation Notblinded
5ml/kgExosurfat randomisationorwhen a/AP02<0.22with seconddoseat12 hoursifstillventilated (andthirfou thdoses ifallocatedund rthe concurrentst dy)
At riskofRDS Lessthan2hoursld Ventilated
Congenitalabnormality
Deathanystage Deathorxygen dependencyat28ys Deathorxygen dependencyat"EDD" Complicationsof prematurity















































































Table18:Summari softhri lsinvolvinge rlyandl tdmi istrationfsurfacta t(c nt nued) StudyMethodsParticipants
Exclusions
Outcomes
Kattwinkeletl(1993)- deliveryroomversus rescueInfa urf(1246 infants)
Randomised Multicentre(9centresbu datafrom8nly becauseofproblemsin 1centre) Sealedenvelopes(str tified bycentre) Notblinded Earlyarmgiven4.5 l surfactantbolusp iort respiration,latearmif ventilatedw thFi02>0.3
In-bornba ies Between29-32we ks gestation
Congenitalmalformation Congenitalsepsis Perinatalasphyxia(not defined) Toomature
Developmentofm derately severeRDS Complicationsf prematurity
Waltieal(1995)- prophylaxisversus rescuetrialofCuros rf (256infants)
Randomised Multicentre(12cent s) Telephonerandomisation (stratificationbycentre) Notblinded 100mg/kgCurosurfwithin 15minutesofbirthrif CXRshowsRDSand Pa02:Fi02<20kPa between3-18hoursf age
Gestation25-31weeks In-borniparticipating centre
Congenitalabnormality Prolongedrupturef membranes(>3weeks)
SurvivalwithoutBPDat28 days Ventilatorandoxygen requirements CXRappearances Complicationsf prematurity
bo
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Table18:Summariesoftherialsinv lvinge lyandlateadministrationofsu fac nt(co tinued) StudyMethodsParticipantsExclus onsOutcomes Verdertal(1999)-N sa CPAPandearlyversus lateCurosurf(60infants)Multicentretr al Sealednve opes (stratificationbycen re) AllbabiesreceivingCPAP, given200mg/kg Curosurfat randomisationiearly armorifa/AP02<0.22 inlatearm.<30weeksgestation Clinicalandr diological RDS. NasalCPAPinu e(>6cm H20 a/AP02between0.35and 0.22
Congenitalabnormality Prolongedrupturef membranes(>2week ) BirthasphyxiawiApgar score<3at5minutes Congenitalpneumonia
Needform chanical ventilationbeyond periodofsurfactant administration Neonatalmortality Oxygenrequirements Complicationsf prematurity







































































































Section 6.3.2 showed that evidence from animal models favoured of administering
surfactant as early as possible to obtain the maximum benefit. However preterm infants are a
heterogeneous group and some treated prophylactically may not develop RDS, they thus
receive unnecessary treatment.
Surfactant therapy is expensive (costs range from £150 per vial ofALEC to £400 per vial of
Curosurf - source British National Formulary 1999) and although these costs are small
compared to the overall cost of neonatal intensive care they may be important to healthcare
purchasers. Surfactant can only be administered to an infant that is intubated, and this has
been associated with some transient side-effects. To be considered effective an early or
prophylactic strategy needs to produce benefits that outweigh these considerations.
Table 18 shows trials that have compared two different strategies for administering
surfactant. A number of different outcomes were studied, and not all trials showed a benefit
of one strategy over the other. Again, variation in early and late strategies may well play a
part when it comes to positive and negative findings in these trials. The following meta¬
analyses look at:
1. Pre-ventilation (i.e. pre-first breath) versus rescue administration strategies. (Section
6.3.2a)
2. Prophylaxis within 15 minutes of birth versus rescue administration strategies. But
excluding studies that screen for surfactant maturity. (Section 6.3.2b)
3. Early administration versus late rescue administration strategies. Including all
prophylaxis, early and screened trials. (Section 6.3.2c)
6.3.2a Meta-analysis ofpre-ventilation versus rescue surfactant
administration strategies
Method
The objective of this section was to assess the effect of intra-tracheal administration of
surfactant prior to the first breath versus rescue treatment of established RDS. The search
strategy outlined in section 5.1.2 was used to examine outcomes in randomised controlled
trials that compared intra-tracheal administration of surfactant given prior to the first breath
versus rescue treatment of established RDS. Data were taken from trials involving any
surfactant and not just those that have been licensed in the UK. Data regarding clinical
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outcomes, particularly relating to neonatal mortality and respiratory complications of
prematurity were excerpted from published reports of the clinical trials and analysed using
the statistics outlined in section 5.1.2.
Studies were considered if they fulfilled the following criteria:
(a) Types of studies - Randomised controlled trials comparing a pre-ventilation strategy of
surfactant administration and a late rescue strategy in infants who develop symptoms
and signs of RDS.
(d) Types of participants - preterm neonates at risk ofRDS.
(e) Types of intervention - Infants randomised to receive surfactant prior to the onset of
respiration/respiratory support versus treatment in only those infants who reach criteria
(defined before the study) at which treatment is given.
(f) Types of outcome measures - Data for the following clinical outcomes are included in
the meta-analysis: neonatal mortality, chronic lung disease (at 28 days in survivors),
chronic lung disease or death (at 28 days), pulmonary air leak (reported as PIE and
pneumothorax), patent ductus arteriosus, severe intraventricular haemorrhage (Papile
grades III and IV).
Results
Only four studies were identified as suitable for inclusion in this meta-analysis - Dunn et al
(1991), Kendig et al (1991), Merritt et al (1991) and Kattwinkel et al (1993). A further
study that compared a pre-ventilation strategy versus an immediate post-resuscitation
strategy has been reported (Kendig et al 1998) but was excluded, as the latter arm was not a
"rescue" arm. Other studies in Table 18 were excluded since in all of these the early arm
received surfactant after the first breath.
Treatment of premature infants using a pre-ventilation surfactant administration strategy
appears to have no clear advantage in outcomes at 28 days. Some trends towards improved
outcomes are seen but these do not reach statistical significance (Figure 7).
Neonatal Mortality: All trials report on the risk of neonatal mortality. The typical
estimate from the meta-analysis suggests a trend to decreased neonatal mortality associated
with pre-ventilation surfactant administration (typical relative risk 0.80, 95% CI 0.58 to
1.11; typical risk difference -1.5%; 95% CI-3.8 to +0.7%).
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Figure 7: Meta-view charts of risk difference and relative risk in trials comparing pre-



























Pulmonary Air Leak: All trials report this outcome, but using the two sub-groups of
PIE and pneumothorax, rather than an all-embracing air leak syndrome. The typical estimate
suggests a trend to decreased risk of PIE associated with pre-ventilation surfactant
administration (typical relative risk 0.70, 95% CI 0.40 to 1.25; typical risk difference -3.6%;
95% CI -9.5 to +2.2%). Similarly, the typical estimate shows a trend to decreased risk of
pneumothorax associated with pre-ventilation surfactant administration (typical relative risk
0.83, 95% CI 0.53 to 1.29; typical risk difference -1.8%; 95% CI -6.0 to +2.4%).
Patent Ductus Arteriosus: The typical estimate shows a trend to increased risk of
significant PDA (requiring treatment) with pre-ventilation surfactant administration (typical
relative risk 1.34, 95% CI 0.89 to 2.00; typical risk difference +7.7%; 95% CI -2.8 to
+18.2%).
Severe Intraventricular Haemorrhage: The typical estimate from the meta-analysis
suggests a trend to increased risk of severe IVH (defined as Papile grades III and IV) with
pre-ventilation surfactant administration (typical relative risk 1.46, 95% CI 0.83 - 2.57;
typical risk difference +6.0%; 95% CI -2.7 to +14.6%).
Chronic Lung Disease: Surviving infants with CLD at 28 days were reported by all
studies. The typical estimate shows a no difference in the risk of CLD with pre-ventilation
surfactant administration (typical relative risk 0.95, 95% CI 0.77 - 1.16; typical risk
difference -0.9%; 95% CI -4.3 to +2.5%).
Chronic Lung Disease OR Death: This reported by all studies. The typical estimate
shows a small trend to decreased risk of CLD or neonatal death with pre-ventilation
surfactant administration (typical relative risk 0.92, 95% CI 0.78 - 1.08; typical risk
difference -2.0%; 95% CI -5.6 to +1.7%).
The implications of these results are discussed in section 6.3.2d.
6.3.2b Meta-analysis ofprophylaxis versus rescue surfactant
administration strategies
Method
The objective of this section was to assess the effect of intra-tracheal administration of
surfactant administered prophylactically (including those where it was administered pre-
ventilation) to infants at risk of RDS versus rescue treatment of established RDS. In
particular tests for surfactant maturity were felt to preclude the study being considered as
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"prophylaxis". The search strategy outlined in section 5.1.2 was used to examine outcomes
in randomised controlled trials that compared prophylactic surfactant versus rescue
treatment of established RDS. Data were taken from trials involving any surfactant and not
just those that have been licensed in the UK. Data regarding clinical outcomes, particularly
relating to neonatal mortality and respiratory complications of prematurity were excerpted
from published reports of the clinical trials and analysed using the statistics outlined in
section 5.1.2.
Studies were considered if they fulfilled the following criteria:
(a) Types of studies - Randomised controlled trials comparing a prophylactic strategy
(without screening for surfactant maturity) of surfactant administration and a late rescue
strategy in infants who develop symptoms and signs ofRDS.
(b) Types of participants - preterm neonates at risk ofRDS.
(c) Types of intervention - Infants randomised to receive surfactant prophylactically (first
dose within 15 minutes of birth) versus treatment in only those infants who reach
criteria (defined before the study) at which treatment is given.
(d) Types of outcome measures - Data for the following clinical outcomes are included in
the meta-analysis: neonatal mortality, chronic lung disease (at 28 days in survivors),
chronic lung disease or death (at 28 days), pulmonary air leak (reported as PIE and
pneumothorax), patent ductus arteriosus, severe intraventricular haemorrhage (Papile
grades III and IV) and necrotising enterocolitis.
Results
Only five studies were identified as suitable for inclusion - Kendig et al (1991) and
Kattwinkel et al (1993) - trials using Infasurf Egberts et al (1993), Walti et al (1995) and
Bevilacqua et al (1996) - trials using Curosurf. Other studies in Table 18 were excluded,
either because they did not fit the definition of prophylaxis or the investigators used one of
the tests of surfactant maturity.
Treatment of premature infants at risk of RDS using a prophylactic surfactant administration
strategy appears to have several clear advantages in outcomes at 28 days with improved
outcomes seen in almost all complications ofprematurity at 28 days (Figure 8).
Neonatal Mortality: All trials report on the risk of neonatal mortality. The typical
estimate suggests decreased neonatal mortality associated with prophylactic surfactant
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administration (typical relative risk 0.57, 95% CI 0.43 to 0.74; typical risk difference -4.9%;
95% CI-7.1 to-2.6%).
Pulmonary Air Leak: The trials report this outcome, using the two forms of PIE and
pneumothorax rather than an all-embracing air leak syndrome. The typical estimate suggests
a trend to decreased risk of PIE associated with prophylactic surfactant administration
(typical relative risk 0.70, 95% CI 0.40 to 1.25; typical risk difference -3.6%; 95% CI -9.5
to +2.2%). Whereas, the typical estimate shows decreased risk of pneumothorax with
prophylactic surfactant administration (typical relative risk 0.59, 95% CI 0.38 to 0.90;
typical risk difference -3.8%; 95% CI -6.8 to -0.8%).
Patent Ductus Arteriosus: The typical estimate shows decreased risk of significant
PDA (requiring treatment) with prophylactic surfactant administration (typical relative risk
0.72, 95% CI 0.56 to 0.92; typical risk difference -9.0%; 95% CI -15.7 to -2.3%).
Severe Intraventricular Haemorrhage: The typical estimate from the meta-analysis
shows a decreased risk of severe IVH (defined as Papile grades III and IV) with prophylactic
surfactant administration (typical relative risk 0.62, 95% CI 0.42 - 0.93; typical risk
difference -6.1%; 95% CI -11.2 to -1.0%).
Chronic Lung Disease: Surviving infants with CLD at 28 days were reported by all
studies. The typical estimate shows a reduction in the risk of CLD with prophylactic
surfactant administration (typical relative risk 0.83, 95% CI 0.70 - 0.99; typical risk
difference -3.3%; 95% CI -6.6 to -0.1%).
Chronic Lung Disease OR Death: This reported by all studies. The typical estimate
shows a decreased risk ofCLD or neonatal death with prophylactic surfactant administration
(typical relative risk 0.76, 95% CI 0.66 - 0.87; typical risk difference -7.0%; 95% CI -10.5
to -3.5%).
The implications of these results are discussed in section 6.3.2d.
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Figure 8: Meta-view charts of risk difference and relative risk in trials comparing





























6.3.2cMeta-analysis of early versus late rescue surfactant
administration strategies
Method
The objective of this section was to assess the effect of early intra-tracheal administration of
surfactant in infants at risk of or with existing RDS versus late rescue treatment. The search
strategy outlined in section 5.1.2 was used to examine outcomes in those randomised
controlled trials that compared early versus late surfactant administration strategies. Data
were taken from trials involving any surfactant and not just those that have been licensed in
the UK. Data regarding clinical outcomes, particularly relating to neonatal mortality and
respiratory complications of prematurity were excerpted from published reports of the
clinical trials and analysed using the statistics outlined in section 5.1.2.
Studies were considered if they fulfilled the following criteria:
(a) Types of studies - Randomised controlled trials comparing any different temporal (i.e.
early vaersus late, where early could include prophylaxis or pre-first breath) strategies
for the prevention of or treatment ofRDS.
(b) Types of participants - preterm neonates at risk of or with existing RDS.
(c) Types of intervention - Infants randomised to receive surfactant either early
(prophylactically or as early rescue treatment) versus late rescue treatment.
(d) Types of outcome measures - Data for the following clinical outcomes are included in
the meta-analysis: neonatal mortality, chronic lung disease (at 28 days in survivors),
chronic lung disease or death (at 28 days), pulmonary air leak (reported as PIE and
pneumothorax), patent ductus arteriosus, intraventricular haemorrhage - given as overall
and severe (Papile grades III and IV) IVH - and necrotising enterocolitis.
Results
All studies in Table 18 are included with the exception of Kendig et al (1998) because this
trial compares two different prophylactic strategies. There is some overlap in the timings of
surfactant in trials considered in this review because the early treatment arm in some trials
may receive their surfactant at a later stage than the so-called late arm in another trial.
Treatment of premature infants at risk of RDS using an early surfactant administration
strategy appears to have several clear advantages in outcomes at 28 days with improved
outcomes seen in almost all complications of prematurity at 28 days (Figure 9).
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Neonatal Mortality: All trials report on the risk of neonatal mortality. The typical
estimate suggests decreased neonatal mortality associated with early surfactant
administration (typical relative risk 0.80, 95% CI 0.71 to 0.90; typical risk difference -3.6%;
95% CI -5.5 to-1.8%).
Pulmonary Air Leak: The trials report this outcome, using the two forms of PIE and
pneumothorax rather than an all-embracing air leak syndrome. More trials report the rates of
pneumothorax than PIE. The typical estimate suggests a decreased risk of PIE associated
with early surfactant administration (typical relative risk 0.54, 95% CI 0.40 to 0.73; typical
risk difference -7.0%; 95% CI -10.5 to -3.6%). Similarly, the typical estimate shows
decreased risk of pneumothorax with early surfactant administration (typical relative risk
0.68, 95% CI 0.59 to 0.73; typical risk difference -4.7%; 95% CI -6.5 to -2.8%).
Patent Ductus Arteriosus: The typical estimate shows no difference in the risk of
significant PDA (requiring treatment) with early surfactant administration (typical relative
risk 0.99, 95% CI 0.90 to 1.09; typical risk difference -0.3%; 95% CI -2.9 to +2.3%).
Intraventricular Haemorrhage (all grades): While more trials reported just severe
IVH (defined as Papile grades III and IV), a few trials also reported overall totals. The
typical estimate from the meta-analysis suggests no difference in the risk of IVH with early
surfactant administration (typical relative risk 1.15, 95% CI 0.88 - 1.51; typical risk
difference +6.2%; 95% CI-8.9 to +18.0%).
Severe Intraventricular Haemorrhage: On the other hand, the typical estimate from
the meta-analysis suggests a decreased risk of severe IVH (defined as Papile grades III and
IV) with early surfactant administration (typical relative risk 0.71, 95% CI 0.53 - 0.96;
typical risk difference -4.7%; 95% CI -8.9 to -0.6%).
Necrotising enterocolitis: The typical estimate shows no difference in the risk of
NEC with early surfactant administration (typical relative risk 1.11, 95% CI 0.83 to 1.47;
typical isk difference +0.5%; 95% CI -0.9 to +1.8%).
Chronic Lung Disease: Surviving infants with CLD at 28 days were reported by most
studies. The typical estimate shows a reduction in the risk of CLD among survivors after
early surfactant administration (typical relative risk 0.92, 95% CI 0.84 — 0.99; typical risk
difference -2.7 %; 95% CI -5.3 to -0.1%).
Chronic Lung Disease OR Death: This outcome was limited to those trials that
reported CLD at 28 days. The typical estimate shows a decreased risk of CLD or neonatal
death with early surfactant administration (typical relative risk 0.89, 95% CI 0.83 - 0.94;
typical risk difference -5.1%; 95% CI -7.6 to -2.6%).
139
6.3.2dSummary of results
The literature supports the view, both in meta-analysis and the majority of randomised
controlled trials that a policy of early surfactant therapy is better than a selective late rescue
therapy. This also applies when the surfactant is given prophylactically compared to a
rescue therapy. Because of the differences between the various trials and lack of any
uniform definition it is not possible to further subdivide the prophylaxis versus rescue trials
into those using an "early" rescue" and a "late" rescue. Whether prophylaxis retains its
beneficial effects compared to an early rescue strategy (such as administration on delivery
suite versus tragetted delivery on admission neonatal unit) cannot be shown.
Using the notion of "number needed to treat" to prevent an adverse event, it can be seen that
in order to prevent one additional neonatal death it would be necessary to treat an extra 28
infants using the early strategy. In contrast using a prophylactic strategy only 20 additional
infants would need to be treated to save that additional infant. This would suggest that a
prophylactic strategy is better.
The disadvantage of a prophylactic strategy is the need to treat infants who do not develop
RDS. In the five trials reviewed having a prophylactic strategy an average of 1.195 doses
were given to each infant, compared to an average of 0.677 doses per infant in the "late"
treatment arm. Translating both "number needed to treat" and number of doses to 100
infants, for every 100 infants treated prophylactically there would be an additional 5
neonatal survivors. They would be treated with 120 doses of surfactant (along with the
respiratory support that this entails) whereas a rescue strategy would use only 68 doses (52
doses less). This means that each additional life saved costs around 10 extra vials of
surfactant. The extra cost of surfactant for each extra life saved for the currently marketed
surfactants in the UK at 1998-99 (source; British National Formulary) prices would be:
ALECi 1500 (£150 per dose)
Exosurfand Survanta £3060 (£306 per dose)
Curosurf£4000 (£400 per dose)
These surfactant costs however may be offset by additional hidden costs in the late arms of
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treating more infants with pneumothoraces, more severe RDS, and other complications of
prematurity.
It is not clear why in the meta-analysis pre-ventilation strategies of surfactant administration
were not seen to improve outcomes in a human neonatal population when the evidence from
experimental and animal studies is fairly conclusive. Kendig et al (1998) has tried to answer
this question using two delivery room strategies. The first strategy was used in the majority
of pre-ventilation trials and used a pre-first breath bolus of surfactant (of a 3 ml volume of
Infasurf), whereas the other strategy employed a series of post-ventilatory aliquots.
Immediate outcomes did not show significant differences between groups however the post-
ventilatory strategy showed an improved survival rate at 36 weeks without chronic lung
disease. The study does not answer why this might be the case, but one possibility may be
poorer surfactant distribution after bolus administration of the 4ml volume in an atelectatic
lung that contains some fluid. If surfactant did not enter some of the airways they could
remain atelectatic and inflammatory processes would begin, leading in turn to chronic lung
disease.
Currently the evidence supports "early" surfactant treatment, preferably in a "prophylactic"
strategy however the evidence to support a pre-ventilation strategy in a human neonatal
population is lacking. Whether using a small volume surfactant (ALEC or Curosurf) in this
manner has any beneficial effect has yet to be demonstrated. The optimum choice would
seem to be to stabilise the "at risk" infant in the delivery room, and to administer surfactant
within 10 to 15 minutes after birth. The disadvantages of this strategy are that it would
prolong the duration the infant spent in a cold environment, monitoring would be limited to
a pulse oximeter and it relies on being able to rapidly stabilise the airway with the ETT in
the correct position.
6.4 Do all "at risk" infants require surfactant therapy?
It is clear from studies in the meta-analysis of prophylaxis versus rescue surfactant strategies
that not all "at risk" infants develop RDS that is severe enough to warrant surfactant
therapy. The various studies have reported that between 31.9% (Egberts et al 1993) and
63.2% (Gortner et al 1998) of infants in the rescue arms did not receive surfactant. With an
increasing use of antenatal steroids by obstetricians it is more likely that infants born
prematurely today would have surfactant that is more mature than their counterparts of the
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same gestation born some 5-10 years ago when most of the early versus late trials were
undertaken.
Screening of infants using tests of surfactant function such as the L/S ratio, stable
microbubble test or the click test, prior to administration of surfactant has been advocated.
Indeed these tests have been used to varying extents in some of the early versus late trials. In
the trial by Konishi et al (1992) it was a requirement that infants had immature surfactant on
testing using the stable microbubble test; Dunn et al (1991) studied only those infants where
the amniotic fluid testing indicated immature surfactant. Although surfactant therapy has
been shown to be largely safe and efficacious there is no data to support its use in those
infants with a mature surfactant profile. These infants are exposed to a therapeutic agent,
that, whilst largely agreed to be safe, is nonetheless of animal origin in many cases and is
administered in an invasive manner with the incumbent dangers that go along with
intubation.
Osborn et al (2000) examined the role of the click test not just as a means to reduce the
number of unnecessary treatments but also to speed up their administration times that
previously were based on a rescue strategy in moderately severe RDS. This strategy
depended on radiological and clinical criteria and had led to a median time to first dose of
over 4 hours. They used the click test to decide if the infant had immature endogenous
surfactant. If this was the case exogenous surfactant was administered prior to chest
radiographs and line placement. Using this strategy they were able to demonstrate a
statistically significant reduction in the median time to surfactant administration from 2.7
hours to just less than 1 hour.
The problem with this study is that the greater body of evidence to date supports the use of
earlier surfactant therapy and that most neonatologists would agree 4 hours was still too
long. It is not clear whether a click test (or similar) performed on the amniotic fluid prior to
delivery could reduce unnecessary surfactant administration, it would not reduce the time to
administration in truly "prophylactic" or early surfactant administration strategies.
6.5 Subsequent doses of surfactant
Although there is strong evidence to support the use of a first dose of surfactant as soon as
possible after birth there is considerably less evidence when the second or subsequent doses
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should be given. A variety of timing intervals have been reported in the medical literature
(and adopted by the manufacturers). These vary from the ALEC regime of a dose at birth, a
second at 1 hour and a third at 24 hours, through doses at six hourly intervals (Survanta), at
8 hourly intervals (Infasurf) and at 12 hourly intervals (Curosurf). In most cases the
subsequent doses are given to any infant that continues to require positive pressure
ventilation and minimal supplemental oxygen.
Kattwinkel et al (2000) examined 2484 infants treated either prophylactically or with rescue
therapy to establish whether there was any difference between a "high" versus "low"
threshold for the re-treatment doses. In this randomised trial "low" corresponded to a
threshold widely recommended by manufacturers - namely that of requiring >30% oxygen
in any ventilated infant. "High" corresponded to ventilation at MAP > 7 cm H20 and an
Fi02 > 40%.
There were fewer infants in the low threshold arm that required supplemental oxygen
(>30%) at 72 hours, although whether this was clinically important is not clear. There were
no differences between the two arms in any important long-term outcomes. In a subgroup
analysis of infants that had "complicated" RDS (where there was proven or a high risk of
sepsis or birth asphyxia) 24% of infants in the low threshold arm versus 34% in the high
threshold arm died (typical relative risk 0.71, 95% CI 0.51 - 0.99; risk difference -10%;
95% CI-19.5 to-0.5%).
This outcome relates to the fact that infants in the "complicated" subgroup were more likely
to have inactivation of their surfactant, thus those in the high threshold arms were more
likely to deplete their surfactant stores and suffer lung damage and it consequences.
6.6 Conclusion
The optimum dosage of surfactant appears to be approximately lOOmg/kg of phospholipid
per dose. The number of doses seems to be very variable, and is dependent on several
factors of which the major one would appear to be degree of immaturity. Most infants
manage with two doses, before they produce sufficient endogenous surfactant. The evidence
that third and subsequent doses add much to outcomes is sparse, although in individual
infants there might be a case if RDS was still considered as the primary reason for an on¬
going high oxygen and ventilation requirement.
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The dosing interval has not been investigated, although nowadays most surfactants are
administered at 12-hourly intervals, the question of whether an individualised regime based
on indices of ventilation and/or oxygen requirements is any better has not been explored.
Evidence from the Kattwinkel et al (2000) study suggests that re-treatment at a lower
threshold may be important in "complicated" cases of RDS where surfactant may be
inactivated, but in "uncomplicated" RDS a higher threshold may suffice.
It appears clear that earlier treatment, whether given prophylactically or as very early rescue
(within 15-30 minutes of birth in intubated infants), is preferable to rescue at later stages. Of
the two "early" strategies, a prophylactic strategy seems on evidence from animal models of
RDS to means of reducing inflammation and complications, but no clinical trials have
compared these two strategies.
This chapter has assumed that all surfactants have similar effects in neonates, however as
the next two chapters demonstrate this is not the case. Chapter 7 examines differences in
composition and the biophysical properties of the different surfactants. It also examines the
performance of surfactant in various animal models of RDS. Chapter 8 examines evidence
from published clinical trials that look at the use of two different surfactants.
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Chapter 7
Evidence of differences between surfactants from in
vitro studies and animal models of RDS
7.1 Differences in surfactant composition
7.2 In vitro (biophysical) differences between surfactants
7.3 Lavaged excised animal lung models of RDS
7.4 Lavaged in vivo lung models ofRDS




As shown in chapter 5 all four surfactants licensed in the UK were more effective than
control treatment in preterm infants with RDS. There are clearly differences, not only in the
surfactants, but also in outcomes as judged by the meta-analyses of the relevant placebo-
controlled trials in that chapter. Whether the differences in constituents, reflecting the
sources of the various products, convey long-term benefits to the infant with any one
surfactant being better than the other is less clear.
When considering the question of whether using an animal-derived or a synthetic surfactant
offers the neonate the best chance of survival with the minimum of impairment (respiratory
or otherwise) - it is necessary to consider evidence from various sources. There are five
areas to be considered: composition, in vitro or biophysical properties, effects in excised
lungs, animal model experiments and the neonatal population. In this chapter the first four of
these factors are discussed. Evidence from studies in neonatal populations is discussed in the
chapter 8.
7.1 Differences in surfactant composition
There is no evidence to suggest that duplication of mature human surfactant constitutes the
optimum or "gold standard" surfactant therapy for preterm infants with RDS. Human
surfactant has been harvested from amniotic fluid but as yet has not been a commercially
viable source of enough surfactant to treat preterm infants with RDS. There are differences
between surfactant produced by a 28 weeks gestation fetus and a term infant (chapter 3),
although the reason for this is unclear and there is no published evidence to suggest that
surfactant that compositionally resembles that of the less mature fetus/neonate would be any
more or any less beneficial than mature surfactant.
Technology to date has limited existing exogenous surfactants either to be synthetic (and
compositionally relatively simple) or to be derived from either human amniotic fluid or,
more commonly, from the lungs of slaughtered animals. The main difference between these
surfactants is that current synthetic surfactants are wholly composed of phospholipids,
whereas the animal-derived surfactants contain surfactant-associated proteins SP-B and SP-
C. In particular these proteins play an important role in the spreading and adsorption of
phospholipids to the air/tissue interface (sections 3.3.3 & 3.3.4).
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The phospholipids in synthetic and animal-derived surfactants also differ. DPPC is the most
abundant phospholipid in both the synthetic and animal-derived surfactants and is
considered to be essential for surface tension reduction. Lavaged human surfactant has a
mixture of saturated and unsaturated phosphatidylcholine molecules with DPPC accounting
for only 54.7 ± 3.9% (Poets et al 1997). By comparison it accounts for 70% ofALEC, 84%
of Exosurf 30-40% of Curosurf and 57% of Survanta / Surfactant TA. Surfactants that
have lower percentage of DPPC appear to be compressed more easily (Holm et al 1996) and
may be more effective at reducing surface tension especially at lower lung volumes.
Thus in terms of composition, the animal-derived surfactants, with lower ratios of DPPC
and particularly the presence of surfactant-associated proteins, would seem to offer
advantages over the currently available synthetic surfactants.
7.2 In vitro (biophysical) differences between surfactants
It is generally accepted that lowering the surface tension of the air-tissue interface is the
major function of surfactant. As a result attention has focused on this property of surfactant
preparations in vitro. The Wilhelmy-Langmuir balance (Clements 1957) and the Enhorning
pulsating bubble surfactometer (Enhorning et al 1965) are two commonly used tools for
performing measurements of surface tension. Surface spreading properties are best
measured using the Wilhelmy-Langmuir balance (or equivalent), whereas dynamic surface
tension is best demonstrated using the Enhorning pulsating bubble surfactometer.
Criteria, proposed by King & Clements (1972) and, subsequently modified by Goerke &
Clements (1986), suggest that:
1. Surfactant should form a DPPC monolayer in the space of a single breath
2. Surface tension should approach zero as the film is compressed
3. Surface tension should be stable at low (near zero) values
4. Surfactant should have a low compressibility so that low surface tensions can be
achieved quickly without surface film collapse
These properties are demonstrable using in vitro methods.
147
Infants with severe RDS have surfactant with an initial surface tension of 30mN/m; this falls
to <20mN/m as the infant improves (Griese & Westerburg 1998). In term infants without
RDS the surface tension <5mN/m (Poets et al 1997). Exogenous surfactant therapy
improves the surface tension in tracheal aspirates of affected infants. Tracheal aspirate
surface tensions of Exosurf-tveated infants fell significantly from 20.9±1.4 to
17.6±1.3mN/m, whereas that from controls (air-treated) infants showed no change
(McMillan et al 1998).
Animal-derived surfactants lower surface tension more in vitro than synthetic surfactants
(Scarpelli et al 1982, Corcoran et al 1994, Takahashi et al 1994). However other factors
may influence in vitro surfactant function: for example, the storage ofALEC under different
conditions affects its properties (Tables 20 and 21). It is interesting to note that none of the
surfactants (Exosurf Infasurf and Survanta) tested by Scarpelli et al (1994) met all the
criteria stipulated above as being essential for surfactant function.
In vitro studies, nonetheless, would seem to support the view that animal-derived surfactants
may offer better surface tension reduction than synthetic surfactants. However caution needs
to be exercised in extrapolating in vitro properties to animal models or neonates. Tween 20,
a synthetic detergent that has little structural resemblance to pulmonary surfactant, reduces
surface tension at an air-water interface by only a small amount yet when instilled into the
lungs of surfactant-deficient lambs improves lung function (Mercurio et al 1989) and gas
exchange (Jacobs et al 1985). The need for caution is also illustrated by the in vitro
properties of dry powder ALEC (section 5.1.1). Dry powder ALEC has superior in vitro
properties to ALEC stored at 4°C or 37°C (Takahashi et al 1994), yet dry powder ALEC was
ineffective in neonates (Milner et al 1983, Wilkinson et al 1985).
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Table 20: Surface tension of various surfactant preparations as measured using the
Wilhelmy-Langmuir balance (Takahashi et al 1994)
Surfactant preparation Surface tension
ALEC (stored at 37°C) 71.0 ± 1.0 mN/m
ALEC (stored at 4°C) 47.2 ±1.1 mN/m
ALECwith added SP-B and SP-C* 32.6 ±1.7 mN/m
Dry powder ALEC 58.0 ± 0.5 mN/m
Exosurf 28.0 ± 0.7 mN/m
Table 21: Maximum and minimum surface tensions of various surfactant
preparations as measured using the Enhorning pulsating bubble surfactometer





ALEC (stored at 37°C) 35.6 ±8.8 mN/m 63.2 ±5.7 mN/m
ALEC (stored at 4°C) 20.8 ± 1.9 mN/m 48.0 ± 4.6 mN/m
ALEC with added SP-B and SP-C* 22.8 ± 1.1 mN/m 38.8 ±2.3 mN/m
Dry powder ALEC 7.4 ± 1.1 mN/m 35.2 ± 2.4 mN/m
Exosurf 26.8 ± 0.8 mN/m 63.2 ± 1.3 mN/m
Surfactant TA 4.4 ± 0.5 mN/m 26.8 ± 0.4 mN/m
* Surfactant proteins SP-B and SP-C derived from bovine lung surfactant extract and
added to ALEC to give 7 parts DPPC: 3 parts PG: 1 part protein
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7.3 Lavaged excised animal lung models of RDS
Excised animal lungs (typically from small rodents) provide information of short-term
nature regarding the effects of surfactant on gas exchange and lung compliance. The lungs
are lavaged to remove surfactant producing an RDS-like state (reflecting ARDS rather than
neonatal surfactant-deficient RDS) for the experiment and the pre-lavaged state provides a
control. Efficacy of surfactant is usually reflected by short-term improvements of lung
compliance (Bermel et al 1984). There are few comparisons of the commercially available
exogenous surfactants using this model, and most of the published work refers to
experimental addition of synthetic protein analogues to a phospholipid mixture.
Examining the "distensibility" of the lung (an indirect way of measuring compliance pre-
lavage and post-lavage), Obladen et al (1983) showed calf lung surfactant extract restored
compliance better than a DPPC: PG mixture. However neither surfactant mixture was able
to restore "distensibility" to the pre-lavage state.
Similarly, Bruni et al (1998) showed addition of synthetic surfactant proteins SP-B and SP-
C to a phospholipid mixture to be more effective than pure phospholipid for restoring (again
only partially) the lung compliance of the excised rat lung. These proteins were shown to be
more effective than a phospholipids mixture with only SP-B or a preparation of Surfaxin
(KL4), however these, in turn, were better than a protein-free preparation of phospholipids
(Walther et al 1998).
This model of surfactant function supports the view that surfactants with surfactant proteins
SP-B and SP-C produce greater improvements in lung compliance, and a combination of the
two is better than SP-B alone. SP-A (although not available in any commercially available
surfactants) does not enhance surfactant spreading but does appear to be protective against
surfactant inactivation by serum proteins.
7.4 Lavaged in vivo lung models of RDS
Whilst the excised lung model is adequate for generating initial physiological data of
surfactant preparations there is the disadvantage in that they are usually taken from mature
animals and the study is usually short-term. A different approach is the in vivo lavaged lung
reported by Lachmann et al (1980). Again these may not be truly relevant to the preterm
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infant with RDS, where structural immaturity is also a factor. The maturity of the lungs in
this model may also mean that they retain the capacity for surfactant production and a
shortened duration of surfactant deficiency post-lavage. Similarly the lungs demonstrate an
ARDS-like picture rather than RDS due to primary surfactant deficiency.
Several investigators have used this model to show what happens to individual surfactant
preparations (Berggren et al 1986, Kobayashi et al 1984) and to investigate the comparative
absence of hyaline membrane formation in high frequency oscillation compared to
conventional ventilation (see section 6.3.1).
Using adult New Zealand white rabbits that had been subjected to repeated saline lavage
Kelly et al (2000) compared partial liquid ventilation (PLV), Curosurf ALEC and untreated
controls. They assessed gaseous exchange, changes in lung compliance and survival to 12
hours post-lavage. The greatest improvements were seen in those rabbits given PLV or
Curosurf, but what was surprising given the results of clinical trials was that results from
rabbits treated with ALEC were no better than from controls.
7.5 In vivo physiological effects in preterm animals
These may be the most relevant models for surfactant deficiency in RDS and it may be
appropriate to extrapolate experimental findings from them to the preterm neonate. The
animal models most commonly used are the preterm rabbit, baboon and lamb.
In rabbits delivery at 27 days gestation (term is 31 days) followed by mechanical ventilation
is sufficient to induce bronchiolar lesions similar to those seen in hyaline membrane disease
(Nilsson 1982) however rabbits can only be ventilated for short periods allowing only short-
term assessment of surfactant function.
The second model that has been used is the baboon. Lungs of fetal (delivered at 75% of
normal gestation) and term baboons subjected to ventilation and high oxygen concentrations
develop histopathological lesions similar to RDS (Escobedo et al 1982, Coalson et al 1982).
This model has not been used to compare different surfactants.
Lambs are regarded as a useful model for RDS as they are often born as twins and these act
as controlled pairs. Whether this is an appropriate way of obtaining controls is not clear, the
151
evidence from humans is that the second twin may be at greater risk of RDS (chapter 1).
However compared to rabbits the larger size of the newborn lamb means that improvements
in blood gases, lung mechanics and survival are easier to assess (Cumming et al 1992).
Cummings et al (1992) found that ventilated lambs treated with Exosurf did as poorly as
controls (no treatment). Other surfactants produced better survival rates at 24 hours. Of
lambs treated with Infasurf with 67% were alive at 24 hours as compared to 33% of
Survanta treated lambs and, surprisingly, only 20% of sheep surfactant treated lambs.
The exogenous surfactant extract Surfactant TA has in vitro surface tension lowering
properties that were as good as natural sheep, rabbit and human surfactant, and a smaller
amount (8pg versus 30pg) was needed to achieve this effect (Ikegami et al 1987). However
when administered to preterm sheep a hierarchy of dynamic compliance measurements was
produced (Table 22) that was different from that achieved in vitro. Furthermore although
these different surfactants appeared equally effective in preventing alveolar protein leak in
vivo when they were recovered by lavage the in vitro performance showed a greater
inactivation by proteins of the human surfactant.
Similar results were obtained with lavaged cow and synthetic (7: 3 ratio of DPPC: PG)
surfactants (Egan et al 1983). Although in vitro the surface tension lowering properties were
very similar, the cow surfactant produced greater improvements in both oxygenation and
measurements of dynamic compliance. The addition of natural surfactant-associated proteins
to phospholipids improved the treatment responses when given to preterm rabbits (Rider et
al 1993).
Thus extrapolation of the results from comparisons of the in vitro properties of surfactant to
animal models is not straightforward. In vitro studies do not take into account the
interactions between the lung environment and the immunological responses of the lungs to
oxidative and mechanical stresses from ventilation.
152
Table 22: Dynamic compliance in preterm lambs 4 hours after treatment with various




Sheep surfactant 0.66 ±0.16
Rabbit surfactant 0.42 ± 0.05
Surfactant TA 0.53 ± 0.09




Animal-derived exogenous surfactants bear a closer resemblance to endogenous human
surfactant than the currently available synthetic surfactants. This is apparent both in the
phospholipid profiles and the presence of the surfactant-associated proteins SP-B and SP-C.
Theoretically the animal-derived surfactants should have properties in vitro and in vivo that
more closely match those of human surfactant.
Studies of the in vitro properties of animal-derived surfactants suggest that they are better
than the synthetic surfactants, ALEC and Exosurf. However results from in vitro
(physiological) testing are not good predictors of clinical efficacy either in preterm animals
or in humans. Caution needs to be exercised in extrapolating these in vitro properties - as
demonstrated by dry powder ALEC, which has good in vitro properties but a poor clinical
effect and Tween 20, which had poor in vitro properties but nonetheless allowed good gas
exchange in an animal model ofRDS.
Overall however animal models of RDS suggest that animal-derived surfactants are more
effective than synthetic surfactants. However the various animal models are not comparable
with each other, and may not be comparable with surfactant-deficient RDS in premature
human neonates (Henry et al 1997). The preterm neonate still has some surfactant at even at
early gestations, and animal models that remove all pre-existing surfactant by lavage, as in
the study by Kelly et al (2000) may, therefore, not be representative. If the animal models
were to be believed, ALEC and Exosurf would work no better than control infants that
received saline or no treatment. Therefore only by undertaking a randomised trial in a
neonatal population can we truly compare two different surfactants in RDS.
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Chapter 8
Comparisons between different surfactants in
neonates
8.1 Early changes in oxygenation, ventilation and respiratory
function
8.2 Changes in radiographic appearances after natural and
synthetic surfactants
8.3 The effects of different surfactants on cerebral blood flow
8.4 Effects of different surfactants on neonatal mortality and
complications of prematurity
8.5 Meta-analysis of the randomised trials comparing an animal-
derived surfactant extract versus a synthetic surfactant




Although, as the previous chapter reports, studies of the biophysical properties of surfactants
and animal models suggest surfactants that contain surfactant-associated proteins may have
advantages over protein-free synthetic surfactants, there are limitations to the conclusions
that can be drawn with respect to a human neonatal population for example, Scarpelli et al
(1992) caution that none of the existing exogenous preparations establish full surfactant
function.
Preterm neonates are heterogeneous in nature, subject to a variety of environmental and
genetic differences that cannot be replicated in the animal and experimental models. Race,
gender and antenatal steroids are among the many variables that effect RDS (chapter 1).
They also have some endogenous surfactant that can supplement an endogenous surfactant
that administered (Ikegami et al 1993).
Several investigators have compared different surfactant preparations in preterm neonates.
Some groups have compared synthetic and animal-derived surfactants; whereas others
compared two different animal-derived surfactants. All published trials of this nature are
shown in Table 23. A summary of each trial is given in Table 24.
The focus in these trials varies considerably. Some trials concentrate on the changes in early
oxygenation and ventilation that occur after surfactant administration, whereas other trials
concentrate on neonatal and longer-term outcomes. Other trials look at the effect of these
early changes on cerebral circulation or radiographic changes after two different surfactants.
The following review of these trials therefore concentrates on these areas separately, before
examining the whole question of animal-derived versus synthetic surfactants as a meta¬
analysis and presenting conclusions based on existing evidence.
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Table 23: Studies comparing two different surfactant preparations in neonatal
populations.
Authors Comparison between Type of study Infants
Alvarado et al 1993 Survanta v. Exosurf Randomised
controlled
Abstract 66
Arnold et al 1996 Survanta v. Exosurf Historic cohort Full report 114
Bassiouny et al 1997 Survanta v. Exosurf Randomised
controlled
Full report 27
Bloom et al 1994 Survanta v. Infasurf Randomised
controlled
Abstract 609
Bloom et al 1997 Survanta v. Infasurf Randomised
controlled
Full report 608
Choukroun et al 1994 Curosurf v. Exosurf Historic cohort Full report 34
Cotton et al 1992 Survanta v. Exosurf Not randomised Abstract 7
Cotton et al 1993 Survanta v. Exosurf Not randomised Full report 17
Da Costa et al 1999 Survanta v. Exosurf Randomised
controlled
Full report 89
Graugaug et al 1994 Survanta v. Exosurf Randomised
controlled
Abstract 34
Graugaug et al 1995 Survanta v. Exosurf Randomised
controlled
Abstract 60
Horbar et al 1993 Survanta v. Exosurf Randomised
controlled
Abstract 617
Horbar et al 1994 Survanta v. Exosurf Randomised
controlled
Full report 617
Hudak etal 1994a Infasurf v. Exosurf Randomised
controlled
Abstract 854
Hudak etal 1994b Infasurf v. Exosurf Randomised
controlled
Abstract 1126
Hudak etal1996 Infasurf v. Exosurf Randomised
controlled
Full report 1033
Hudak et al 1997 Infasurf v. Exosurf Randomised
controlled
Full report 871
Kukkonen etal 2000 Curosurf v. Exosurf Randomised
controlled
Full report 228
Levine et al 1991 Exosurf v. human Historic cohort Full report 67
surfactant
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Table 23: Studies comparing two different surfactant preparations in neonatal
populations (continued).
Authors Comparison between Type of study Infants
Malathi & Ng 1995 Exosurf v. Survanta Non-randomised Full report 77
Modanlou et al 1994a Survanta v. Exosurf Randomised
controlled*
Abstract 291
Modanlou et al 1994b Survanta v. Exosurf Randomised
controlled*
Abstract 291
Modanlou et al 1997 Survanta v. Exosurf Randomised
controlled*
Full report 203
Murdoch et al 1998 Curosurf v. Exosurf Randomised
controlled
Full report 20
Pearlman et al 1993 Survanta v. Exosurf Quasi-randomised Abstract 121
Peliowski et al 1998 bLES v Exosurf Randomised
controlled
Abstract 635
Rollins et al 1993 Curosurf v. Exosurf Not randomised Full report 66
Sehgal et al 1994 Survanta v. Exosurf Randomised
controlled
Full report 41
Schlessel et al 1995 Infasurf v Exosurf Randomised
controlled
Abstract 39
Speer et al 1995 Curosurf v. Survanta Randomised
controlled
Full report 75
Stenson et al 1994 Curosurf v. Exosurf Not randomised Full report 73
Szymankiewicz et al
1999
Alveofact v. Survanta Not randomised Full report 54
van Overmeire et al
1999
Alveofact v. Survanta Randomised
controlled
Abstract 131
Vermont Oxford 1994 Survanta v. Exosurf Randomised
controlled
Abstract 1318
Vermont Oxford 1994 Survanta v. Exosurf Randomised
controlled
Full report 1296
* Trials reported by Modanlou et al (1994a, 1994b and 1997) are composite of infants
randomised to Exosurfand Survanta, and additional historic Exosurfcontrols.
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Table24\Summari softheclinicalria sinvolvingwodiffer ntsurfactant StudyMethodsParticipants
Exclusions
Outcomes




Notrandomised Singlecentre Notblinded Randomised(methodot stated) Singlecentre Blinded(methoots ated) Quasi-randomised (alternatecalendar months) Singlecentrestudy Notblinded
Preterminfants(ges ation andbirthweightnot stated) Preterminfants Lessthan24hourld Birthweight<1250grams RadiologicalDS Ventilatedwi hFi02>0.4 Clinicalfeaturesconsistent withRDS
Notstated Notstated Notstated
Chestradiographdisea e severityovfirst48 hours EarlyimprovementsnFRC andoxygenation Nolongtermoutc mes reported Daysofventilation Daysofsupplementary oxygen Lengthofhospitalt y Mortality Daysofventilation Neonatalmor ity Complicationsf prematurity
Table24:Summari softhclinicalria sinvolvingwodifferentsurf ctants(continued) StudyMe ho sPar icipantsExclusioOutcome Rollinset3/(1993)- comparisonbetween CurosurfandExo(66 infants) Horbaretal(1994)-trial betweenSurvantaand Exosurf(614infants)Non-randomised comparisonftwo historicalc horts Twocentres NotblindedExosurfinfantseligiblef rAOSIRIStrial Randomised Multicentre(11centr s) Uniquerandomisationlist heldinachcentre stratifiedbyirthweight NotblindedOSIRIStrial(a/AP02 <0.22or"atriskf RDS",>2hoursld ventilated),Curosurf infantseligibleforEURO VIstudy(<72hoursld, radiologicalndcli ical RDS,a/AP02<0.22) In-born Lessthan6hourld. Ventilatedwi hFi02>0.3. Radiologicalappearancef RDS. Felt"likelytobenefitfr m surfactant".
(congenital abnormality)dEURO VI(severecongenital malformations)
MatureL/Sratio. Previoustreatmentw thny surfactant. Clinicallyu stable (hypotensive, hypoglycaemic,fitting) Pre-existingpneumothorax orpneumope icardium Lifethreat ningcongenital orchromosomal anomalies
Earlyimprovementsn ventilationa d oxygenation Complicationsf prematurity Neonatald athrCLDa 28days Earlyimprovementsn ventilationa d oxygenation Complicationsf prematurity
Table24:Summari softhclinicalri lsinvolvingwodifferentsurfa t n s(c ntinued) StudyMethodsParticipants
Exclusions
Outcomes
Grauaugef/(1994)nd Grauaugetl(1995)- trialbetweenSurv nta andExosurf(60b bies) Sehgaltal(1994)-trialof SurvantaandExosurf (41infants)
Randomised(methodot stated) Singlecentre Blinded(methoots ated) Randomised Singlecentre Sealedenvelopes(not stratified) Noblinding
Stensontal(1994)- comparisonbetween CurosurfandExo(88 infants)
Non-randomised comparisonftwo historicalc horts Twocentres Notblinded
In-born Lessthan33weeks' gestation Birthweight>600grams Ventilatedwi h supplementaloxyg n Birthweight600-1750 grams. Clinicallystable (normotensive, normoglycaemic,and seizures). Clinicalandradiological RDS. Ventilatedwi hFi02>0.4. Curosurftreatedinf nts eligibleforEUROVI study(<72hoursld, clinicala dradiological RDS,a/AP02<0.22) Exosurftreatedinf nts ventilatedw thoxygen requirement
Nonestated Pre-existingpneumothorax orpneumopericardium Severecongenital anomalies
Ifapnoeacouldn tbe inducedorfleak aroundETT Ifinitialmeasured compliancesuggested "maturesurfactant" present
Differencesindy amic elastance MortalityandCLD Complicationsof prematurity Earlyimprovementsn ventilationa d oxygenation Mortality Complicationsof prematurity Differencesinstaticlu g compliance MortalityandCLD Complicationsf prematurity
Table24\Summari softheclinicalria sinvolvingwodiffer ntsurfactan s(continued) StudyMethodsParticipants
Exclusions
Outcomes
Choukrounetal(1994)- comparisonbetween CurosurfandExo(34 infants) Speeretal(1995)-trial betweenSurvantaand Curosurf(75infants)
Non-randomised comparisonftwo historicalc horts Singlecentre Notblinded Randomised Multicentre(5cen s) Sealedenvelopes(str tifie bycentrea d birthweight) Notblinded
Infantsreceivingscue surfactantforRDS (a/AP02<0.22) Birthweight500-1500 grams. Clinicalandradiological RDS. 1-24hoursld. VentilatedwithFi02>40%
Congenitalmalforma ion Prolongedrupturef membranes>3weeks gradeIIIorVH birthasphyxia majorcongenitala omaly pneumothorax,congenital infection, hypoglycaemia, hypotension,acido is unlesstreat d
Differencesindy amicand staticlungcomplian e Earlyimprovementsn ventilationa d oxygenation Earlyimprovementsn ventilationa d oxygenation Mortality Complicationsf prematurity
Schlesseletal(1995)-trial betweenInfasurfand Exosurf(36infants). Malathi&Ng(1995)- comparisonfSurvanta andExosurf(77infants)
Randomised(methodot stated) Historiccohorts(n randomised) Singlecentre
Eligibilitycriter anotstatedN Preterminfant Ventilatedwi hMAP>7cm H20andFi02>0.4
Notstated
Earlylungfunctiona d oxygenation Earlyimprovementsn ventilationa d oxygenation Mortality Complicationsf prematurity
Table24\Summariesoftheclinicaltrialsinvolvingtwodiffere tsurfa t nts(co inued) StudyMethodsParticipantsExclusionsOutcomes Hudaketal(1996)-trial betweenInfasurfand Exosurfusedare cue therapy(1033infants) Vermont-OxfordNeonatal Network(1996)-trial betweenSurvantaand Exosurf(1296infants)Randomised Multicentre(21centres) Sealednvelopes Blindedusingdrug administrators Randomised Multicentre(38centres) Randomisationlistheldi eachcentre(stratifiedby birthweight)Nospecifiedgestationor birthweight Radiologicalndclinical RDS. Ventilatedw tha/AP02< 0.22. Lessthan72hoursld. Birthweight600-1500 grams. VentilatedwithFi02>0.3. Lessthan6hourld. Clinicalandr diological RDS.
Previouslyr ce ved surfactant. Lethalcongenitalor chromosomalano aly. Clinicallyunstable (hypotensive, hypoglycaemic, bradycardic) Pre-existingpneumothorax orpneumoperica dium MatureLISr tio Previoussurfactant treatment Lethalcongenitalor chromosomalano aly. Clinicallyunstable (hypotensive, hypoglycaemic, bradycardic) Pre-existingpn umothorax orpneumoperica dium
Pulmonaryairleakinfirst sevendays. SeverityofRDSaft r surfactantthe py DeathduetoRDS( eath duetorespiratoryfail r duringthefirst14day ). Neonataloutcomesfdeath andBPDt28days. Cross-overtreatment Neonatald athand/orCLD Complicationsf prematurity
Table24:Summari softheclinicalrialsinv lv ngtwodifferentsurfact nts(cont nu d) StudyMethodsParticipants
Exclusions
Outcomes
Arnoldeta(1996)— comparisonbetween SurvantaandExosurf (144infants)
Retrospectivereview-n n- randomisedinitially (surfactantac ordingto neonatologists preference),thinfants enrolledandra domise aspartoflarger multicentretrial Twocentres Notblinded
Anybabtre tedwithith r SurvantaorExosurf
Congenitalinfection (positivebl odcultures within24hoursfbir ) Majorcongenital malformations.
Durationofventilatio Durationofxygetherapy
Bloometal(1997)- "rescue"trialofInfasurf versusSurvanta(608 infants)
Randomised Multicentre(13centr s) Sequentiallynumbered maskedvi lsof surfactant(stratifiedby centrea dbirthweight) Blinded
Birthweight<2000grams. Age<48hours. Clinicalandradiological RDS. VentilatedwithFi02>0.4 ORa/AP02<0.22.
Cardiorespiratory malformation Chromosomalabnor lity Errorsinsu factant administration(mixed types,wrongdosage) Congenitalsepsisr pneumonia
Numberofd ses Oxygenandventilator requirements Complicationsf prematurity
Bloometal(1997)- "prophylaxis"trialof InfasurfversusSurvanta (374infants)
Randomised Multicentre(7centr s) Sequentiallynumbered maskedvialsof surfactant(stratifiedby centrea dgestation) Blinded
Gestation<29weeks In-born
Birthweight>1250grams Notstabilisedby15minutes ofage Cardio-respiratory malformation Chromosomalabnor lity Congenitalsepsis
DevelopmentofRDS(Fi02 >0.4) Numberofd ses Oxygenandventilator requirements Complicationsf prematurity
Table24\Summariesoftheclinicaltri lsinvolvingtwodiffere tsurfa t ts(co tinued) StudyMethodsParticipantsExclusionsOutcomes Hudaketal(1997)-tria betweenprophylactic InfasurfandExosurf (846infants)Randomised Multicentre(10centres) Sealednve opes Blindedusingdrug administratorsIn-born Gestation<29weeks
Pre-viable Notintubated Notstabilisedby15minutes ofage Lethalcongenitalor chromosomalano aly.
RDSat24hoursfage. DeathattributabletoRDSin thefirsttwoeeksof life. Survivalwithoutchroniclung diseaseat28d ys. Airleaksyndrome Complicationsf prematurity
Bassiounyetl(1997)-tria betweenExosurfand Survanta(27infants) Modanloueta(1997)-tri ofSurvantaversus Exosurf(122infants)
Quasi-randomised (alternatedays) Singlecentr Notblinded Randomised(withhist r c cohortforcomparison) Singlecentr Sequentiallycodedards (notstratified) Notblinded
PrematureinfantswithRDSNostated Mechanicallyventil tedwith a/AP02<0.22 Lessthan24hourld In-born. Birthweight500-1500 grams. Clinicalandradiologic l RDS. Ventilated. Lessthan8hourld. Hadana/AP02<0.22OR anFiQ2>0.4ORboth.
Majorcongenitalan malies.
Changesia/AP02r tio aftertre tment Earlyimprovementsin ventilationa d oxygenation Complicationsf prematurity
Table24\Summari softheclinicalrialsinv lv ngtwodifferentsurf ctants(conti ued) StudyMethodsParticipantExclusionsOutcomes Pelioskita(1998)-trial betweenLESand Exosurf(635infants) Murdoch&Kempley(1998) -effectsofEx surfr Curosurfoncerebral circulation(20infants) Overmeireta1999- randomisedtrialbetween SurvantaandAlveofact (131infants)Randomised(methodt statedbutstratifiey weightandcentre) Multicentre(?Numberof centres) Blindingmethodnotstate Randomised(methodt stated) Notblinded Randomised(methodt stated) No.ofcentresn tstated BlindingmethodnotstatedBirthweight<1250gramsNotst t d Gestation25-36weeks Ventilated Lessthan33weeks' gestation
Sepsis Congenitalabnormal ies Notstated
Survivalto36weeks' gestationwithoutCLD Earlyimprovementsn ventilationa d oxygenation Complicationsf prematurity Durationofxygetherapy Changesicerebralblood flowvelocity Cranialultrasound outcomes Earlyimprovementsn ventilationa d oxygenation Complicationsf prematurity
Table24\Summariesoftheclinicaltrialsinvolvingtwdiffe entsurfactants(continued) StudyMethodsParticipantsExclusionsOutcomes DaCostaeal(1999)-trial ofSurvantaversus Exosurf(89infants) Szymankiewiczetal(1999) -comparisonbetween SurvantaandAlveof ct (54infants) Kukkonenetal(2000)- comparisonbetween CurosurfandExosurf (224infants)Randomised Singlecentr Sealednvelopes Notblinded Non-randomised comparison Singlecentr Notblinded Randomised Threecentres Notblinded Stratifiedbycentreand birthweightIn-bornandout-b rninfants <8hoursld VentilatedwithFi02>0.4 RadiologicalRDS >1000gramsbirthweight <37weeksgestation Infants<32weeks gestation Ventilatedw thFi02>0.4 RadiologicalDS In-born. Clinicalandr diologic l RDS. Ventilated. Hadana/AP02<0.22.
Congenitalmalformations Congenitalinfection Persistentpneumothorax Pre-existinggradeIIIorV IVH Ventilatedw thFi02>0.4 RadiologicalDS IUGR Congenitalmalformat on
Ventilationandoxygen tion at24hoursfage IncidenceofCLD/deathat 28days Complicationsf prematurity Differencesindynamiand staticlungcompli nce Earlyimprovementsin ventilationa d oxygenation Durationofventilati na d 02dependency Complicationsf prematurity Incidenceofsepsis
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8.1 Early changes in oxygenation, ventilation and
respiratory function after surfactant.
Although neonatologists frequently explain to parents that infants with RDS have stiff lungs
and that surfactant helps to improve their compliance, this explanation is very much an over¬
simplification of the actual process. Compliance does improve after surfactant, however this
is preceded by improvements in functional residual capacity (FRC) as a result of alveolar
recruitment (Edberg et al 1990). Hence oxygenation changes are seen more readily than
changes in ventilation (carbon dioxide excretion).
Studies specifically of the changes in oxygenation, ventilation and respiratory function are:
• Cotton et al (1993) - non-randomised study between two cohorts treated with
either Survanta or Exosurf
• Grauaug et al (1994 and 1995) - randomised trial between infants treated with
Survanta or Exosurf, examining effect on lung elastance
• Stenson et al (1994) - non-randomised study between two cohorts treated with
Curosurfor Exosurf
• Choukroun et al (1994) - non-randomised comparison of effects ofExosurf and
Curosurfon pulmonary mechanics
• Schlessel et al (1995) - randomised trial examining effects of Infasurf and
Exosurfon pulmonary mechanics
• Bassiouny et al (1997) - effects of Survanta and Exosurf on early a/AP02
values
Overall it is apparent that animal-derived surfactants (whatever the origin) have a more
rapid onset of action than Exosurf (the only synthetic surfactant to have been compared in
these studies). At its simplest level Bassiouny et al (1997) report improvements in early
a/AP02 values that are greater and of earlier onset in Survanta-treated than in Exosurf-
treated infants. This finding is reported in the larger randomised controlled trials as
improvements in Fi02 and MAP. Using a multiple-breath nitrogen washout technique,
Cotton et al (1993), demonstrated that these improvements in oxygenation closely mirrored
improved FRC. A greater FRC and improved oxygenation was seen earlier in Survanta-
treated than in Exosurf-treated infants.
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Compliance may be measured either using a single breath (static technique) or more recently
by on-line monitoring on modern ventilators (dynamic technique). The latter is dependent on
ventilator rate and other variables that can make it a less reliable technique. Stenson et al
(1994) examined static respiratory compliance (Crs) in two historic cohorts treated with
either Curosurfor Exosurf. Infants receiving Curosurfwere treated according to the EURO
VI study protocol (Halliday et al 1993), those receiving Exosurf according to the
manufacturer's instructions.
Significant improvements in Crs were seen in the Curosurf group at three and twelve hours,
in the Exosurfgroup Crs fell at 3 hours and exhibited only a small improvement at 12 hours.
The Curosurfgroup also demonstrated greater and earlier reductions in Fi02 and changes in
ventilator requirements than the Exosurfgroup.
These findings were similar to those of Choukroun et al (1994) who measured both dynamic
(Cdyn) and static compliance (Crs) in infants treated with Curosurf or Exosurf. There were
improvements in static compliance measurements after both surfactants, but improvements
occurred earlier after Curosurf (evident at 6 hours) than Exosurf (evident after 24 hours).
Dynamic compliance changed after 6 hours with Curosurf but changes were not evident
until 72 hours after Exosurf.
Schlessel et al (1995) also examined dynamic compliance (but used a standardised ventilator
rate during measurements) in infants randomised to treatment with Infasurf or Exosurf.
Improvements were seen in measurements of compliance and tidal volumes in all infants
irrespective of surfactant allocation, but the Infasurf group had earlier and greater
improvements than the Exosurf group however differences between the two groups had
diminished by 24 hours.
Grauaug and colleagues (Grauaug et al 1994 and 1995) report the effects of Survanta and
Exosurfon lung elastance. Elastance, which is the reciprocal of compliance, is related to the
volume of the lung, the resistance to the velocity of airflow and the inertia to the
acceleration (inertia in turn is related to the pressure gradient and the cross-sectional area of
the airways). Early improvements in elastance (and hence compliance) were noted in the
Survanta group but differences between the two groups did not persist beyond 24 hours.
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In essence all studies report that lung function, and its effects on ventilation and oxygenation
occur earlier in infants treated with an animal-derived surfactant, however the differences
persist for only 24-48 hours. The question then arises whether this brief period of lower
ventilator and oxygen requirements seen in animal-derived surfactants is enough to produce
longer-term advantages. Longer-term complications are more important both to the family
and to providers of neonatal intensive care because of their resource implications. Longer-
term outcomes are examined in sections 8.4 and 8.5, and the resource implications are
examined in chapters 9 and 10 in relation to a comparison between ALEC and Curosurf.
8.2 Changes in radiographic appearances after natural and
synthetic surfactants
This aspect is examined in one study comparing two historic cohorts: Levine et al (1991)
used a standardised scoring system to evaluate the severity of RDS from the appearances of
the chest radiograph (Edwards et al 1985). One cohort had been treated with human
amniotic fluid-derived surfactant, and a later cohort with Exosurf. The authors reported no
demonstrable differences in the radiological scores after treatment with either surfactant.
The authors reported that Exosurf treated infants had scores that were slower to improve.
However the time scale is recorded as age from birth and these infants had been treated
using a rescue strategy, whereas infants in the earlier cohort were treated prophylactically. It
would not be unreasonable to expect to find the infants treated prophylactically had lower
scores earlier (chapter 6).
It also could be argued that radiological appearances are not as reliable or sensitive in
assessing disease severity compared to clinical assessment or pulmonary function testing.
Radiographic appearances do not correlate with lung function testing (Dimitriou et al 1995),
and radiographic clearing of RDS occurs approximately 18-20 hour prior to the
improvement in pulmonary compliance (Shimada et al 1990). Nonetheless Levine and
colleagues concluded, "Exosurf, by radiologic criteria, is nearly as effective as human
surfactant in ameliorating RDS". No correlation was made in this study to longer-term
clinical outcomes in either group of infants.
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8.3 The effects of different surfactants on cerebral blood
flow.
As stated in section 8.3, animal-derived surfactants act faster than synthetic ones, bringing
about changes in arterial oxygen (Pa02) and carbon dioxide (PaC02) that can affect
systemic, and, more importantly, cerebral circulations. There had already been concern from
placebo-controlled trial of animal-derived surfactants of the effects of this on long-term
cerebral outcomes with one trial (Horbar et al 1990) being stopped early by the FDA
because of a high rate of severe IVH in Survanta-treated infants.
Only one small study (Murdoch & Kempley 1998) specifically examines this aspect of
surfactant therapy in small groups of infants treated with either Curosurf or Exosurf.
Anterior cerebral artery blood flow velocity (CBFV) was assessed before surfactant
administration and then at 1, 5, 30, 60 and 120 minutes intervals using Doppler ultrasound.
Following Curosurf there was a rapid and sustained decrease (by up to 36% of baseline
values) in CBFV. Velocities returned to baseline values after two hours. In the Exosurf
group there was also a significant, albeit smaller, increase in cerebral blood flow velocities
(up to 20% of baseline values).
The authors rejected changes in PaC02 as the reason for the altered CBFV after Curosurfon
the grounds that observed changes were small although others have disagreed (Fenton et al
1992a). Small changes in PaC02 cause alterations in arterial blood pressure and cardiac
output that affect the cerebral circulation (Fenton et al 1992b). Similar effects on systemic
and cerebral blood flow were also reported after treatment with Survanta in a porcine model
of RDS (Moen et al 1998).
In contrast to measurements of CBFV near infrared spectrometry has shown that total
cerebral blood volume remains relatively unchanged after surfactant therapy (Edwards et al
1992, Roll et al 1999). It seems likely that changes in venous return match arterial blood
flow velocity.
It is not clear whether this means animal-derived surfactants, because of their rapid onset of
action and effects on the systemic circulation, have a cost that is reflected in terms of a
challenge to the maintenance of the cerebral circulation. Reduced cerebral blood flow may
lead to an increase in periventricular ischaemia particularly due to venous stasis/infarction
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and subsequent development of PVL (Volpe 1997). Low cerebral blood flow has been
shown to be associated with an increased risk of intraventricular haemorrhage (Meek et al
1999).
The incidence of PVL is not widely reported in animal-derived versus synthetic surfactant
trials, nor is it reported in the Cochrane review of these trials (Soli 1999c). Where it is
reported (Hudak et al 1996, Hudak et al 1997) there is a doubling of the numbers of infants
with PVL after treatment with the animal-derived surfactant. There were, however, trends to
greater mortality in the Exosurf-treated infants and it was not determined whether these had
PVL before they died.
8.4 Effects of different surfactants on neonatal mortality and the
complications of prematurity
Outcomes at 28 days form the basis for most comparisons between different surfactants, and
are also used in the Cochrane review of natural (animal-derived) versus synthetic surfactants
(Soil 1999c). Almost all comparisons between any surfactants employ a rescue strategy, the
exceptions being Hudak et al (1997) and part of the study by Bloom et al (1997). The
importance of this has been debated in chapter 6.
Most studies have compared an animal-derived and a synthetic surfactant; the exceptions to
this were comparisons ofSurvanta with Curosurf (Speer et al 1995), with Infasurf (Bloom
et al 1997) and with Alveofact (van Overmeire et al 1999 and Symankiewicz et al 1999).
None of these studies was able to support the use of one animal-derived surfactant over the
other, suggesting that if there are differences between animal-derived surfactants they may
be insignificant as far as neonatal outcomes are concerned.
In the animal-derived versus synthetic surfactant trials, the synthetic surfactant used is
Exosurf whereas the commonest animal-derived surfactant is Survanta. Other surfactants
that have been less extensively compared are Curosurf (Kukkonen et al 2000), Infasurf
(Hudak et al 1996 and 1997) and bLES (Peliowski et al 1998). Various entry criteria were
utilised (Table 24). Alvarado et al (1993), Horbar et al (1993), Vermont Oxford Neonatal
Network (1996), and Modanlou et al (1997) studied infants with birthweight <1500 grams.
Seghal et al (1994) infants with birthweights 600-1750 grams, and da Costa et al (1999)
infants of >999 grams. Pearlman et al (1993), Hudak et al (1996) and Kukkonen et al (2000)
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did not have any birthweight or gestation limits. Hudak et al (1997) enrolled infants that
were <29 weeks gestation.
Among the rescue trials a variety of criteria for oxygen requirement at entry were used.
Alvarado et al (1993) required that infants be in supplemental oxygen >40%. The studies of
Horbar et al (1993) and the Vermont Oxford Neonatal Network (1996) required that infants
be in supplemental oxygen >30%. Hudak et al (1996), Modanlou et al (1997) and
Kukkonen et al (2000) required that infants had an a/AP02 ratio <0.22 (corresponding to
approximately 40% oxygen). Investigators set out a variety of age criteria; age at entry
varied from 6 hours of age (Horbar et al 1993, Vermont Oxford Neonatal Network 1996) to
72 hours of age (Hudak et al 1996). Da Costa et al (1999) required infants are in
supplemental oxygen >40% at a mean airway pressure >7 cmH20 at less than 8 hours of age.
All the studies reported earlier and greater improvements in immediate respiratory support
associated with treatment with the animal-derived surfactant. Alvarado et al (1993) reported
fewer days on mechanical ventilation, fewer days on supplemental oxygen, and fewer days
of hospitalisation associated with treatment with animal-derived surfactant. Some trials were
able to report significant improvements in neonatal outcomes (Table 25). The results from
these randomised trials are discussed further in the following meta-analysis.
8.5 Meta-analysis of the randomised trials comparing
animal-derived versus synthetic surfactants
Method
The objective of this section was to assess the effect of intra-tracheal administration of
animal-derived surfactant versus synthetic surfactant in the treatment of RDS using either
prophylaxis (prevention) or rescue treatment. The search strategy outlined in section 5.1.2
was used to examine outcomes in randomised controlled trials that compared one animal-
derived surfactant versus a synthetic surfactant. Data were taken from trials involving any
surfactant and not just those that have been licensed in the UK. Data regarding clinical
outcomes, particularly relating to neonatal mortality and respiratory complications of
prematurity were excerpted from published reports of the clinical trials and analysed using
the statistics outlined in section 5.1.2.
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Studies were considered if they fulfilled the following criteria:
(a) Types of studies - Randomised or quasi-randomised trials comparing any animal-
derived surfactant with any synthetic surfactant in the prevention or treatment ofRDS.
(g) Types ofparticipants - preterm neonates at risk of or with clinical and radiological
evidence ofRDS requiring assisted ventilation.
(h) Types of intervention - Infants randomised to receive intratracheal administration of
either an animal-derived or synthetic surfactant preparation to prevent or treat RDS.
(i) Types of outcome measures - Data for the following clinical outcomes are included in
the meta-analysis: neonatal mortality, pulmonary air leak (reported as pneumothorax and
all forms of air leak), patent ductus arteriosus, necrotising enterocolitis, intraventricular
haemorrhage, chronic lung disease (at 28 days and 36 weeks corrected gestational age in
survivors), chronic lung disease or death (at 28 days and 36 weeks corrected gestational
age).
Results
Several studies from Table 23 were identified as suitable for inclusion. These are listed
below:
• Alvarado et al (1993) - trial between Survanta and Exosurf
• Pearlman et al (1993) - quasi-randomised trial between Exosurfand Survanta.
• Horbar et al (1994) - randomised trial between Exosurf and Survanta
• Grauaug et al (1995) - randomised trial between Exosurfand Survanta
• Vermont Oxford Neonatal Network (1996) - randomised trial between Exosurf
and Survanta.
• Hudak et al (1996) - randomised trial between Exosurfand Infasurf in
established RDS.
• Hudak et al (1997) - randomised trial between Exosurfand Infasurf in
prevention (prophylaxis) of RDS
• Modanlou et al (1997) - randomised trial between Exosurfand Survanta. With
some historical cohorts receiving Exosurf (data excluded from this analysis).
• Murdoch & Kempley (1998) - randomised trial of cerebral haemodynamics after
Curosurfor Exosurf.
• Da Costa et al (1999) - randomised trial between Exosurfand Survanta in a
developing country.
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• Kukkonen et al (2000) - randomised trial between Exosurfand Curosurf
The following trials from Table 23 were excluded for reasons stated;
(a) Comparisons of two animal-derived surfactants:
• Speer et al (1995) - randomised trial between Survanta and Curosurf
• Bloom et al (1997) - randomised trial between Infasurfversus Survanta
• Van Overmeire et al (1999) - randomised trial between Survanta and Alveofact
(b) Non-randomised studies ofanimal-derived (or human) versus synthetic surfactants:
• Levine et al (1991) - comparison of radiological appearances in two cohorts
treated with human surfactant or Exosurf
• Cotton et al (1993) - trial between Survanta and Exosurf
• Rollins et al (1993) - comparison between Curosurfand Exosurf
• Stenson et al (1994) - comparison between Curosurfand Exosurf
• Choukroun et al (1994) - comparison between Curosurfand Exosurf
• Malathi & Ng (1995) - comparison ofSurvanta and Exosurf
• Arnold et al (1996) - comparison between Survanta and Exosurf
(c) Randomised trials between animal-derived (or human) and synthetic surfactants but
in which published reported outcomes were not suitablefor inclusion in this meta¬
analysis:
• Sehgal et al (1994) - trial between Survanta and Exosurf
• Schlessel et al (1995) - trial between Infasurfand Exosurf
• Bassiouny et al (1997) - trial between Survanta and Exosurf
• Pelioski et al (1998) - trial between bLES and Exosurf
Treatment of preterm infants with an animal-derived surfactant led to improvements in
oxygenation and ventilatory requirement that occur more rapidly than in those infants
treated with synthetic surfactant. It has the following impact on outcomes at 28 days (Figure
10):
NeonatalMortality: All included trials except Grauaug et al (1995) report on the risk
of mortality, in most studies this is restricted to neonatal (28 day) mortality rather than
overall predischarge mortality. The typical estimate from the meta-analysis suggests a
decrease in the risk of neonatal mortality associated with animal-derived surfactants (typical
relative risk 0.85, 95% CI 0.74 to 0.98; typical risk difference -2.5%; 95% CI -4.6 to
-0.5%).
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Bronchopulmonary Dysplasia / Chronic Lung Disease (at 28 days postnatal age):
Surviving infants with BPD/CLD at 28 days were reported by all studies except Alvardao et
al (1993), Grauaug et al (1995), Hudak et al 1996), Murdoch & Kempley (1998) and
Kukkonen et al (2000). The latter reports CLD at 36 weeks corrected gestational age. The
typical estimate shows no difference in the risk of BPD/CLD at 28 days (typical relative risk
0.94, 95% CI 0.85 - 1.04; typical risk difference -2.4%; 95% CI -6.1 to +1.4%).
Bronchopulmonary Dysplasia / Chronic Lung Disease at 28 days OR Neonatal
Death: Again the studies of Alvardao et al (1993), Grauaug et al (1995), Hudak et al 1996),
Murdoch & Kempley (1998) and Kukkonen et al (2000) did not report thios outcome. The
typical estimate from the meta-analysis of the other studies shows a decrease in the risk of
BPD/CLD at 28 days or neonatal death in infants who had received an animal-derived
surfactant (typical relative risk 0.92, 95% CI 0.86 - 0.99; typical risk difference -4.0%; 95%
CI -7.5 to -0.5%).
Chronic Lung Disease (surviving infants at 36 weeks corrected gestational age):
This clinically more useful predictor of long-term respiratory morbidity (Shennan et al
1988) was only reported in trials that have been published in full in peer-reviewed literature.
Nonetheless sufficient numbers have been reported in the trials of Horbar et al (1994),
Vermont Oxford Neonatal Network (1996), Hudak et al (1997) and Kukkonen et al (2000)
to allow meaningful analysis. The typical estimate shows no difference in the risk ofCLD at
36 weeks post-conception in surviving infants who had received an animal-derived
surfactant (typical relative risk 0.97, 95% CI 0.86 - 1.11; typical risk difference -0.9%; 95%
CI ^1.4 to +2.6%).
Chronic Lung Disease (in surviving infants at 36 weeks corrected gestational age)
OR death before discharge: This is similar to the CLD/neonatal death category, this
analysis makes the assumption that most infants are discharged at around 36 weeks post-
conceptual age, and the numbers of infants who stay longer and who subsequently die are
very small. The typical estimate shows a trend to reduced risk of CLD at 36 weeks post-
conception or death before discharge in infants who had received an animal-derived
surfactant (typical relative risk 0.93, 95% CI 0.85 - 1.02; typical risk difference -2.7%; 95%
CI-6.2 to +0.8%).
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Figure 10: Meta-view charts of trials comparing animal-derived and synthetic
surfactants.
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Pulmonary Air Leak: Reported using the two forms of pneumothorax or all forms of
air leak (which includes pneumothorax). The typical estimate suggests a decrease in the risk
of pneumothorax associated with animal-derived surfactant use (typical relative risk 0.58,
95% CI 0.48 to 0.71; typical risk difference -4.7%; 95% CI -6.4 to -3.0%). Similarly, the
typical estimate also shows a decrease in the risk of all forms of air leak associated with
animal-derived surfactant use (typical relative risk 0.60, 95% CI 0.48 to 0.71; typical risk
difference -7.7%; 95% CI -10.7 to -4.6%).
Patent Ductus Arteriosus: The typical estimate suggests no difference in the risk of
significant PDA (requiring either medical or surgical treatment) with either surfactant
(typical relative risk 0.97, 95% CI 0.90 to 1.05; typical risk difference —1.4%; 95% CI —4.9
to +2.1%).
Intraventricular Haemorrhage: The typical estimate from the meta-analysis suggests
a trend (that almost reaches statistical significance) to increased risk of IVH (of any grade)
after animal-derived surfactant (typical relative risk 1.09, 95% CI 1.00 - 1.19; typical risk
difference +2.7%; 95% CI -0.1 to +5.6%). However when looking specifically at Papile
grades III and IV of IVH, the typical estimate from the meta-analysis suggests a lesser trend
to increased risk of severe IVH after animal-derived surfactant (typical relative risk 1.09,
95% CI 0.92 - 1.29; typical risk difference +1.0%; 95% CI -1.0 to +3.0%).
Periventricular leukomalacia: This is reported only in the two Infasurf versus
Exosurf trials (Hudak et al 1996 and Hudak et al 1997), a small Survanta versus Exosurf
trial (da Costa et al 1999) and the Curosurf versus Exosurf trial (Kukkonen et al 2000).
Nonetheless the typical estimate suggests an increase in the risk of PVL associated with
animal-derived surfactant (typical relative risk 1.76, 95% CI 1.13 to 2.76; typical risk
difference +2.0%; 95% CI +0.5 to +3.6%).
Necrotising enterocolitis: The typical estimate suggests an increase in the risk of
NEC associated with animal-derived surfactant (typical relative risk 1.38, 95% CI 1.07 to
1.78; typical risk difference +2.3%; 95% CI +0.5 to +4.1%).
The implications of this meta-analysis are discussed in section 8.7.
8.6 Differences between animal-derived surfactants
Just as there are compositional and in vitro differences between animal-derived and
synthetic surfactants, there are differences between the various animal-derived surfactants.
These may account for differences seen with speed of onset action but reported neonatal
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outcomes in trials undertaken to date show great similarity irrespective of the source of the
animal-derived surfactant.
The most obvious difference between the animal-derived surfactants is that of composition
and the manufacturing process. Survanta and Curosurf are both obtained through extraction
of minced lung whereas Infasurf Alveofact and bLES are all obtained through lavage of
intact lungs. This means that Survanta and Curosurfmay contain phospholipids that do not
originate within the surfactant system, which might make them more susceptible to
inactivation by serum proteins compared to lavaged surfactants (Seeger et al 1993). In
addition Survanta is manufactured by adding synthetic phospholipids, to the minced lung
extract.
There are few trials that compared two animal-derived surfactants (Table 23), of these only
Speer et al (1995), Bloom et al (1997) and van Overmeire et al (1999) look at neonatal or
longer-term outcomes. Speer et al (1995) found a significantly increased risk of PDA
requiring treatment in infants treated with Curosurf compared to Survanta, but no other
advantage of either surfactant over the other. Bloom et al (1997) could not find any
advantage to using Infasurf over Survanta. Van Overmeire et al (1999) and Symankiewicz
et al (1999) and disagreed whether Alveofact or Survanta worked fastest, but van
Overmeire et al (1999) reports there were no differences in the neonatal and longer-term
outcomes.
8.7 Conclusion
The results of the meta-analysis between animal-derived and synthetic surfactants support
the view that the former would be the more desirable choice for treatment of infants with or
at risk of RDS. There are earlier improvements in the ventilator and oxygen requirements
and of mortality. In addition, where it was reported, animal-derived surfactants decreased
the both duration ventilation and oxygen therapy, and there was a clear advantage for the use
of animal-derived surfactants where reduction of air leaks and pneumothoraces are
concerned.
However there may be a price to pay in terms of adverse neurological outcomes for using an
animal-derived surfactant. There were trends to a higher incidence of all grades of IVH
(almost but not quite reaching statistical significance), a trend to increased severe IVH and a
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significant increase of PVL after animal-derived surfactant. However these outcomes were
restricted to the survivors and it cannot be determined whether infants who died in either
group had any of these outcomes. Nonetheless evidence from the studies of cerebral blood
flow suggests the need to exercise caution, particularly with responses to rapid changes in
blood gases following administration of animal-derived surfactants.
The paper by Arnold et al (1996) appears to put the differences of effects of the two types of
surfactant into perspective. The authors suggest that the differences in neonatal outcomes as
analysed using a proportional-hazards (Cox) regression analysis - a multivariate form of
survival analysis that allows for differences in baseline characteristics - for the two different
types of surfactant is less than that seen when comparing groups of male infants and female
infants, or Caucasian and non-Caucasian infants. In other words, the effect of choosing one
surfactant type over the other is small, and that population demographics such as gender and
race are more important in determining outcome from RDS.
Whether the results of comparisons between the large volume surfactants (all those
compared are given in volume of 3-5 ml/kg) can be extrapolated to the two small volume
surfactants (ALEC and Curosurf) is not clear. Only three randomised trials and three non-
randomised studies between two surfactants have used either Curosurf or ALEC, and none
compare these directly, yet they are the most widely used animal-derived and synthetic
surfactants in the UK.
The published meta-analyses (Halliday 1996, Soil 1999c) and that in section 8.5 have
concentrated on clinical outcomes at 28 days. Apart from significant reductions in
pulmonary air leaks, which were evident in individual trials, after using animal-derived
surfactants, it is only by including the most recent trials that any difference in mortality
could be demonstrated. None of the meta-analyses have examined the question of
pharmacoeconomics or whether one type of surfactant offers a reduction in costs of neonatal
care compared to another?
Thus in terms of UK-based neonatal practice several questions remained. For these reasons
it was decided to perform a randomised comparative trial between ALEC and Curosurf that
was large enough to answer the following questions:
• Firstly, were there any cost benefits to using one surfactant over the other?
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(The primary outcome)
• Secondly, were there any differences in clinical outcomes (mortality and the
complications of prematurity)?
This study is discussed in chapter 9 and the implications of its results on the provision of
neonatal intensive care within one health authority in chapter 10.
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Chapter 9
A randomised comparison between Curosurf
(poractant alfa) and ALEC (pumactant)
9.1 Introduction
9.2 Methods
9.3 Outcome definitions used in the study
9.4 Early changes in oxygenation and ventilator requirements





Although the evidence presented in chapters 7 and 8 suggests that animal-derived
surfactants have better in vitro properties, produce better outcomes in animal models and
would appear to be clinically more efficacious than synthetic surfactant there remain
unanswered questions, particularly with respect to ALEC and Curosurf which are the most
widely used animal-derived and synthetic surfactants in the United Kingdom.
Published meta-analyses (Halliday 1996 and Soil 1999c) both used data from trials that
compared either Survanta or Infasurf against Exosurf. All these surfactants have a large
volume (3-5 ml/kg) compared to ALEC and Curosurf and when compared to the infant's
tidal volumes (5-8 ml/kg). Differences in the in vitro properties of ALEC, Curosurf,
Exosurf and Survanta have been discussed in chapter 7 and extrapolation of clinical
outcomes from studies comparing bovine surfactants and Exosurfmay not reflect clinical
differences between ALEC and Curosurf
Comparisons involving either ALEC or Curosurf with any other surfactants are limited.
Speer et al (1995) have compared Survanta and Curosurf and found no differences in long-
term outcomes, but the trial enrolled small numbers of infants and had insufficient power to
demonstrate these. Rollins et al (1993) and Stenson et al (1994) both compared Curosurf
with Exosurf using historic cohorts. Despite the limitations imposed by the use of historic
cohorts Stenson et al (1994) showed that Curosurf had a more rapid effect on static lung
compliance as well as oxygenation. Rollins et al (1993) showed a reduction in several
clinical outcomes (IVH, PIE, PDA and NEC) with Curosurf use, but antenatal steroid use
was 37% higher than in the Exosurfcohort.
There are two randomised comparisons between Curosurf and Exosurf. Murdoch &
Kempley (1998) showed more rapid changes in cerebral blood flow after Curosurf, but not
longer-term differences in neurological outcomes in a very small study. More recently
Kukkonen et al (2000) compared neonatal outcomes after treatment with Curosurf or
Exosurf. Whilst there were no significant differences in the long-term outcomes, a
secondary finding was that of a possible increase in sepsis after Curosurf use. Interpreting
this secondary outcome is difficult because there were several Exosurf-trcated infants who
received rescue therapy with Curosurf due to a perceived superiority of that surfactant by
the attending clinicians. There are no previously published trials comparing ALEC against
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any other surfactant in a neonatal population.
Importantly at the time of initiating the trial comparing Curosurf and ALEC there was still
some equipoise in whether animal-derived or synthetic surfactants were equally efficacious.
The Halliday (1996) meta-analysis had demonstrated a reduction in neonatal mortality with
animal-derived surfactants but the conclusions were reached after including data from
several abstracts. Two of these abstracts, notably the trials involving Infasurf (Hudak et al
1994a and 1994b) were later published in full (Hudak et al 1996 and 1997) with outcomes
that were reported on 100 fewer infants than in the abstracts.
The only way to resolve the issue was to undertake a randomised comparison that compared
the two surfactants in a neonatal population. However, despite the reservations of
extrapolating from the Halliday (1996) meta-analysis with its dependence on bovine-derived
surfactants and Exosurf, it seemed unlikely a single randomised controlled trial would carry
sufficient statistical power to unequivocally show whether one surfactant was clinically
more efficacious. With this in mind the primary aim of this study was to examine the
differences in the cost ofmanagement of RDS between groups of infants treated with either
Curosurf or ALEC. Mortality was expected to be equal in the two groups, or at worst not
significantly different.
The argument for using an economic as opposed to clinical outcome was strengthened by
the price differential between the two surfactants. ALEC cost £150 per vial during 1997-8
(although this was later reduced to £105 per vial in October 1999), whereas Curosurf cost
£400 per 1.25ml vial (source: British National Formulary). If the manufacturers'
recommended regimes were followed the surfactant costs for a 1 kg infant would be £450
for ALEC (3 dose regime) and £1200 for Curosurf (200 mg/kg initial dose followed by 100
mg/kg).
The healthcare costs levied by preterm infants with lung disease relate primarily to the
length of time for which they require intensive or high dependency nursing and medical
care. These costs can be divided into marginal costs and fixed/semi-fixed costs. The
workload, the cost of drugs and other expendables affect marginal costs whereas fixed and
semi-fixed costs relate to building maintenance, power supply, staff and equipment. Fixed
and semi-fixed costs alter in steps that vary according to the size of the annual workload of
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the individual unit, smaller units having a relatively larger initial step than larger units,
whereas marginal costs bear an almost linear relationship to the time an infant spends in
intensive care. In a large unit fixed and semi-fixed costs contribute approximately 80% of
the total cost, and marginal costs around 20%.
In 1994-95 high dependency cot usage in the former Northern region totalled 5679 days by
1314 infants (data from Northern Neonatal Consortium annual reports). Infants therefore
spent an average of 4.5 days in high dependency care at a daily cost of £912 per day (1999-
2000 costing in the Northern Neonatal Consortium). Fixed and semi-fixed costs account for
£800 and marginal costs for the remainder.
The biggest single factor that determines whether an infant receives high or low dependency
care is respiratory support. Thus small improvements in respiratory morbidity, for example
no longer requiring respiratory support, can give rise to marginal cost savings that could
offset the initial cost of the surfactant. Whilst fixed and semi-fixed costs would not be
influenced by improvements in respiratory morbidity, marginal costs relating to drugs and
disposables might. A reduction of 10% (0.5 high dependency days per infant) would
theoretically save £70,000 at marginal rates within the former Northern region.
Reducing high dependency workload may also be achieved by exchanging longer-term
morbidity for short-term mortality; in other wotrds those infants that die early receive less
intensive care. Thus preventing death from an otherwise fatal disease can actually increase
healthcare costs (Bonneux et al 1998). However a therapeutic intervention that has a worse
mortality rate is not clinically or ethically acceptable and ideally both respiratory morbidity
and mortality need to be reduced. If there is no significant difference in neonatal mortality
between the animal-derived and synthetic surfactants, the level of respiratory morbidity
should therefore be the major determining factor for any difference in the amount of high
dependency care.
Economic analyses have previously shown that surfactant therapy reduced the cost of
neonatal care compared to controls (Tubman et al 1990, Diwaker et al 1993, Phibbs et al
1993, The Victorian Infant Collaborative Study Group 1997), but no analysis of the costs of
care between two different surfactants has been published.
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The question then arose as to how to measure the healthcare costs from the infants in a
robust manner. One possibility was to adopt one of the classifications of care as a proxy for
healthcare costs. Several classifications of care are used in the UK. In 1984 the then British
Paediatric Association (BPA) and the British Association for Perinatal Paediatrics (BAPP)
recommended a simple classification to audit workload. In 1992 a more comprehensive
system was recommended (British Association of Perinatal Medicine and Neonatal Nurses
Association 1992). In 1993 simpler dependency scales were published, supported by
detailed observations of nursing activity in the Merseyside regional neonatal intensive care
unit (Williams et al 1993) and the Northern Region (Northern Neonatal Network 1993a).
The latter classification is used in all units in the former Northern region. Infants are
classified into one of four groups (A to D) according to the amount of care they require
(Table 26). Most of the intensive care is "respiratory" and includes all forms of ventilation
and continuous positive airways pressure (CPAP), and is thus directly relevant to a study
comparing two surfactants. Categories A and B care are designated as "high dependency"
care, whereas C and D are "low dependency". The original study (Northern Neonatal
Network 1993a) showed that the length of nursing time high dependency infants receive is
twice that of the low dependency infants, thus they consume 2-3 times the marginal costs in
a neonatal intensive care unit. In turn this allows costing of the care that infants receive.
The primary outcome measure in the proposed comparison of Curosurf and ALEC was the
number of high dependency days as measured by the Northern region categories of care.
This method for measuring levels of care had been used routinely in the neonatal units of the
former Northern region of England and has been shown to be a robust tool for healthcare
purchasing and planning. Other clinical outcome data, including mortality, were collected as
secondary endpoints.
The protocol, study design and consent forms for the trial were reviewed by consultant
neonatologists in the former Northern region and Liverpool Women's Hospital. Ethical
approval was sought and obtained from the Northern and Yorkshire Multi-centre Research
Ethics Committee, and from the Local Research Ethics Committees of all participating
centres.
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Table 26: The Northern region categories of care (Northern Neonatal Network 1993a).
Category Qualifying criteria
Category A*
Any infant that requires respiratory support (including high frequency oscillation,
conventional ventilation, CPAP).
Category B*
Infants not in category A who:
• Require more than 40% oxygen to maintain adequate arterial
oxygenation
• Have received all their fluids parenterally in the previous 24 hours
• Have a drain, stoma or catheter in situ
• Are less than 1000 grams
• Have had surgery in the preceding 24 hours
Category C **
Infants not in categories A or B who:
• Are receiving supplemental oxygen but require < 40%
• Are less than 1750 grams
• Have some parenteral fluids
• Have had a seizure or apnoeic episode in the preceding 24 hours
• Have received some of their feeds via oro- or naso-gastric tubes
Category D **
Infants that are fully bottle or breast fed and weigh > 1750 grams
* Categories A and B are "high dependency" days
** Categories C and D are "low dependency" days
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9.2 Methods
Newborn infants treated in participating centres in the former Northern region, Liverpool
Women's Hospital, Merseyside, St James University Hospital, Leeds and Leicester Royal
Infirmary were enrolled. Four units in the former Northern region (the Royal Victoria
Infirmary in Newcastle upon Tyne, North Tees General Hospital in Stockton on Tees, South
Cleveland Hospital in Middlesbrough and Sunderland) offer level III neonatal intensive
care. These and the other hospitals mentioned above were defined as major centres.
Ten other hospitals ("non-provider units") in the former Northern region with maternity
units but not the facilities for long-term neonatal intensive care were also approached and
asked to recruit infants for the trial. Historic data from 1996-97 suggested that
approximately one third of infants born in the Northern region of an eligible gestation were
born in these "non-provider" units. Inborn infants are those born in one of the major centres
(whether transferred antenatally or originally booked at those centres), outborn infants are
those born elsewhere and transferred postnatally to a major centre.
Infants were enrolled if they were between 25 and 29+6 weeks gestation by best obstetric
estimate. These gestations were chosen as they corresponded to those for which ALEC
received its market licence, in contrast there are no gestation criteria for the use of
Curosurf. In most cases gestation was calculated from an early (first trimester) obstetric
ultrasound, but it could also be estimated from the last day of the mother's menstruation if
this was corroborated by a later ultrasound scan.
Women who were admitted to the maternity units were approached to inform them about the
trial and invite them to participate. Written and verbal information was given, but written
consent was required in accordance with the ethical committee guidelines. In most cases this
was attempted antenatally, but occasionally a postnatal consent was obtained. In all cases
consent was obtained before administration of surfactant. Where parents declined to enter
their infant(s) in the trial, surfactant treatment was given according to the preferences of the
neonatologists in that centre. Reasons for non-enrolment, particularly where parental
consent was withheld was recorded. This latter aspect was deemed important in view of
perceived concerns regarding the use of animal products by the general public in the wake of
the BSE "crisis" (Lacey 1999).
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Only those infants that were intubated for respiratory care were enrolled. This meant that
different centres enrolled slightly different populations because of the practices within those
units. Three centres (Liverpool Women's, South Cleveland and Sunderland Royal Hospitals)
have adopted a policy of giving surfactant in the delivery room. The other centres transfer
the infant to the intensive care area before administering surfactant.
Where possible infants were excluded if they were known to have a severe congenital
malformation likely to affect cardio-respiratory outcome or overall mortality. This was not
possible in all cases and when a significant malformation was later discovered, data
collection continued but outcome data from these infants were excluded from subsequent
analyses.
Infants were randomised to receive either ALEC or Curosurf using a central telephone
randomisation point on the neonatal unit at the Royal Victoria Infirmary (RVI). They were
randomised either immediately before delivery, in the case of Liverpool Women's Hospital,
Sunderland and South Cleveland Hospitals, or as soon as possible after delivery in the other
units. The timing of surfactant administration and the need for some units to undertake this
antenatally was one reason for stratification by centres. All enrolled infants were allocated a
unique trial number.
Within the former Northern region infants who were enrolled by a non-provider unit (minor
centre) were randomised according to the major centre where the infant would receive its
intensive care after transfer. Thus, for example, if an infant was born at Ashington General
Hospital and was to be transferred postnatally to the RVI that infant would be randomised
using the envelopes for the RVI. Rarely, a major centre may have been unable to accept
referral after the infant has been bom if it became full in the intervening period. In these
cases the surfactant allocation and trial number remained the same but results were analysed
according to the major centre to which the infant was transferred.
No attempt was made to blind the participating clinicians with regards to surfactant
allocation. The slight differences in reconstitution (powdered ALEC is reconstituted prior to
use with saline, whereas Curosurf is available ready to use), dosing (a weight-related dose
for Curosurf), administration techniques (ALEC is administered whilst still cold and
Curosurf requires warming prior to use) and the known differences in the speed of onset of
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action were thought to make blinding difficult without employing surfactant administration
teams. Surfactant administration teams, which have been used in a number of other
surfactant trials, were not used because of the number of centres involved in the study and it
was impractical and too costly to provide 24 hour cover for all these centres.
The immediate aim after stabilisation of the infant was administration of the first dose of
surfactant. The study protocol specified that the first dose should be administered within 30
minutes, if at all possible, to try and encourage the use of prophylactic surfactant. ALEC
was given at a dose of lOOmg (1.2 ml) of phospholipids irrespective of birthweight;
Curosurf was administered at a dose of lOOmg/kg (1.25 ml/kg). Both surfactants were
stored and administered according to the manufacturers' guidelines. ALEC was stored at
4°C. The cold powder was mixed with the supplied dilutant (0.9% saline) prior to use, and
the resulting mixture administered via a feeding tube cut to the length of the endotracheal
tube. Curosurf was warmed to 37°C prior to administration, and the calculated dose
administered via a cut feeding tube pass though the ET tube. In the case of the hospitals
where surfactant was administered in delivery suite the dose was based on the expected
weight for the infant's gestation similar to the strategy employed in the trial by Bevilacqua
et al (1996) for prophylactic Curosurf.
In both arms a second dose of the allocated surfactant was administered twelve hours after
the first if the oxygenation index was calculated to be 5 or greater. Oxygenation index was
calculated using the formula:
OXYGENATION INDEX = (Fi02 x MAP) / (Pa02 x 7.5)
Where: Fi02 is the percentage of inspired oxygen
MAP is the mean airway pressure (in cm H20)
Pa02 is the partial pressure of arterial oxygen (in kPa)
No cross-over was allowed unless the supervising consultant felt that a faster acting animal-
derived surfactant was warranted (for example in a severely ill infant on maximal
conventional or high frequency oscillatory ventilation). In these cases it was felt unethical to
deny treatment that was known to act rapidly; where this was administered the surfactant
used was Survanta. Similarly, third and fourth doses of the allocated surfactant could also
be given at the discretion of the consultant supervising the infant's care at the time.
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To avoid over- and under-ventilation of the infants, enrolling clinicians were asked to
maintain Pa02 between 6.5-10.5 kPa and PaC02 between 4.5-7.0 kPa. All other aspects of
the infants' care, including ventilation strategies, were determined by local guidelines.
Data were collected prospectively for all enrolled infants and included demographic data
and complications of prematurity. High and low dependency scoring, using the Northern
region categories of care, was collected separately by nursing staff within the units and two
research fellows. Scores for the high dependency days collected by the latter were
disaggregated so that reasons for allocating the category could retrospectively be analysed
should the qualifying criteria for each category change in future. This was performed
because some of the reasons for allocating a "B" category day do not relate to respiratory
care (Table 26) and the study was comparing two products that exerted their primary
influence on the respiratory system.
To try and ensure the two arms were composed of infants with a similar disease spectrum,
critical risk index for infants (CRIB) scores (International Neonatal Network 1993) were
collected prospectively. These scores are derived from maximum oxygen, minimum oxygen
and worst base deficit during the first 12 hours after birth, gestation at birth, birthweight and
the presence of congenital malformations.
9.3 Outcome Definitions
High dependency days were defined as category A and B days according to the Northern
region categories of care (Northern Neonatal Network 1993a). Data collection was
performed at the same time every day on a daily basis.
Neonatal mortality was defined as death within the first 28 postnatal days. Death prior to
discharge was when the infant died in either the unit where he/she received intensive care,
or the unit where they received low dependency care before their discharge home.
Chronic lung disease (CLD) was defined in two ways: dependency upon supplemental
oxygen at 28 postnatal days (Heneghan et al 1986) and dependency upon supplemental
oxygen at 36 postmenstrual weeks (Shennan et al 1988).
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Pneumothorax was defined as intrathoracic, extra-pulmonary air leak necessitating the
insertion of a chest drain. Lesser degrees of pulmonary air leak such as PIE were not
recorded because of the variation in its reporting by different clinicians and radiologists.
Cerebral ultrasound scans were performed on day 3 and at 6 weeks postnatal age (or as near
to these as possible). Radiologists not involved in the trial reported scans. Using their
reports the scans were scored separately for each hemisphere. Haemorrhage was scored
using the staging proposed by Papile et al (1978): Stage 0 - no haemorrhage; stage I -
localised sub-ependymal haemorrhage; stage II - intraventicular haemorrhage, stage III -
intraventricular haemorrhage with ventricular enlargement, stage IV - parenchymal
haemorrhagic lesions. Ventricular size was scored using ventricular index (Levine 1981):
stage 0 - no dilatation, stage I - dilatation <4mm above 97th centile corrected for gestation,
stage II - dilatation >4mm above 97th centile). Parenchymal lesions were staged simply as
stage 0 - no cyst; stage I - porencephalic cyst; stage II - cystic leukomalacia.
Significant patent ductus arteriosus (PDA) was defined as a murmur associated with clinical
signs of a left to right shunt clinically requiring medical or surgical closure. The diagnosis
was confirmed by echocardiography where possible.
Necrotising enterocolitis (NEC) was defined according to a simplified version of the clinical
staging system proposed by Bell et al (1978). Only Bell stage 2 or worse (typical
radiological appearance) was recorded and analysed.
Pulmonary haemorrhage was defined as the spontaneous appearance of blood or
bloodstained fluid in the endotracheal tube. The presence of blood following endotracheal
toilet was ignored.
Significant retinopathy of prematurity (ROP) was defined as "threshold disease" (Report of
a Joint Working Party 1996). That is stage III ROP present in eight cumulative "clock
hours" or five contiguous "clock hours" with "plus" disease (the presence of tortuous
vessels) in zone I or II (Cryotherapy for Retinopathy of Prematurity Cooperative Group
1988). Eye examinations were performed by ophthalmologists according to accepted
international guidelines (Report of a Joint Working Party 1996).
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9.4 Early Changes in Oxygen and Ventilator Requirements
Data regarding early oxygenation and ventilation requirements were obtained retrospectively
from the intensive care charts of all enrolled infants where these were available. The
measurements that were recorded included fraction of inspired oxygen concentration (%
Fi02), mean airway pressure (MAP) in cm H20 and arterial oxygen concentration (Pa02) in
kPa. These were recorded at admission to the neonatal unit (t=0), two hours after birth (t=2),
at six hours of age (t=6) and every six hours thereafter until 72 hours of age (t=72).
Data for Fi02 were recorded on an hourly basis by nursing staff throughout the duration of
respiratory support. From these data were extracted Fi02 for the first 72 hours or the infant
died, whichever occurred first. MAP was recorded (or calculated from the ventilator
settings) for as long as the infant required respiratory support. The measurements therefore
include MAP whilst on conventional ventilation, high frequency oscillation and CPAP.
When the infant was breathing spontaneously the measurements stopped.
9.5 Statistics and sample size calculations
Sample size calculations were made to enable important differences in time in high
dependency care to be identified in surviving infants. Historic data from 236 ventilated
infants of 25-29 weeks gestation in Newcastle and Liverpool during 1996-97 demonstrated a
median duration of 6 days in high dependency care. The distribution of these data followed
an exponential decay distribution with large numbers of infants requiring a short duration of
intensive care and small numbers of infants requiring a longer duration. This was then used
for the calculation of sample size.
It was calculated that to detect a 25% difference in median time in high dependency care
with 80% power at the 5% significance level 241 infants would need to be randomised to
each arm of the study. This was intended to give samples of adequate size amongst survivors
and assumed a predischarge mortality of 20% in each group with no significant difference in
mortality rates between the two groups. The study protocol also stipulated that a Data and
Safety Monitoring Committee (DSMC) would meet after recruiting approximately half the
required numbers. No formal rules for stopping the trial were drawn up because the decision
to recommend early cessation would depend on outcomes relating to safety and mortality as
well as clinical efficacy.
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The null hypothesis for this trial assumed that there would be no difference in the cost of
caring for infants treated with either Curosurf or ALEC. All analyses were performed on an
"intention to treat" basis.
The differences between measurements of oxygen and ventilator requirements during the
first 72 hours of life were analysed using summary measures as suggested by Matthews et al
(1990). The reason for using this method of analysis is that measurements in an individual
infant are usually correlated to those obtained before and after the current measurement.
These then reflect the progression of the clinical condition, for example an infant may begin
life with an oxygen requirement of 40% which falls rapidly to 21% after surfactant and stays
there, whereas the next infant in that group might require 100% and only slowly begin to
improve. A mean Fi02 value for these infants would not be representative of either. In both
cases the second Fi02 is related to the first.
Similarly graphical representation of values at time points with "error bars" and an indicator
of the statistical difference at each time point, whilst commonly used in medical literature
and visually understandable to the clinician, are also statistically inappropriate and wrong
(Matthews et al 1990).
The response following surfactant in each individual infant was calculated and summarised
using a geometric mean of the area under a graph plot of time versus the measurement in
question. For example, the area (AUC) under the graph of an Fi02 plot would be calculated
for each infant as:
AUC - ViT,(t2- ti) x (y2 - yi)
Where tq = time and Y\ = Fi02 (%) value at time tq
and t2 = time and y2 = Fi02 (%) value at time tj-
If measurement were performed for a total duration of n hours, then AUC/n gives the
geometric mean Fi02, this also allowed for deaths and missing measurements (for example
if the charts were destroyed or measurements not recorded). The differences between
summary data from the two groups of infants can then be analysed using the Mann Whitney
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U test for non-parametric data.
9.6 Results
The DSMC met in December 1999, nineteen months after the trial commenced. Data on trial
recruitment (207 infants as of December 1st), post-randomisation exclusions (16 for
suspected violation of study protocol) and available outcome data in 189 infants were
presented (data on 2 infants recruited in South Cleveland and Sunderland Royal Hospitals
respectively on November 30th were unavailable at the time). The investigators later revised
the postnatal exclusions and the final figure (13) is lower than that presented to the DSMC,
but did not affect the outcome.
The DSMC, blinded to treatment allocation, noted an unexpected and highly significant
difference in pre-discharge mortality that could not explained by differences in gestational
age or gender. They recommended that the trial be stopped. Following this advice the trial
co-ordinators terminated recruitment on 14th December 1999 by which time five more
infants had been recruited. The DSMC recommendation can be found in Appendix 1.
9.6.1 Enrolment
The total eligible birth cohort from all centres was 403 (Figure 11). Data on the total eligible
population were derived from several sources: computerised databases held in each of the
four neonatal provider units in the former Northern region, a regional survey of all infants
<32 weeks gestation (chapter 10), admission records in Liverpool, Leeds and Leicester
neonatal intensive care units. Reasons for non-enrolment were determined from maternal
and infant notes, retrospective review of the staff involved in the infant's care after delivery
and prospective collection of responses from parental refusals.
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Figure 11: The consort diagram for the trial between Curosurfand ALEC
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Two hundred and twelve infants (198 born in the level III units and 14 transferred to these
centres postnatally) had been randomised to the trial. Thirteen infants were excluded post-
randomisation. Reasons for excluding these infants were:
• Incorrect assessment of gestation (3 infants - 2 Curosurf and 1 ALEC. These
were triplets that were retrospectively recognised to have been assessed to be 24
weeks and 5 days at randomisation).
• Stillbirths (2 infants in each arm who were randomised antenatally and died
either in-utero or never responded to resuscitation).
• Congenital malformation (1 infant in the Curosurf arm was recognised to have
a tracheo-oesophageal fistula - confirmed on post-mortem examination).
• Problems with randomisation in one infant allocated to Curosurf (parents
withdrew consent after randomisation but before treatment - this infant received
Survanta outside the study).
There were minor deviations from the trial protocol in several randomised infants: one
infant randomised to receive Curosurf received Survanta, as the Curosurfhad become out¬
dated, another infant allocated to receive Curosurf received ALEC. Three infants (all
randomised antenatally) in each arm were not ventilated after delivery and received no
surfactant. Data from the two infants who received the wrong surfactant type and the six
who received no surfactant are included in the outcomes and were analysed by intention to
treat.
9.6.2 Demographics of enrolled infants
Demographic data is shown in Table 27. There were more males and twins in the Curosurf
arm and slightly less mature infants in the ALEC arm, all factors that increase the likelihood
of and severity of RDS (chapter 2), but otherwise the two arms were well matched.
Enrolment by centre is demonstrated in Table 28. Although there were some variations
between centres regarding birthweights and gestational ages this was felt to probably reflect
the role of the centres such as Liverpool and Newcastle being fetal and surgical, as well as
neonatal, tertiary referral centres. Within centres the infants were well matched.
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Gestation in weeks (median, IQR) 28.3 (26.4 - 29.1) 27.8 (26.3 - 28.9)
Birthweight in grams (median, IQR) 1026 (514- 1680) 948 (448- 1750)
Birthweight z-scores (mean, SD) -0.57 (1.2) -0.65 (1.2)
Males 64 53
Multiple births
No. of twins 30 21
No. of triplets 1 2
Antenatal steroids
Any 93 93
2 or more doses 69 78
Method ofdelivery
Vaginal delivery (including breech) 48 50
Caesarean section 51 50
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9.6.3 Time to first dose of surfactant and total number of doses
The time to first dose of surfactant was similar in both groups. The median times of
administration were 16 minutes (interquartile range [IQR] 7-41 minutes) in the Curosurf
arm, and 13 minutes (IQR 7-34 minutes) in the ALEC arm. The distribution of these times
is shown in Figure 12.
The number of doses required by the infants in the two arms did not differ (Table 29).
Infants required a mean 1.7 doses in the ALEC arm and 1.6 doses in the Curosurfarm. Five
infants treated with ALEC compared to two infants treated with Curosurf received more
than two doses of surfactant, and more infants in the ALEC arm received a second dose.
Neither of these results reached statistical significance.
9.6.4 Early changes in ventilator and oxygen requirements
Blood gas data, oxygen requirements and ventilator settings during the first 72 hours were
available in 187 infants (93 / 100 in the ALEC group and 94 / 99 in the Curosurfgroup). In
particular the availability of arterial blood gases was very variable because some units
preferred to use non-invasive means ofmonitoring arterial oxygen.
There were early, and expected, improvements in oxygen requirements in the Curosurf arm
compared to the ALEC arm. There was a small reduction in Fi02 at t=0 in the Curosurfarm
compared to ALEC, reflecting surfactant administration in the delivery room in some units
and the onset of monitoring later in the neonatal unit. Differences in oxygen requirements
were apparent between the two groups of infants at two hours of age and remained
significantly lower throughout the whole period of 72 hours (Figure 13). When analysed as
summary data for serial measurements using the method suggested by Matthews et al
(1990), the differences in geometric means during the whole of the first 72 hours were
statistically highly significant (p<0.0001).
Similarly there were lower median values for MAP in the infants that received Curosurf.
Differences became statistically significant by 2 hours of age and remained lower until 36
hours, after which the values were similar (Figure 14). Again when analysed as summary
data the difference in geometric means was also highly statistically significant (p=0.0049).
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Time to first dose (mins.)
Histograms of time to first dose of allocated surfactant (for times less then 2 hours). Three
patients were given a first dose ofALEC after 2 hours (at 121, 143, 162 minutes) and five
patients were given a first dose of Curosurfafter 2 hours (at 135, 164, 169, 695, 840
minutes).
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Table 29: Number of doses of surfactant given.








Total number of doses (all infants) 159 170
Figure 13; Mean (+/- SEM) appropriate Fi02
during the first 72 hours of life
Time after birth (hours)
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Figure 14: Changes in mean airways pressure (mean +/- SEM)
between Curosurf and ALEC arms during the first 72 hours
Time from admission (hours)
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The mean oxygenation index (OI) was lower in the Curosurf arm on admission to NICU
than in the ALEC arm (mean [SEM] of 8.7 [0.6] versus 11.2 [0.9], p = 0.06), however the
difference may reflect the fact surfactant was administered in the delivery room in
approximately 50% of infants - it was not possible due to limitations in monitoring in the
delivery suites to collect data earlier These early values are therefore a mixture of pre- and
post-surfactant values. At 6 hours of age the OI was significantly lower in the Curosurf
group (5.6 [0.5] versus 11.3 [1.1], p < 0.0001). The OI of infants who died were
significantly higher than infants who survived (Figure 15). However in the Curosurf infants
who died the OI fell whereas in the ALEC infants who died the OI rose, this is most likely a
reflection of the number of respiratory-related deaths in the ALEC arm (section 9.6.5).
9.6.5 Mortality
This is considered next as this was the outcome on which the Data & Safety Monitoring
Committee had based its decision to recommend early termination of the trial. There were
31 deaths prior to discharge in the ALEC arm, and 14 deaths prior to discharge in the
Curosurf arm (Odds ratio 0.37; 95% CI 0.18 - 0.74; p = 0.004). Of these 25 and 11
respectively were during the neonatal period (OR 0.38; 95% CI 0.71 - 0.81; p = 0.011).
Because there were imbalances in the two groups particularly with respect to gender and
gestation logistic regression was performed. This took also into account effects of treatment
centre, gender, use of antenatal steroids, birthweight and whether the infant was a singleton
or not. Following this odds ratio for predischarge death was 0.31 (95% CI 0.14 - 0.72, p =
0.006) and for neonatal mortality was 0.36 (95% CI 0.15 - 0.84, p = 0.019).
The cause of death was determined independently by two consultant neonatologists who,
blinded to surfactant administration reviewed the clinical notes and post-mortem reports.
Each reviewer, who had not been one of the study organisers, was asked to state the cause of
death, or where the death was multifactorial, the disease or event that led to the cascade
leading to events. For example an infant might have moderately severe RDS that was
improving, had they developed symptoms and signs of patent ductus arteriosus and a
pulmonary haemorrhage occurred, the clinicians might have increased ventilator pressures
which could have led to a pneumothorax; this would have been classified as being death due
to pulmonary haemorrhage secondary to PDA, even if RDS and pneumothorax were co-
factors.
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Figure 15: Changes in Oxygenation Index (mean +/- SEM)









Causes and age of death are shown in Table 30. Three quarters of the deaths in both arms
were during the neonatal period. The deaths were also classified as being due to either
respiratory or non-respiratory causes by the neonatal consultants that determined the cause
of death. More pre-discharge deaths in the ALEC arm (21%) were attributed to a respiratory
cause than in the Curosurf arm (5%), this result was highly statistically significant (OR
0.20, 95% CI 0.07 - 0.56, p = 0.001).
The difference between surfactants in neonatal and pre-discharge mortality rates was
maintained across the spread of gestational ages (Table 31), and across the centres (Table
32). At all gestations and in all centres the results favoured Curosurf, but the differences
within centres and at given gestations were not significantly different. Timings of the deaths
are shown in the Kaplan-Meier plot (Figure 16).
9.6.6 Other complications of prematurity
None of the complications of prematurity that were actively sought as part of the secondary
outcomes were significantly different between the ALEC and Curosurf groups (Table 33).
Curosurf reduced pneumothoraces whereas there were more clinically significant PDAs
requiring treatment in that group. The proportion of infants surviving with CLD at 28 days
and at 36 weeks corrected post-menstrual age were similar, as was the proportion of infants
discharged home on oxygen.
There were differences between centres in the rates of pneumothoraces. Newcastle had the
greatest proportion of pneumothoraces overall (table 34), and unlike other centres there was
no appreciable difference between pneumothorax rates in the Curosurf and ALEC arms.
The reason why there was so is unclear.
The duration of positive pressure ventilation in surviving infants (either conventional
ventilation or HFOV) was similar in the two arms. Infants in the Curosurf arm required a
median of 3 days ventilation whereas those in the ALEC arm required a median of 5 days
(Mann Whitney U test; p = 0.45).
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Table 30: Cause of death of infants
Age Surfactant M/F BWt Gest. Cause of death
(days) (gram) (week)
Early neonatal deaths
1 ALEC F 910 25 Severe RDS and air leak
1 ALEC F 690 25 Infection (suspected GBS)
1 ALEC F 728 26 Severe RDS, air leak
1 ALEC M 880 26 Severe RDS and air leak with PPHN
1 ALEC M 910 26 Severe RDS and PPHN
1 ALEC M 1126 27 Severe RDS, air leak
1 ALEC M 1310 27 RDS with air leak
1 ALEC F 930 29 Severe RDS / pulmonary hypoplasia
2 ALEC M 917 26 Severe RDS, air leak, air embolus
2 ALEC M 1370 28 Severe RDS
2 ALEC F 1040 28 RDS with air leak
3 Curosurf M 530 26 Severe RDS, pulm. haem.
3 Curosurf F 620 26 Intrapartum asphyxia/multi-organ failure
3 ALEC M 734 27 Severe RDS, air leak
3 ALEC F 825 28 Severe RDS
3 Curosurf M 514 29 Acute renal failure, twin-to-twin
transfusion, pulm. haem.
4 Curosurf M 840 28 Severe RDS
5 Curosurf M 580 25 Severe RDS + infection
5 Curosurf M 1100 29 Severe RDS with air leak
7 Curosurf F 585 25 Perforated NEC
7 ALEC M 735 26 Pulm. haem. 2°ry to PDA.
7 ALEC F 865 29 Hydrops
Late neonatal deaths
8 ALEC M 859 25 Acute renal failure ?Sepsis
8 ALEC M 750 25 Severe RDS leading to NEC
8 ALEC M 1378 28 Severe RDS with air leak
8 ALEC M 1220 28 Antenatal myocardial ischaemia and
hydrops
8 ALEC M 1049 29 Pulm. haem. 2°ry to PDA
10 Curosurf M 965 25 Intrapartum asphyxia and multi-organ
failure
10 ALEC F 690 25 Staph, epidermidis septicaemia
10 ALEC M 692 28 Severe RDS
10 ALEC M 720 28 Air leak
11 ALEC F 762 25 Fungal septicaemia
11 Curosurf M 958 26 Enterobacter / Candida septicaemia
11 ALEC F 760 26 NEC
11 Curosurf M 1220 28 TPN hydrothorax (longline complication)
28 Curosurf M 570 25 Pulm. haem. 2°ry to PDA
Post-neonatal deaths
30 Curosurf M 685 28 NEC
59 Curosurf M 765 26 Widespread cerebral ischaemia and PVL
110 ALEC M 550 25 CLD
123 ALEC F 548 27 CLD
133 ALEC M 734 29 CLD
143 ALEC M 600 26 CLD
147 ALEC M 780 25 CLD
217 ALEC M 700 28 Hypovolemia 2°ry to incarcerated hernia
372 Curosurf M 558 26 CLD
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Table 31: Neonatal and pre-discharge deaths according to gestation
Neonatal mortality
Curosurf ALEC
Overall 11/99(11.1%) 25 / 100 (25.0%)
25 weeks 4/12(33.3%) 6/13 (46.2%)
26 weeks 3 / 17 (17.6%) 6 / 22 (27.3%)
27 weeks 0 /14 (0%) 4/17(23.5%)
28 weeks 2 / 24 (8.3%) 6 / 24 (25.0%)
29 weeks 2 / 32 (6.3%) 3/24(12.5%)
Pre-discharge mortality
Curosurf ALEC
Overall 14/99(14.1%) 31/100 (31.0%)
25 weeks 4/12(33.3%) 8/13 (61.5%)
26 weeks 5/17 (29.4%) 7/22 (31.8%)
27 weeks 0/14 (0%) 5/17 (29.4%)
28 weeks 3/24(12.5%) 7 / 24 (29.2%)
29 weeks 2 / 32 (6.3%) 4/24(16.7%)
Table 32: Neonatal and predischarge deaths according to centre and surfactant allocation
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Table 34: Pneumothorax rate according to centre and surfactant allocation




Curosurf 3 / 41 (7.3%)
Newcastle (RVI)


















It has been shown that oxygenation and mean airway pressure were reduced sooner in
infants treated with Curosurf (section 9.6.4). More infants in the ALEC arm required rescue
modalities of respiratory support (HFOV and inhaled nitric oxide) in those centres that
offered them. For HFOV the proportions were 22% in the ALEC arm and 13% in the
Curosurf arm, for inhaled NO the proportions were 5% and 2% respectively. Most of the
infants that required rescue treatment died (60% of those that received HFOV and 57% of
those that received inhaled NO) although this probably reflects the disease severity at the
time of initiating rescue treatment.
The critical risk index in infants (CRIB) score was significantly lower in the Curosurf arm
than the ALEC arm (3.0 [IQR 0.1-5.9] versus median 6.0 [IQR 3.0-10.0]; Mann Whitney U
test p = 0.0002). When broken down into the component parts of CRIB (maximum oxygen,
minimum oxygen, worst base deficit, gestation, birthweight and congenital malformations)
the differences were found to be entirely due to higher values for the maximum and
minimum appropriate oxygen concentrations in the ALEC arm (Table 35). CRIB scores of
infants who died (8.3 in the Curosurf arm and 9.9 in the ALEC arm) were nonetheless
statistically significantly higher than in infants who survived (3.5 in the Curosurf arm and
4.7 in the ALEC arm).
The original intention of collecting CRIB data had been to ensure that infants recruited to
both arms of the trial were equally sick prior to surfactant administration. However it has
become clear during analysis of these data that CRIB was inappropriate for this purpose as it
was severely affected by the differential effect the two surfactants had on minimum and
maximum oxygen requirements after they were given.
9.6.8 Days of high dependency care
With the difference in mortality this outcome became of secondary importance, particularly
with the trial terminating early. There was no statistically significant difference between
surviving infants in the two groups for the median number of high dependency (HD) days
(22 days [IQR 5-52] in the ALEC group and 18 days [IQR 6-39] in the Curosurf group).
The median duration of low dependency (LD) care was also similar (47 days [IQR 37-57] in
tht ALEC group and 51 days [IQR 39-63] in the Curosurfgroup).
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Table 35: Median values of the components in CRIB scores between the ALEC and
Curosurfarms
Curosurf ALEC p value*
Gestation (weeks) 28.3 27. 8 NS
Birthweight (grams) 1026 949 NS
Maximum oxygen 50% 77% 0.001
Minimum oxygen 21% 28% <0.0001
Worst base excess -5.0 -5.5 NS
* Fishers Exact test
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The overall median duration of neonatal care in surviving infants (high and low
dependency) was 69 days [IQR 49-87] in the Curosurfarm and 75 days [IQR 50-100] in the
ALEC arm with infants in both arms being discharge at a median gestation of 38 weeks
post-conception.
Among infants that died the duration of HD care was similar in the two arms (median of 8
days [IQR 3.3-12.8] in the ALEC arm with median of 8.5 days [IQR 0-20.5days] in the
Curosurf arm). The late deaths affected these results so that the mean duration of HD care
in the two arms were 31 days in the ALEC arm and 37 days in the Curosurf arm.
The differential mortality rates and the late deaths in the ALEC arm made the primary
outcome (cost of care in surviving infants) difficult to assess. Not least because the median
duration of HD care in both surviving and non-surviving infants was calculated to be 11.0
days [IQR 0.0-31.0] in the ALEC arm and 16.0 days [IQR 0-32.0days] in the Curosurfarm,
yet the mean (±1 St. Dev) was 30.9 (±40.0) and 27.0 (±40.0) days respectively.
Using HD care RVI costs quoted earlier (i.e. HD days cost £912 each, of which £800 is at
fixed/semi-fixed rate and £ 112 at marginal rates, LD days cost 20% of HD days) applied to
the means ofHD and LD days the pre-discharge costs can then be calculated. Thus the mean
cost of treating an infant with ALEC was £34,565 (£28,181 at HD rates and £6,384 at LD
rates) and for Curosurf this was £32,941 (£24,624 at HD rates and £8,317 at LD rates).
More importantly mean marginal costs were £3,461 and £3,024 respectively, a slight
advantage for Curosurfbut one that disappears when taking into account the costs of 2 vials
of ALEC (£300) versus 2 vials of Curosurf (£800) as the more expensive Curosurfwould
add to these marginal costs by £500 per infant.
However when the costs of producing one survivor are examined the difference becomes
larger because of the differential in mortality. The overall cost (at RVI rates) of treating the
100 infants with ALEC was £3,456,500, this resulted in 69 survivors. The cost per survivor
was therefore £50,094 (of this £5,016 was marginal HD cost). For Curosurf the cost of
treating the 99 infants in that arm of the trial was £3,261,159 with a resulting 85 survivors.
The cost per survivor was therefore £38,366 (of which £3,522 was at marginal HD rates).
This means that Curosurf use resulted in a saving (per survivor) of £11,728 (£1,408 at
marginal rates).
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Thus despite being the more expensive surfactant preparation, Curosurf actually saved
£1,408 per surviving infant in marginal costs. The effects of this saving on a regional basis
within the former Northern region are explored in chapter 10.
9.7 Discussion
The result of this study with respect to mortality was unexpected and led to the
recommendation from the DSMC to terminate the trial prematurely. That mortality was
collected as a secondary outcome measure shows how unexpected this result was. Meta¬
analysis had suggested that there might be a slight advantage for animal-derived surfactants,
but this only approached statistical significance with the inclusion of results from 3300
infants (Soil 1999c). None of the previous individual trials between animal-derived and
synthetic surfactants had shown such a clear difference despite larger numbers of infants
recruited. The following discussion first concentrates on the mortality rates and the decision
to terminate the trial prematurely, before comparing this trial with existing data from other
trials and meta-analyses, and ending with a discussion of the implications.
The decision of the DSMC to recommend termination was not reached lightly particularly as
mortality was not the primary outcome of the trial. Nonetheless it was regarded by the
committee as an important outcome in itself. The main purpose of a DSMC is to protect
patients - primarily those included in the trial but also other patients with the disease in
question (Hampton 2000). Either there was something intrinsically wrong with the trial
design or there was a difference in treatment effect that had not been appreciated prior to the
trial. In either case the correct ethical decision was termination of the trial.
Some of the deaths reported cannot be attributed to treatment effect; for example a death at
over 200 days of age due to hypovolemia secondary to incarcerated inguinal hernia.
However it was decided to include all deaths prior to discharge irrespective of cause. This
has been done in other neonatal surfactant trials, particularly the Ten Centre Study (1987)
and Two Centre Study (Morley et al 1988).
The neonatologists that reviewed the notes to determine the cause of death were blinded to
surfactant allocation, although they were aware that ALEC had a higher mortality rate than
Curosurf. They were also asked to differentiate those deaths that were primarily respiratory
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and whether these could be attributed to RDS and either its short-term or long-term
complications. More infants in the ALEC arm died from a respiratory cause, whereas non¬
respiratory death rates were similar. Whilst Curosurfmay not have prevented all the excess
respiratory deaths in the ALEC arm, in two groups of infants that were randomised and that
had similar pre-treatment profiles, the assumption has to be that it is the better surfactant of
the two for treating RDS. Curosurf reduces oxygen and ventilator requirements more
rapidly, and because both oxygen and barotrauma (or volutrauma) are thought to be
important in the pathogenesis of CLD it can be reasonably argued that Curosurf may
influence this late outcome as well as RDS.
A statistical difference in mortality rates between the two surfactants had not been expected
prior to the trial, and whilst it is possible that this was a true treatment effect, other pre¬
existing variables that are discussed in chapter 1 may have influenced severity of RDS. One
notable difference between the two arms was gestational age breakdown, favouring
treatment with Curosurf, whereas there was an excess of male infants in the Curosurf arm,
which favoured the ALEC group. The imbalances that did happen were within the bounds of
chance variation. The use of analysis of covariance methods to allow for the imbalance is a
widely accepted and effective statistical tool. Indeed, if stratification had taken gestation and
gender into account then they would have to have been included as covariates in the
analysis.
In retrospect these imbalances could have been avoided by further stratification (for example
using two groups of 25-27 weeks and 28-29 weeks gestation, and by gender). But the
introduction of additional strata into the randomisation process would have made it more
complicated and time consuming. Owing to the demands on medical and nursing time after
the delivery of a preterm infant, the randomisation process was designed to be simple and as
quick as possible so that staff could concentrate on the patient.
Whether prior knowledge of surfactant type may have influenced the decision to intubate the
infant for respiratory support is difficult to assess. This bias can only affect those patients
that are randomised and the randomisation process was through a single centre using sealed
opaque envelopes. Only thirteen patients were withdrawn post-randomisation and all of
these were for legitimate reasons that could not be influenced by the trial investigators. It is
believed their withdrawal did not bias the treatment comparison.
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The four infants that were randomised antenatally (all to ALEC) and subsequently had their
delivery postponed (because the indication for preterm delivery disappeared or settled) are
the only instance where a reasonable argument for bias can be mounted. The decision for
postponing the delivery, however, was not made by the investigators and the obstetricians
making the decision would have been unaware of the allocation. It should also be noted that
as only four potential patients are being discussed there is, in any case, the potential for only
a small bias. In the event that the infants were not intubated, they were treated according to
their clinical condition at the time, which is an unavoidable risk of the antenatal
randomisation process. Similarly infants that died in-utero (stillborn) or that could not be
resuscitated were enrolled unavoidably.
The question then arose as to whether the results obtained in this trial were consistent with
those seen in earlier trials of the same surfactants. Evidence from the placebo controlled trial
of Curosurfwhen treatment had been administered at a median of 9 hours of age and infants
had established RDS (they required an Fi02 > 0.6 for enrolment) suggested a reduction in
mortality from 51% in the control arm to 31% in the treatment arm (Collaborative European
Multicenter Study Group 1988). The trials of Egberts et al (1993), Walti et al (1995) and
Bevilacqua et al (1996) used cohorts that more closely resembled our trial population with
their timings of surfactant administration. In the "prophylaxis" arms of these three trials, the
neonatal mortality rates were 10.7%, 11.2% and 20.6% respectively.
With ALEC the evidence from previous trials was limited. Only five trials have been
published with this surfactant (Morley et al 1981, Milner et al 1983, Wilkinson et al 1985,
Ten Centre Study 1987, Morley et al 1988) and only the last two used a preparation similar
to that currently available commercially. As the infants <30 weeks gestation from the Two
Centre trial (Morley et al 1988) were included in the Ten Centre Study, that left only the one
trial with which to compare mortality rates. Neonatal mortality in the Ten Centre treatment
arm was 14.5%, much lower than 31% despite a higher rate of use of antenatal steroids in
our trial.
This difference between mortality rates in ALEC treated arms of the Ten Centre and the
current trial could not be explained by comparison of the population characteristics (median
gestation and birthweight, proportion of males were similar, but the antenatal steroid use
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favoured infants in our trial. Further details about the Ten Centre Study were sought and
kindly supplied by Professor Colin Morley.
Differences in disease severity, changes in patterns of care or demographic variables of the
populations in studies carried out more than a decade apart may explain some of the
differences. 10.7% of infants in the treatment arm of the Ten Centre Study were not
ventilated (and received only a pharyngeal dose of pumactant), whereas it was a condition
that infants in our trial were eligible only if intubated and ventilated. This may be reflected
in the fact that gestation-specific mortality in the more immature (25-26 weeks gestation)
ALEC-treated infants in our study was similar to that in the Ten Centre study, but was
higher in the more mature infants (27-29 weeks). The differences in mortality between the
studies at each gestational week did not reach statistical significance (test for interaction p =
0.08).
The only other trial comparing Curosurf and a synthetic surfactant (Exosurf) did not show
any difference in longer-term outcomes (Kukkonen et al 2000) but this had used a late
"rescue" strategy trial whereas the comparison between ALEC and Curosurfwas, at worst,
early treatment, with "prophylaxis" in some centres.
Both the published meta-analyses (Halliday 1996 and Soli 1999c), and the one presented in
chapter 8, had suggested that there would be fewer deaths in the animal-derived arm of the
study but that within a single trial this would not achieve statistical significance. It may be
that the use of different surfactants than in the meta-analyses has contributed to the finding
of a much greater mortality after synthetic surfactant in this study. In vitro properties were
different for all four of the currently available surfactants in the United Kingdom, but
extrapolation of these differences to clinical studies is unreliable. There was a significant
reduction in the number of pneumothoraces in the Curosurf group, which agrees with the
meta-analyses, however clinically significant PDAs were higher in the Curosurf group, the
meta-analyses had suggested this would be lower.
An important difference between this and other trials ofALEC was the dosing schedule. In
the Ten Centre Study, ALEC was given up to four times; the first dose was a pharyngeal
deposit prior to intubation, the second was immediately after intubation, the third one hour
later and a fourth dose at 24 hours. For commercial development the pharyngeal dose had
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been dropped but the manufacturer's data sheet still recommended the use of the other three
doses.
The evidence supporting the second dose of ALEC at one hour was not very strong but
reasons quoted by Professor Morley (personal communication) were:
• If a infant <30 weeks gestation was still ventilated and in oxygen at one
hour there was a high probability that severe RDS was developing
• Procedures during the first hour after birth may have removed some of
the surfactant
• Further doses may help to overcome the protein inhibition
• There is a slow loss of molecules from the surface and the surface
tension properties deteriorate which can be restored with a further dose
of surfactant
All of these are equally applicable to any surfactant irrespective of source or type, but the
main reason specifically for the time schedule for ALEC seemed to be procedures such as
endotracheal suction that can remove surfactant.
Prior to the trial both Liverpool Women's Hospital and the Royal Victoria Infirmary in
Newcastle had used ALEC. Liverpool administered a dose in delivery suite followed by a
second dose 12 hours later, the RVI administered the first dose as soon as possible on the
neonatal unit and the second dose 24 hours later. Historic data in the two years prior to the
trial had shown pre-discharge mortality rates of 26.5% (Liverpool) and 25.4% (Newcastle)
in infants of 25-29 weeks gestation that had been ventilated. This historic data also
suggested there was no difference between a 12 or 24 hour schedule, although theoretically
an earlier dose (of any surfactant) at 12 hours might replenish phospholipids that had been
lost through inactivation, endotracheal suction and recycling and prevent periods of low
surfactant activity and hence RDS. These mortality rates were thus comparable with the trial
ALEC arm, but much higher than the Ten Centre Study data.
The implication of mortality rate differences between the ALEC arms of the Ten Centre
Study and the current trial is that either the 1-hour dose of ALEC did matter or the
populations of the two trials were inherently different. There is no doubt that neonatal
populations have changed, obstetricians are presenting neonatologists with infants that
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previously would have died in-utero and the trend is towards a sicker and more immature
population (Olsen et al 1995). There are also inherent differences between the geographic
populations of the two trials. The Ten Centre Study reported a control group mortality of
29.5% whereas at the time of this study the mortality in Newcastle General Hospital (the
predecessor of the RVI) was close to 36.9% in the 25-29 week gestation band (data from the
NGH neonatal unit annual reports 1989-90). These infants were not receiving surfactant
and represent the closest that we can get to a "control" (non-surfactant treated) group for our
population. If this 8% differential in mortality rate were to continue after surfactant was
introduced in Newcastle then mortality rates of 26-28% might be expected.
As explained earlier in chapter 6 most commercially available surfactants are administered
based on a dose of 100 mg/kg of phospholipids and are given at intervals that range from 1
hour to 24 hours, although the commonest interval is 12 hours. The evidence that 100 mg/kg
is the "correct" dose and that any dosing schedule is correct is, at best, limited. Whilst we
cannot ignore the fact that ALEC was not used according to the manufacturer's guidelines,
the fact remains that development of the schedule was largely empirical and there is no
published evidence that this is better than the dosing schedule used in our trial.
There is no doubt that Curosurf reduced both ventilation and oxygen more rapidly than
ALEC. Curosurf was able to reduce the mean 01 in even this sicker group of infants
whereas in the ALEC group the OI was higher at 6 hours than on admission. Kuint et al
(1994) suggest that the immediate response to surfactant has prognostic value in predicting
outcome, although they were not comparing two different surfactants with differing speeds
of onset. However they admit that factors other than speed of onset of action have an
influence on mortality - the most important being birthweight and gestation.
This is the only study that has shown a significant advantage in mortality for an animal-
derived over a synthetic surfactant (Figure 17). The reason why this is the case when meta¬
analyses (Soil 1999c and that in chapter 8) only approach statistical significance with many
more infants is unclear but this is the only study to have compared ALEC with any other
surfactant.
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Figure 17: Relative risk of
mortality reported in trials

























The excess numbers of deaths in the ALEC arm were attributable to RDS and its
complications. In randomised trials Curosurf has been compared to one other animal-
derived surfactant, Survanta (Speer et al 1995) and one synthetic surfactant, Exosurf
(Murdoch & Kempley 1998, Kukkonen et al 2000). In none of these trials was there a
statistically significant difference in mortality rates. The other advantages for animal-
derived over synthetic surfactants - those of speed of action and reducing the numbers of
pulmonary air leaks - were also evident for infants treated with Curosurf.
Although the study did not demonstrate significantly reduced costs after treatment with
Curosurf there were some reductions in marginal costs for high dependency care. However
these would be offset by the higher costs of Curosurf itself and by the greater numbers of
survivors requiring low dependency care.
9.8 Conclusion
Of the two surfactants Curosurf reduces predischarge and neonatal mortality compared to
ALEC. There were significant reductions in the oxygen and ventilator requirements of
infants who received Curosurf and these changes presumably were responsible for the
significantly lower rates of pneumothoraces and respiratory related deaths seen in this arm.
The primary outcome of the study became of a secondary importance after the differential in
mortality was seen nonetheless it still remains an important consideration in the provision of
neonatal care. There are other ways in which the reduced mortality might impact on care; an
increasing number of survivors mean greater competition for the available neonatal intensive
care cots. With increasing competition for cots there would have to be a greater number of
perinatal transfers.
How the perinatal services in the former Northern health region of England are organised is
discussed in the next chapter. This chapter also shows the influence of place of maternal
booking and birth on mortality in the "at risk" infants born at <32 weeks gestation and




Surfactant deficient lung disease in the former Northern
health region of England
10.1 Introduction
10.2 The development of a collaborative neonatal service in the former
Northern health region
10.3 The current status ofneonatal services in the former Northern region
10.4 Survey of all admissions of infants <32 weeks to neonatal units in the
former Northern region
10.4.1 Demographics of the regional population of infants <32 weeks
10.4.2 Mortality after admission to the neonatal units
10.4.3 Resource usage in SCBU - ventilation and intensive care days
10.4.4 Does the hospital of booking or of birth influence mortality?
10.5 The implications of the Curosurfand ALEC trial for the neonatal




As the last chapter has shown using Curosurf instead ofALEC can have clear implications
for the funding and provision of neonatal intensive care. Just as with the SHPIC report
(1996) that used data from hospitals in Dundee and Glasgow to illustrate the cost-
effectiveness of surfactant versus no treatment, it is possible to use data from infants born in
the former Northern region to estimate the impact a change from one surfactant to another.
This chapter begins by tracing the development of a collaborative neonatal service in the
region and explains how this currently provides neonatal intensive care for the 33,000
livebirths annually. Data on all infants <32 weeks gestation (i.e. those most at risk from
RDS) admitted to the region's neonatal units are discussed in relation to the hospital of
booking and of birth and access to neonatal intensive care facilities.
The chapter finishes by looking at a hypothetical situation whereby all infants <32 weeks
gestation who require surfactant are treated with Curosurf and discusses the changes in
mortality that might be seen if the results of the Curosurfversus ALEC trial were duplicated
in this unselected population.
10.2 The development of a collaborative neonatal service in
the former Northern health region
The neonatal services in the North East of England have developed from predominantly
obstetric-orientated domiciliary service in the 18th century to a collaborative consortium of
four level III neonatal intensive care units. These units now perform most of the neonatal
intensive care that is required by a proportion of the region's 33,000 annual livebirths.
The first maternity hospital in Newcastle upon Tyne - a Lying-in Hospital in 1760 - was
founded at a time when most births occurred at home and maternal, let alone infant,
mortality was as high as 6 per 1000. Reductions were not seen in this figure until the 20th
century. By this time obstetrics was beginning to move from a domiciliary to a hospital-
based service, not only in Newcastle but also elsewhere in the UK.
The Princess Mary Maternity Hospital (PMMH) and the building of a maternity ward at the
Newcastle General Hospital (NGH) in 1903 were seen as significant steps in the
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development of a modern obstetrical service in Newcastle. But it was not until 1939 that a
spacious and well-equipped nursery that was to function as the premature infant unit was
added to the NGH. Following this with the appointment of Dr James Spence as honorary
paediatrician to the PMMH care of the newborn infant began to receive the same emphasis
as the care of the mother. Spence is reported to have made the first paediatric ward round in
an English maternity hospital. In 1942 he was appointed Professor of Paediatrics in overall
charge of the RVI, the Infants' Hospital and the University Clinic ofChild Health.
With the advent of successful neonatal ventilation in the 1960s (reported first by Delivoria-
Papadopoulos & Swyer 1964) many infants that would otherwise have died from respiratory
failure could now be offered a chance of survival. In the late 1960's there was an increasing
number of reports of infants being successfully ventilated (Tunstall et al 1968, Reynolds
1970, Llewellyn et al 1970, Strang 1970, Raiha & Vapaavouri 1970). Both Newcastle
neonatal units continued to develop separately and began to ventilate increasing numbers of
infants (Figure 18). However, North Tees General Hospital in Stockton on Tees lays claim
to being the first hospital in the region to ventilate a neonatal patient {Personal
communication - Dr Myint Oo).
In the 1970's and 1980's neonatal intensive care was beginning to become the low-volume
high-intensity specialty that it is today. As in the rest of the United Kingdom, neonatal care
in the former Northern region grew on an ad hoc basis according to the perceived need at the
time. This was despite calls for a more centralised service based on special care facilities
within local hospitals and specialised intensive care unit in regional centres (Department of
Health and Social Security 1971).
Nonetheless it was recognised that with developments in ventilator technology and
innovations in neonatal care it was becoming increasingly difficult for smaller hospitals to
continue to offer neonatal care for infants in whom outcome depended on respiratory
support. This led to the development of a "Paediatric Flying Squad" to transfer affected
infants. This service was initially based at NGH but duties were later shared on an informal
basis with the PMMH. This arrangement was later formalised by the use of a single
telephone "hotline" switched between the units on a weekly basis (Tacchi 1994).
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Figure 18: The trends of ventilation workload
in the two Newcastle neonatal units 1972-92
Data obtained from the annual reports ofPMMH and NGH
(no data available from PMMH 1986-91)
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This arrangement coped with most of the region's infants who required intensive care during
the next five years, by which time rising demand led to some overflow to three other
neonatal units in Sunderland, Middlesbrough and Stockton on Tees. This pattern of service
provision developed in part as a result of the scattered nature of the region's population. The
service provided by the five units then evolved into an informal collaborative between the
units providing neonatal intensive care.
The NHS underwent significant changes with the introduction of the internal market,
outlined in the 1989 White Paper "Working for Patients" and which passed into law as the
NHS and Community Care Act 1990. The advent of the internal market threatened the
existing clinical collaborative network by devolving neonatal intensive care services to local
units (Pope & Wild 1992). The clinicians were faced with the choice of continuing to
collaborate, entering into open competition or amalgamating into a centralised service.
Collaboration was felt to be the most attractive option, not only to those involved but also to
the population the service provided for. In addition mathematical modelling suggested that
collaboration would be more efficient in using the available resources (Northern Neonatal
Network 1993b). As a result the arrangement was formalised into the Northern Neonatal
Network in 1993, beginning to contract their services to the healthcare purchasers in the
1993/94 financial year.
The telephone "hotline" has remained pivotal to the success of this clinical collaboration. A
single call via the "hotline" initiates referral and subsequent transfer, freeing the referring
clinician to give optimum care and attention to the infant.
10.3 The current status of neonatal services in the former
Northern region
With the amalgamation of the PMMH and NGH in Newcastle to a single unit at the Royal
Victoria Infirmary (RVI) in 1993 the neonatal intensive care services in the former Northern
region currently comprise four level III units - North Tees General Hospital in Stockton on
Tees, South Cleveland Hospital in Middlesbrough and Sunderland Royal Hospital and the
RVI. Between them these units provide almost all of the region's long-term neonatal
intensive care. The RVI also has neonatal and paediatric surgical facilities and a regional
fetal medicine service. Cardiac services are based at the Freeman Hospital in Newcastle
upon Tyne.
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This "centralisation" through collaboration has meant that transfers have become an
inevitable component of the region's perinatal service. There are eleven level I neonatal
(special care baby) units scattered around the region (Figure 19). These units have neither
the facilities nor the staff to undertake long-term neonatal ventilation. Instead infants who
are preterm or sick are stabilised in these units and transferred postnatally. Transfers within
the region are coordinated through the RVI. Postnatal transfers are undertaken by one of two
transfer teams, one based in Newcastle, the other in Middlesbrough. These teams perform
all acute neonatal transfers in the region, as well as transfers for other specialties such as
paediatric surgery, paediatric intensive care and the ECMO service. Non-acute transfers,
such as the return of an infant to a local hospital after intensive care, are the responsibility of
the local units.
There is close collaboration between the neonatal provider units, the obstetricians serving
these hospitals and regionally-based survey offices. Data collected by the survey offices has
resulted in a number of population-based outcomes studies in preterm infants (Wariyar et al
1989a, Wariyar et al 1989b, Tin et al 1997).
There are currently around 33,000 total births in the region annually and in keeping with
national trends there has been a reduction in the annual number of births in the region in the
past 5 years (Figure 20). The regional perinatal mortality has improved gradually over the
past 16 years and currently stands at 8.3 per 1000 total births (Figure 21).
Although most of the neonatal intensive care is undertaken in the four level III units the
nature of premature labour and the geography of the region means that there still significant
numbers of births that occur in units that do not provide long-term neonatal intensive care.
To examine the workload that neonatal respiratory care places on these units a prospective
survey was designed. The next section reports on the results of this survey over a 24 month
period.
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Figure 19: Neonatal units in the former Northern region
232
Figure 20: Birthrate in the former Northern region 1981 - 1999
Data obtained from annual reports issued by the
Northern Region Maternity Survey Office
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10.4 Survey of outcomes of infants born at <32 weeks
gestation in the former Northern region 1998-99.
Introduction
Most of population of the former Northern region is located in the former mining and
industrial communities in the east. This is mirrored by the distribution of the level III
NICUs. Nonetheless pockets of population served by smaller maternity units can be found
throughout the whole of the region. Eleven of these have special care infant units (level I
NICUs) that can undertake short-term intensive care prior to the arrival of the neonatal
transport team. Once an infant has completed his/her intensive care these units then take
over the latter stages of that infants care prior to discharge.
Staff in the level I units resuscitate and stabilise any preterm infants that are bom in their
hospital. The process of stabilisation might include intubation and ventilation,
administration of surfactant and the siting of venous and/or arterial lines. In other words
they provide full intensive until the arrival of the transfer team. In a smaller proportion of
the more mature infants who develop mild respiratory distress they might institute nasal
CPAP.
The aim of this survey was to examine the workload that this group of hospitals undertakes
relative to their own delivery rates and to the work undertaken in the four neonatal provider
units.
Methods
All infants born between 1st January 1998 and 31st December 1999 and who were admitted
to any of 10 of the 11 the level I SCBUs and who fulfilled the following criteria were
notified centrally by a nominated nurse using a simple form. The hospitals involved were
Ashington, Bishop Auckland, Carlisle, Darlington, Durham (Dryburn), Queen Elizabeth
Hospital (Gateshead), Hartlepool, North Shields, South Shields and Whitehaven (West
Cumberland Infirmary). Each admission of an eligible infant generated a new form and thus
it was possible for some infants to be notified on several occasions depending on their
clinical course.
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Infants were notified if they:
• Were <32 weeks gestation and/or
• Were <1500grams at birth and/or
• Required any form of respiratory support (either continuous positive airways
pressure or mechanical ventilation) irrespective of gestation at birth
This section concentrated on the infants who fulfilled the first criterion.
Data from the level I units were supplemented by information retrieved from the four
databases held in the four level III units in the region. These are common to all four units
and completed by the consultant neonatologists and have been described elsewhere (Fenton
AC, Milligan DWA, Ward Piatt MP for the Northern Neonatal Network. A Networked
Regional Database - making it work. Presented at the 2"d Annual RCPCH meeting, York
1998). Data from eligible infants born in the 11th hospital (Hexham) with a level I SCBU
were retrieved by hand from admission books. Data were further checked against a transport
database profiling all postnatal transfers in the region.
Data on the delivery rates in the hospitals were obtained by contacting the delivery suites in
all the hospitals. The regional birthrate was obtained from the Maternity Survey Offices,
which collects demographic data on all births, whether in hospital or at home, in the region.
The same survey office also receives notifications of all the deaths of infants <1 year of age
throughout the region. This also served as a cross-validation of the mortality data as well as
providing data concerning deaths after discharge from the neonatal unit.
Infants were divided into three groups. Group A were infants that were booked and born in
one of the four level III units. Group B were those infants booked in a level I unit but who
were transferred antenatally to a level III unit. Approximately 120 antenatal transfers are
undertaken annually in the region and approximately two-thirds deliver in the tertiary
centres (Fenton et al 2000). Group C were those that were booked and born in the level I
units. Some, but not all of these infants were transferred postnatally.
Data were analysed using non-parametric statistical tests (Mann Whitney U test, Fisher's
exact test and ANOVA as appropriate).
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Results
(a) Demographics of the regionalpopulation ofinfants <32 weeks gestation.
Seven hundred and seventy one infants less than 32 completed weeks post-conception were
alive at admission to any one of the four level III or eleven level I neonatal units in the
region between 1st January 1998 and 31st December 1999. An additional 18 infants >23
weeks gestation were notified to the regional Maternity Survey Office as showing signs of
life after birth but who were not admitted to a neonatal unit.
The hospital of booking is shown in Figure 22 and hospital of delivery in Figure 23. For
comparison the annual delivery rates in the hospitals are shown in Figure 24. The
collaborative nature and the requirement for both antenatal and postnatal transfers are shown
in Figure 25. The largest groups were those infants booked and born in hospitals with level
III neonatal units, or those booked in level I units and transferred either antenatally or
postnatally. 48.4% of infants were booked for delivery in hospitals with level I units
compared to 44.6% booking in hospitals with level III units. At delivery these proportions
had changed to 26.3% and 70.4% respectively. In addition to the number of in-utero
transfers 56.7% of those infants born in the hospitals with level I neonatal care facilities
were transferred postnatally. This reflects the nature of provision of neonatal intensive care
within the region.
The small number of transfers out of the region demonstrates the efficiency of the
collaboration. In a survey of in-utero transfers during 1999 there were only 3 transfers out of
the region with two infants delivered in the hospitals receiving the transfer (Fenton et al
2000). In contrast there were 48 infants transferred into the region either antenatally or
postnatally. These were predominantly from units in Scarborough and Northallerton just
south of the region, but which fall within the former Yorkshire region.
Gestation at birth of these infants is shown in Figure 26. The overall mean (± 1SD) gestation
was 28.6 (± 2.2) weeks, and the birthweight was 1235 (± 378) grams. Infants transferred
antenatally were statistically significantly more immature and smaller than in the infants that
were born in level I units. Mean gestations were respectively 28.4 (±2.3) and 29.0 (±2.0)
weeks (p=0.012) and mean birthweights were 1167 (±357) and 1330 (±361) grams
(p<0.0001). Reflecting a predominance of intrauterine growth retardation in this group.
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Figure 23: Place ofbirth of infants <32 weeks admitted


































































































































"Other" are 3 infants, two were booked at hospitals in the region
and born abroad when their mothers were on holiday,
the other was born in an ambulance enroute
from Whitehaven to the RVI
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Figure 24: Livebirths rates in 1999 in hospitals
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Figure 25: Early neonatal course in relation to place ofbirth
and transfer status
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Figure 26: No. of infants (<32 weeks) treated within the
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(b) Outcomes after admission to the neonatal units
Pre-discharge mortality for the whole group of infants <32 weeks admitted to SCBU was
17.6%. Gestation-specific mortality is shown in Figure 27. Most of the deaths occurred
early: 20.6% in the first 24 hours after birth, 39.0% by 48 hours and 56.6% by the end of the
first week (Figure 28). Four infants died after discharge (only one of these deaths could be
attributed to complications of prematurity). 77.2% of infants were discharged home and
5.1% transferred to a hospital outside the region. The latter were predominantly those
infants from mothers that had booked elsewhere and who were either transferred or who
were bom whilst staying in the region on holiday.
(c) Resource usage in SCBU- ventilation and high dependency days
The "centralised" provision of neonatal intensive care is also reflected by the distribution of
respiratory support. During the two year period a total of 615 (79.8%) infants received some
respiratory support (either positive pressure ventilation or CPAP). Overall in the period
there were 5785 ventilator days and 4292 CPAP days, an average of 7.5 ventilator days and
5.6 CPAP days per infant (Table 36). Of the CPAP days 377 were from infants who were
not ventilated. Only 25 ventilator days and 74 CPAP days were received by infants that
remained in the level I neonatal units from birth until discharge (7 of the ventilator days
were in infants that died before transfer could be effected). Further short-term respiratory
support was also provided by level I units for the 115 infants transferred postnatally. These
figures reflect only the days of respiratory support received on one of the special baby care
units (level I and level III units). Some of the infants that were transferred to the surgical
unit at the RVI or to the cardiac unit at the Freeman Hospital were also ventilated but data
from the duration of stay in these units was unavailable.
(d) Does the hospital ofbooking or ofbirth influence mortality?
The former Northern region has a population of nearly 3 million people and whilst most
people live in the industrial cities in the east there are pockets of populations throughout. In
the case of preterm or sick infants bom in West Cumberland Hospital in Whitehaven where
there are only level I neonatal facilities the closest level III unit is nearly 100 miles away.
One of the major concerns expressed by people unfamiliar with a collaborative approach to
perinatal care was whether outcomes would vary according to the distance from centres of
perinatal expertise. In particular would outcomes be worse in hospital that did not offer
long-term intensive care.
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Figure 27: Mortality rates of infants <32 weeks gestation booked
for delivery and admitted to special care baby units
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Figure 28: Kaplan-Meier plot of survival among infants <32 weeks
gestation admitted to special care baby units in the former
Northern region 1998-99.
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Table 36: Respiratory support in infants <32 weeks gestation admitted to the special
care baby units in the former Northern region 1998-99.
No. of infants with:
Any respiratory support 615 (79.8%)
Period ofpositive ventilation 506 (65.6%)
Period ofCPAP 433 (56.2%)
No respiratory support 156 (20.2%)
No. of infants:
Both positive pressure ventilation and CPAP 324 (42.0%)
Positive pressure ventilation only: 182 (23.6%)
CPAP only 109(14.1%)
Total number days of:
Positive pressure ventilation 5785
CPAP 4292
Either mode of respiratory support 10077
Average number days (per infant) of:
Positive pressure ventilation 7.5
CPAP 5.6
Either mode of respiratory support 13.1
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The biggest problem in trying to determine whether place of birth affects mortality is that
case selection greatly affects the results. This can be seen in a simple comparison between a
group of infants booked and born in hospitals offering level III neonatal intensive care
compared to those booked in a hospital with level I facilities and undergoing postnatal
transfer. Using the data from 1998-99 it would appear that mortality is greater in the
postnatally transferred group of infants (20.7% versus 17.9%). The significance of case-
selection is highlighted by the differences in gestation and illness severity between the two
groups. Postnatally transferred infants are more immature (28.1 weeks versus 28.5 weeks,
p<0.05) and have higher CRIB scores (mean score 6.1 versus 3.6, p<0.0001).
To overcome selection bias it is necessary to consider the whole population. Only infants
booked for antenatal care and delivered in one of the region's hospitals were included in this
analysis. To begin with the infants were divided firstly by level of care offered in their
booking hospital (level I or level III). This population is still subject to selection bias to
some extent in that the women booking in the west of the region would not reasonably be
able to attend perinatal services in any of the four level III units.
The gestation (28.7 ± 2.1 weeks in level I versus 28.5 ± 2.2 weeks in level III), birthweights
(1253 ± 368grams versus 1228 ± 381grams) and CRIB scores (4.2 ± 4.7 versus 3.6 ± 4.5) of
infants were similar irrespective of the place of booking. Pre-discharge mortality by
gestation and by level of care offered at the booking hospital is shown in Figure 29. There is
no statistical difference between the two groups at any gestation.
To look more closely at immediate perinatal care infants were also subdivided to three
groups according to place of delivery and immediate postnatal course;
• Booked and born in hospital with level III neonatal facilities
• Booked hospital with level I facilities but transferred antenatally to level III
• Booked and born in a unit with level I facilities, the sickest of these infants were
transferred postnatally
Although the infants transferred antenatally were smaller at birth reflecting antenatal
detection of growth retardation (1167g versus 1331 g in the level I infants and 1227g in the
level III infants); gestation and CRIB scores were similar in the three groups. Additionally
there was no difference in pre-discharge mortality at any gestation (Figure 30).
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Figure 29: Mortality (+/- 95% CI) by gestation according to
















Figure 30: Mortality (+/- 95% CI) by gestation according to transfer and
place ofbirth within the former Northern region 1998-99
Gestation (weeks)
One argument against centralised provision of neonatal care is that sicker infants born in
units without long-term neonatal intensive care might have a higher mortality than if they
had been born in a unit with these facilities. Evidence suggests that in order to maintain their
skills medical and nursing staff require a minimum amount of exposure to sick preterm
infants and that the number of deliveries in the smaller level I units are insufficient to allow
this.
To examine this argument all the infants in the three groups previous analysis were further
subdivided into those with a CRIB score < 10, and those with a CRIB score >10. This cut¬
off was selected because data (The International Neonatal Network 1993) suggests that
infants with CRIB scores >10 have mortality in excess of 50%. There were no differences
between the mortality rates of the three groups in infants with low CRIB scores, but there
was an apparent increase in mortality in the mortality of infants booked and born in level III
hospitals when they have the higher CRIB scores (Figure 31).
This result does not achieve statistical significance, and the apparent difference may be due
to the small numbers of infants in these groups. However another reason may be that the
provision of perinatal care in the Northern region with collaboration between units, an
integrated perinatal transfer service and a high standard of short term intensive care in the
level I units ensures that all infants receive the optimum management irrespective of their
hospital of booking or birth.
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Figure 31: Mortality by CRIB score and place ofbirth:
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10.5 The implications of the Curosurf and ALEC trial for the
neonatal services in the former Northern region
Using data from the survey outlined above and data from the study comparing Curosurfand
ALEC it is possible to estimate the impact of a wholesale change from one surfactant to the
other might have. Prior to the study between Curosurf and ALEC in the previous chapter
the type of surfactant used was determined largely by cost and unit choice. The RVI and all
the level I units used ALEC almost exclusively, Sunderland used Survanta in infants <29
weeks and North Tees and South Cleveland used Curosurf.
If we restrict the analysis to those gestations in the study (25-29 weeks) and only those
infants both booked and born in the region we can assess what might happen if either only
ALEC or only Curosurfwere used exclusively.
During the two year period there were a total of 371 infants of 25-29 weeks gestation born
and admitted to one of the neonatal units, of which 317 were ventilated and received a
variety of surfactants. Demographics of these groups, with the Curosurf and ALEC arms for
comparison, are shown in Table 37. Mortality among ventilated infants of 25-29 weeks
gestation in the region with a variety of surfactants was 24.0%.
As shown in the last chapter, Curosurf significantly reduced pre-discharge mortality
compared to ALEC. Thus if the trial results were reproduced among a region-wide cohort of
infants of 25-29 weeks gestation then among the 158 ventilated infants per year there would
be 109 survivors ifALEC was used as the sole surfactant in the region (i.e mortality would
increase by a factor of 1.3 [= mortality rate in ALEC arm of trial / region mortality]) or 136
if was Curosurf (similarly mortality is altered by a factor of 0.6 [= mortality rate in
Curosurfarm of trial / region mortality]).
Thus if Curosurf was exclusively used the patterns of care and the costs would change
because most deaths occur early; although Curosurf-treated infants on average spend less
time in high dependency care, the additional survivors would spend longer in low
dependency care thus consuming more resources. These additional costs would have to be
met by the healthcare providers and purchasers.
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Extrapolating to include the whole cohort of infants <32 weeks gestation and if the
differential in survival rates between the two surfactants was sustained outside the gestation
range in the study: We would only be able to affect mortality in those infants who were
intubated, ventilated and received surfactant. There were 468 infants booked, born and
admitted within the region that required ventilation during the 2 years studied. The mortality
rate in these infants was 26.1%. With the inclusion of more immature infants, mortality in
an ALEC treated arm might be expected to increase to 33.9% (= 26.1% x factor of 1.3 as
above), and if Curosurfwas used the mortality rate might be 15.7% (= 26.1% x factor of 0.6
as above). This makes the assumption that the differential in mortality seen in the 25-29
week gestation infants is maintained in the more immature 23-24 week infants and the more
mature 30-31 week infants.
Annually this equates to 234 ventilated infants with a projected 155 survivors ifALEC were
used or 197 survivors if Curosurfwere used. Therefore if Curosurfwere used in preference
to ALEC there would be an additional 42 infants surviving to discharge. Compared to the
present cohort when a mixture of surfactant types were used and mortality in the ventilated
infants was 26.1% (no. of surviving infants = 173), if there was a wholesale region-wide
change to Curosurf an additional 24 infants might theoretically survive to discharge
annually.
Assuming there is the additional capacity within the region's neonatal intensive care units to
absorb these extra survivors, there are also the additional (marginal) costs to be found.
Using data from the trial where average duration of low dependency days was 45.6 days for
Curosurf-treated infants (chapter 9), these additional survivors would theoretically cost the
region an extra £122,573 in low depencency care. The increase in the low dependency costs
would be offset by a slight reduction in high dependency costs but another problem would
be extra capacity to cope with these survivors.
This does not take into account the additional burden of morbidity from chronic lung
disease. There were no differences in the rates of CLD at 36 weeks in the study comparing
Curosurf and ALEC and with the higher proportion of survivors after treatment with
Curosurf there would be an increase in the absolute numbers of infants with CLD.
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10.6 Conclusion
This survey has concentrated on a group of infants that consume a large proportion of the
resources of the perinatal services in the former Northern region. This is also the group of
infants that are at greatest risk of surfactant deficient lung disease (that is RDS) and its
complications. Previous data from the former Northern region has shown that RDS does
occur in more mature infants but that it is much less common and less severe as the infant
approached term gestation (Madar et al 1999).
Current provision of neonatal intensive care within the region appears to be efficient. The
"centralised" provision does however mean that transfers within the region are inevitable.
Some would argue that any perinatal transfers between units offering level III units are
inappropriate (Parnamum et al 2000). In our region these account for 25% of in utero
transfers (Fenton et al 2000), and 6.4% of the postnatal transfers in the <32 week group.
Mortality in the years 1998-99 in our region was not different from other studies that have
looked either at mortality in an earlier cohort (Tin et al 1997) or in other healthcare regions
(Draper et al 1999, Costeloe et al 2000).
Despite the geographical distances involved, infants born at gestations <32 weeks do not
have a higher mortality rate than if they had been booked at level III units. Some of this is
due to the anticipation of obstetricians in transferring "at risk" pregnancies antenatally, but
importantly even those infants that are born in the hospitals with level I facilities only do not
have a higher mortality than those booked and born in hospitals with level III facilities.
Moreover even when these infants are sick (CRIB scores >10), there is no significant
difference in mortality. Clearly mortality is not the only outcome and this does not take into
account morbidity, which others have found to be increased in postnatally transferred infants
(Halliday et al 1986). But these data do answer one of the criticisms levelled at the Curosurf
and ALEC trial that infants recruited from level I units might affect overall outcomes
(Morley 2000).
Infants born at gestations <32 weeks consume a large amount of resources, and 98% of the
respiratory intensive care in this group is carried out in one of the level III units. Therapies
that influence respiratory outcomes could greatly affect the workload in these units.
The final section of the results postulates how a region-wide change to Curosurf would
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affect resources. Up until the time of the trial the type of surfactant used was determined
largely by cost, but was also influenced by the choices of clinicians in these units. If the
projections of an additional 25 surviving infants per year are accurate, the region would
have the capacity to absorb the extra workload but at the cost of reducing extra-regional
intake. The additional survivors would therefore have a double impact - costing an
additional £122,573 in low dependency care per year and reducing the monies earned from
extra-contractual referrals. This clearly illustrates the impact that surfactant therapy has on
health service resources even though surfactant treatment itself is only administered on a





Respiratory distress syndrome (RDS) affects a large number of infants annually. Whilst
understanding of the disease and its sequelae has improved over the years it is clear that
many questions remain unanswered. Management of infants "at risk" of RDS is resource
intensive and costly but nonetheless compared to treatments for other life-threatening
diseases is cost-effective (Walti & Monset-Couchard 1998).
Firstly positive pressure ventilation, then antenatal steroids and more recently postnatal
surfactant have greatly improved mortality in preterm infants. However these therapies
should not be viewed in isolation but rather as part of the whole "package" of improving
perinatal care.
This thesis has concentrated on exogenous surfactant therapy and looked at its development
as a therapeutic agent. Since the first report of successful exogenous surfactant therapy
(Fujiwara et al 1980) there has been a large amount of evidence from controlled trials
showed that administration of surfactants is effective, such that further placebo-controlled
trials of surfactant would be considered unethical. There remain unanswered questions; in
particular how much, when and how surfactant should be administered, whether synthetic
surfactants that were compositionally very simple could be as effective as surfactants of
natural origin.
Evidence from the medical literature and reviewed in this thesis suggests that surfactant
should be given as early as possible, that multiple rather than single doses should be used
and that currently bolus intra-tracheal administration is the only effective method of
administration. Evidence from in vitro studies and now studies in neonatal populations
support the use of the animal-derived products over the currently available synthetic protein-
free surfactants. The surfactant proteins SP-B and SP-C that are retained in the
manufacturing processes of most animal-derived exogenous surfactants would appear to be
the main reason for the difference in clinical efficacy between synthetic and animal-derived
surfactants, although differences in phospholipids may also be important. Synthetic
surfactants are currently being developed that contain synthetic analogues of both SP-B and
SP-C but they are not widely available as yet.
Neonatal medicine is a low-volume high-cost specialty. A large proportion of the resources
of any neonatal unit are directed to caring for infants born <32 weeks gestation who have
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surfactant deficiency lung disease. The final part of this thesis looked at the organisation of
perinatal care in the former Northern health region of England which operates a centralised
system of specialised services (fetal medicine, neonatal intensive care, neonatal and
paediatric surgery and cardiology) in four large hospitals, but with district general hospitals
delivering non-specialised management.
Despite the centralisation of specialist care in the region, mortality among infants born
before 32 weeks gestation is the same whether the mother booked at a hospital with level I
or level III neonatal intensive care facilities. This has been achieved through collaboration
between the units and a well-organised transfer service.
The study of the two surfactants that was central to this thesis has resulted in a region-wide
(and arguably a national) change in practice. The effects of this change in practice have yet
to become evident, but evidence put forward in the final chapter suggests that this change
could have important implications for the provision of neonatal intensive care in the region
both financially and in terms of workload.
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Report of the Data and Safety Monitoring Committee
The following is the report of the findings of the Data & Safety Monitoring Committee for
the randomised trial between CurosurfandALEC (CandA trial). Permission to include this
was given by Dr Janet Rennie, Chair of the Committee.
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CandA Trial: A randomised trial of Curosurf v ALEC surfactants
Data & Safety Monitoring Committee, CandA trial
Royal Society ofMedicine, Wimpole Street, London






Chairman, Senior Lecturer in Neonatal Medicine,
King's College Hospital, London
Professor ofNeonatal Medicine, Nottingham
Professor of Medical Statistics,
Institute of Child Health, London
Fellow ofNew Hall College, Cambridge,
Faculty of English, University of Cambridge
Mother with experience of premature babies
Advice by telephone from:
Professor Henry Halliday
Professor John Matthews
Professor ofNeonatal Medicine, Belfast
Statistician to CandA, Professor of Medical Statistics,
Newcastle
Meeting note:
Dr Rennie reminded the group of the aim of the trial, which was to compare two
surfactants, one natural and one artificial.
The primary aim of the study was to compare the number of days spent in high dependency
care, with 482 infants required to demonstrate a 25% difference in the expected median of 6
days of high dependency care.
No difference in mortality was expected, although a meta-analysis of Survanta v Exosurf
had shown an odds ratio for mortality of 0.8 in favour of natural surfactant, so mortality
was a secondary outcome measure in the CandA trial.
Other secondary outcomes were: chronic lung disease; number of ventilator days;
pulmonary haemorrhage; pneumothorax; seizures; retinopathy of prematurity; patent ductus
arteriosus; abnormal cranial ultrasound; necrotising enterocolitis.
There were no stopping rules but an interim analysis at the half-way point had always been
planned. The DSMC was asked to meet at 6 monthly intervals, but recruitment was slow.
The slow recruitment led to the date for the interim analysis being set for December.
Although rather less than half the total number was reached by then it was decided to go
ahead because the trial had been running for 20 months.
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The results of an interim analysis prepared by Professor Matthews were presented and
discussed by Professor Cole.
The following centres had participated in the trial, which began in April 1998:
Liverpool (Women's and Fazakerley)
Newcastle
Middlesbrough (S Cleveland hospital)
Stockton-on-Tees
Sunderland
Leicester and Leeds (2 babies each, late entrants)
In total 337 babies had been eligible; 207 had been randomised. The reasons for non-
enrolment included lack of time to gain consent, a request for consent felt to be
inappropriate, parental refusal, no need for ventilation after prenatal consent had been
obtained. Recruitment was better in Liverpool than in the other centres but there was no
major difference between centres in the reasons given, so the enrolment process appeared
valid. S Cleveland had randomised only 16 of 51 eligible babies with 3 post-enrolment
exclusions which gave rise to some discussion but was not felt to invalidate the results.
207 babies of 25-29 weeks gestation were randomised.
16 were withdrawn;
randomised before birth but not born, or born stillborn; 7
randomised before birth not intubated, 2
wrong gestation 4
malformation detected postnatally (TOF) 1
problems with randomisation 1
other 1
Again the trial committee felt that this was an acceptable number of post-randomisation
exclusions considering the difficult nature of neonatal trials, and that the analysis and
randomisation process remained valid.
The group decided to tackle mortality first; although this was a secondary endpoint clearly
this was the major outcome of interest in any trial. The Committee considered the results
without knowledge of the randomisation code. The expected mortality was about 20%.
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Surfactant 1 Surfactant 2
Number enrolled 96 93
Discharged alive 74 51
Dead 13 30
Still in hospital 9 12
Hazard ratio 2.66 with 95% confidence interval 1.36 to 5.22 (P < 0.004)
Everyone on the committee expressed surprise and disquiet about this unexpected result.
Clearly a difference in mortality had not been expected, and those enrolling babies had
been in equipoise about the outcome. We all felt that if there were any possibility that this
was a genuine result then it would be difficult, if not impossible, for the trial to continue.
Even if the mortality was equal in the two arms for the remaining half of the trial, with no
"extra" deaths on surfactant 2, then the outcome would still be worse for this group overall,
and time would be lost in drawing the attention of other clinicians to the result.
We discussed the degree of excess mortality that we considered clinically important, and
certainly a difference of 10% was felt by us all to be important. A smaller difference would
have been considered important had we been asked to state our prior prejudice.
The Kaplan-Meier survival "life table" curves were also strikingly different, with a cluster
of deaths on surfactant 2 between 100 and 150 days.
The clinicians in the group wondered if the babies randomised to group 2 had done badly
because of an excess of very small babies, or male babies, or multiples. We felt, in view of
the importance of the question, that it was reasonable to telephone Professor Matthews and
ask him to help with this. At this stage we did not know the code.
Professor Matthews reported back the following additional information:
_ _ Surfactant 1 n=96 Surfactant 2 n=93
33 girls: 64 boys 44 girls: 49 boys
Mean gestational age 27.4 weeks 27.2 weeks
25 weeks (number) 12 13
26 weeks 17 21
27 weeks 14 15
28 weeks 24 24
29 weeks 30 20
Information about singleton/multiple deliveries was not available.
The group remained concerned; there was no obvious excess in the number of very tiny
babies allocated to surfactant 2 that could account for the excess mortality. Correcting the
hazard ratio for sex resulted in an increased hazard ratio of 2.93 with 95% confidence
interval 1.49 to 5.76 (P < 0.002).
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On the primary outcome of time spent in high dependency care, there was no difference
between the two groups of surviving babies.
Professor Matthews had provided the randomisation code in a sealed envelope. We decided
to open it in order to consider the results together with the meta-analysis that showed that
there was a disadvantage for artificial surfactant. The meta-analysis suggested that
surfactant 2 would be ALEC but we recognised that an excess of pulmonary haemorrhages
in the babies treated with Curosurf or some other unexpected complication might have
equally severe effects.
The code showed that surfactant 2, the surfactant with excess mortality, was ALEC.
The committee was unanimous in deciding that our recommendation should be to stop the
trial. This decision was not taken lightly, the committee were all aware of the serious
implications of curtailing a scientific trial early. We were aware that further analysis may
reveal the reason for the difference to be other than the trial treatment. However, having
found such an important difference in the number of deaths between the groups, and having
failed to explain it by any of the more usual and obvious confounders, we all felt that it was
unethical to ask clinicians in contributing centres to continue to randomise babies.
Randomising clinicians could no longer remain in equipoise regarding the two treatments
on offer.
Dr Rennie conveyed the decision by telephone urgently to the two main centre co¬
ordinators, Dr Ben Shaw and Dr David Milligan. Dr Milligan offered to inform the other
centres.
Janet M Rennie MA MD FRCP FRCPCH DCH
Consultant and Senior Lecturer in Neonatal Medicine
On behalf of the CandA DSMC, 14th December 1999
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APPENDIX 2
Statement issued by Britannia Pharmaceuticals Ltd.
The following is the statement issued by Britannia Pharmaceuticals following publication
of the results of the randomised trial between Curosurfand ALEC (CandA trial).




Voluntary Suspension of Marketing and Use of
ALEC™ (pumactant)
A UK trial comparing the lung surfactant ALEC™ (pumactant) with another lung
surfactant in Neonatal Respiratory Distress Syndrome (NRDS), has been
prematurely terminated because of a higher observed mortality in the ALEC™
treated babies. The results of the study will be published in the Lancet this week.
The finding is unexpected in light of the previously published clinical trials and UK
clinical experience with the product over the last eight years. When Britannia first
became aware of these findings, the Medicines Control Agency (MCA) were
immediately informed and close discussions followed.
Britannia consider that the results of the study need detailed consideration together
with all other relevant data on the safety and efficacy of ALEC™. The company is
continuing to work closely with all parties to clarify the situation as soon as
possible.
While a detailed assessment is considered, Britannia has decided voluntarily to
suspend the marketing and distribution of ALEC™ immediately, and to recommend
that the product is not used until the implications of the trial are fully understood. All
relevant healthcare personnel are being informed and stock can be returned for a
refund.
Following a detailed review by the MCA and UK Committee on Safety of
Medicines, Britannia will update relevant healthcare professionals on the place of











Maxwell Noble (Deputy Managing Director),




Data from the randomised comparative trial between poractant
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APPENDIX 4
Data from infants <32 weeks gestation treated in the former
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0
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0
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1Booked/bomlevelI,PNtransfer
16
40
Dischargedaliv
70
21
8
FALSE
None
762
Carlisle
Carlisle
31
1794
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